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Summary
Inflammatory bowel diseases (IBD) comprise a group of disorders that involve acute and
relapsing stages of intestinal inflammation. The pathogenesis of IBD is associated with
a mucosal barrier defect and the infiltration of pro-inflammatory immune cells into the
lamina propria (LP). Under homeostatic conditions, intestinal resident LP cells have
been shown to be hyporesponsive towards bacterial antigens. Currently, little is known
about the molecular mechanisms that initially lead to the onset of an inflammatory
response in these cells. This thesis aimed towards a better understanding of these initial
mechanisms by utilizing a human ex vivo intestinal organ culture model, the so-called
loss of epithelial layer (LEL) model.
In this model, normal human colonic mucosa is subjected to EDTA treatment, thereby
detaching the epithelial layer from the underlying LP. The thus created barrier defect
is associated with the induction of a global inflammatory response in resident LP
cells, as could be shown by global gene expression profile analysis and subsequent
quantitative gene expression analysis of approx. 590 immune-system related genes in
LP cells isolated by laser-capture microdissection. Furthermore, a significant overlap
to a published gene expression profile of total mucosa biopsies of ulcerative colitis
(UC) patients demonstrated the physiological relevance of the inflammatory response
initiated in the LEL model. Additionally, the expression of several genes induced in the
LEL model are linked to single-nucleotide polymorphism loci enriched in IBD patients.
In order to identify pathways, biological functions and potential upstream regulators
associated with the observed inflammatory response, a bioinformatic analysis via
Ingenuity Pathway Analysis (IPA) of the global gene expression profiles was performed.
An enrichment of growth factors and translation specific kinases among upstream
regulators predicted by IPA, suggested the induction of protein synthesis in LP cells at
the onset on inflammation.
Supporting these in silico findings, a rapid upregulation of protein translation in LP
cells after the onset of inflammation was detected in situ by utilizing Ortho-propargyl-
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puromycin (OPP) Click-It technology®. Remarkably and in contrast to nonstimulated
peripheral blood mononuclear cells, no detectable protein synthesis levels were observed
in the mucosa under homeostatic conditions.
The upregulation of protein synthesis in LP cells at the onset of inflammation was
subsequently shown to be associated with the activation of the mammalian target of
rapamycin (mTOR) pathway as indicated by an increase in Ser235/236 phosphorylation
levels of the mTOR downstream target ribosomal protein S6 (RPS6) in OPP+ LP
cells including macrophages. This finding could be further validated by inhibition
experiments employing the mTOR inhibitor Torin1, which led to a significant decrease
of RPS6Ser235/236 phosphorylation in these macrophages in situ as well as in emigrated
myeloid cells and a marked decrease in protein synthesis in situ.
Finally, secretion of the chemokines CCL2, CCL19, CCL22 and CXCL1 by LP cells
was decreased in the presence of Torin1 as measured by Luminex® multiplex analysis
of LEL organ culture supernatants. These results suggest a participation of the mTOR
pathway in the recruitment of leukocytes to the intestinal mucosa during the initial
phase of intestinal inflammation. Furthermore, the concomitant inhibition of IL-18 as
well as the increase of MIF and M-CSF secretion by Torin1 support the notion that
mTOR is involved in - and potentially coordinates - multiple aspects of the initial
inflammatory response of LP cells such as the induction of inflammasome activation
(IL-18), the differentiation of macrophages (M-CSF), and the restriction of MIF-induced
pro-inflammatory processes.
In summary, the results in this thesis led to the following conclusions: The LEL model
was shown to represent a physiological relevant tool to study molecular mechanisms
driving the initial onset of an intestinal inflammatory response in resident LP cells. The
onset of the observed global inflammatory response after LEL was shown to be regulated
by the mTOR pathway, which modulated the secretion of inflammatory mediators. The
findings of this thesis therefore suggest the mTOR pathway as a potential target in IBD
therapy.
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Zusammenfassung
Chronisch-entzündliche Darmerkrankungen (CED) zeichnen sich durch rezidivierende
und kontinuierliche Entzündungen des Darmes aus. Die Pathogenese dieser Erkrankun-
gen wird mit einem Barrieredefekt der intestinalen Mukosa und der Infiltration von
pro-inflammatorischen Immunzellen in die Lamina Propria (LP) assoziiert. Residente
LP Zellen hingegen besitzen unter homöostatischen Bedingungen einen anergen Phäno-
typ und zeichnen sich durch ihre Hyporesponsivität gegenüber bakteriellen Antigenen
und Nahrungsantigenen aus. Die molekularen Mechanismen, die an der initialen
inflammatorischen Antwort in diesen Zellen beteiligt sind, sind derzeit noch weitgehend
unbekannt und wurden daher in der vorliegenden Arbeit mittels eines humanen,
intestinalen Organkultur-Modells untersucht.
In diesem sogenannten ’loss of epithelial layer (LEL)’-Modell wird gesunde humane
Mukosa des Kolons ex vivo mit EDTA behandelt. Dies führt zu der Ablösung der
Epithelzellschicht von der darunterliegenden LP. Der so ausgelöste Barrieredefekt geht
mit der Induktion einer globalen inflammatorischen Antwort daher, wie globale sowie
quantitative Genexpressionsanalysen von laser-mikrodissezierter LP zeigen konnten.
Die physiologische Relevanz dieser Antwort wurde nachfolgend anhand der signifikanten
Übereinstimmung mit einem publizierten Genexpressionsprofil von Mukosa-Biopsien
von Colitis Ulcerosa (CU) Patienten bestätigt. Außerdem war im LEL-Model die
Expression mehrerer Gene hochreguliert, welche mit CED assoziierten Einzelnukleotid-
Polymorphismus Loci verknüpft sind.
Mit dem Ziel, Signaltransduktionswege, biologische Funktionen sowie potentielle über-
geordnete Regulatoren zu detektieren, welche für die initiale inflammatorische Antwort
von Bedeutung sind, wurde anschließend eine bioinformatische Analyse der globalen
Genexpressionsprofile durch die Software ’Ingenuity Pathway Analysis’ duchgeführt.
Eine Anreicherung von Wachstumsfaktoren und Translations-spezifischen Kinasen,
innerhalb der Gruppe der bioinformatisch vorhergesagten übergeordneten Regulatoren,
wies nachfolgend auf die Induktion der Proteinsynthese in LP Zellen zu Beginn der
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inflammatorischen Antwort hin.
Diese in silico vorhergesagte Induktion der Proteinsynthese zu Beginn der inflam-
matorischen Antwort konnte anschließend mittels Ortho-Propargyl-Puromycin (OPP)
Click-It® Technologie in u.a. CD68+ Makrophagen der LP in situ nachgewiesen
werden. Unter homöostatischen Bedingungen war in der Mukosa - im Gegensatz zu
ruhenden Leukozyten des peripheren Blutes - unter den angewandten experimentellen
Bedingungen keine Proteinsynthese nachweisbar.
Die Induktion der Proteinsynthese war assoziiert mit der Aktivierung des mTOR
(mammalian target of rapamycin) Signalweges, wie durch die Induktion der Ser235/236
Phosphorylierung des mTOR Zielproteins ribosomales protein S6 (RPS6) in u.a. CD68+
Makrophagen zu Beginn der inflammatorischen Antwort mittels Immunfluoreszenzanal-
yse gezeigt werden konnte. Inhibitionsexperimente mit dem mTOR Inhibitor Torin1
bestätigten die Kontrolle der RPS6Ser235/236 Phosphorylierung durch den mTOR Signal-
weg. Darüber hinaus konnte nachgewiesen werden, dass die beobachtete Hochregulation
der Proteinsynthese in LP Zellen, wie z.B. Makrophagen, in großen Anteilen durch
mTOR vermittelt wird.
Die vielseitige funktionelle Bedeutung der mTOR Aktivierung für die Induktion der
inflammatorischen Antwort konnte anhand von Überständen des LEL-Modells in
Luminex® Multiplex Analysen gezeigt werden. So wies die erniedrigte Sekretion der
Chemokine CCL2, CCL19, CCL22 und CXCL1 in Gegenwart von Torin1 einerseits auf
die Bedeutung des mTOR Signalweges für die Kontrolle der Rekrutierung peripherer
Leukozyten zur intestinalen Mukosa hin. Andererseits konnte durch die gleichzeitige
Torin1 vermittelte Inhibition der Sekretion von IL-18 sowie der Steigerung der MIF-
als auch M-CSF-Sekretion gezeigt werden, dass mTOR außerdem in die Induktion
der Inflammasom-Aktivierung (IL-18), die Differenzierung von Makrophagen (M-CSF)
sowie die Restriktion von MIF-induzierten pro-inflammatorischen Prozessen involviert
ist.
Die Resultate dieser Arbeit führen zu folgenden Schlussfolgerungen: Das LEL Modell
ist ein adäquates und physiologisch relevantes Modell, um molekulare Mechanismen zu
untersuchen, die der initialen inflammatorischen Antwort in residenten LP Zellen zu-
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grunde liegen. Der mTOR Signalweg ist an dieser initialen inflammatorischen Antwort
durch die Kontrolle der Sekretion von inflammatorischen Mediatoren durch LP Zellen
beteiligt. Die Erkenntnisse dieser Arbeit legen daher den mTOR Signalweg als poten-
tiellen Ansatzpunkt in der zukünftigen Therapie von CED nahe.
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1. Introduction
1.1. The immune system of the human intestine
The intestine represents the largest compartment of the immune system and contains
higher numbers of immune cells than any other tissue. It is also the human organ
that harbours the largest number of bacteria: With a number as high as 1013-1014, the
intestine contains more bacteria than the total cell number of the human body, with an
increasing bacterial diversity and number from small to large intestine [Xu and Gordon,
2003; Sekirov et al., 2010]. In spite of the close proximity of both immune cells and
commensal bacteria as well as dietary antigens, the intestine normally remains in a
homeostatic state. Even more so, reduced numbers and/or diversity of microbiota are
associated with a variety of diseases ranging from psychiatric conditions to metabolic
disease, allergy and autoimmunity [Belkaid and Hand, 2014]. Although the mechanisms
that ensure the maintenance of the homeostatic state are still not completely understood,
one main factor is thought to be the mucosal barrier between bacteria of the lumen
and immune cells in the mucosa. A disrupted barrier has been associated with the
manifestation of chronic inflammatory bowel disease (IBD) [Turner, 2009].
1.1.1. The intestinal mucosa
In order to explain the mechanisms that are currently thought to ensure and main-
tain intestinal homeostasis, first, a short overview will be given over the structure and
the functions of the intestine and the intestinal mucosa. The human gut is divided
into the small and large intestine, the former being further regionally differentiated as
duodenum (closest to stomach), jejunum and ileum, while the large intestine consists of
1
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Figure 1.1.: The mucosa of the large intestine. The lamina propria hosts a variety of
immune cells including dendritic cells (DC), macrophages, T cells, B cells
and eosinophils. Figure was created based on Mowat and Agace [2014].
caecum (closest to ileum), ascending, transverse and descending colon and finally rectum.
Whereas the main function of the small intestine is the disintegration and absorption of
nutrients, the large intestine mediates water absorption and processing of nondigestable
material.
Most immunological processes occur in the mucosa, the multi-levelled layer of the gas-
trointestinal tract which borders the gut lumen. The luminal side of the small and large
intestine of the mucosa is covered with an unicellular epithelial layer, which is adjacent
to the lamina propria (LP), loose-connected tissue that hosts most immune cells. Be-
neath the LP is the muscularis mucosae (a thin muscle layer), which is located next to
the submucosa and the muscle layer (Mowat and Agace [2014]; for a schematic figure of
the mucosa of the large intestine, see Figure 1.1).
The unicellular epithelial layer at the luminal side of the small intestinal mucosa forms
finger-like projections with LP in their core. These so-called ’villi’ extend into the lumen
and increase the surface area of digestively active epithelium. In addition, epithelial
invaginations that extend into the mucosa are defined as ’crypts’ [Peterson and Artis,
2
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2014]. Stem cells at the base of these crypts enable the constant renewal of the intes-
tine: the turnover of the human duodenum is thought to take 1.50 (±2.90, N=3) days,
whereas it takes 4.12 (±1.32, N=53) days in the human colorectal region [Darwich et al.,
2014].
The majority of epithelial cells of the small intestine are enterocytes, however, addi-
tionally, also Paneth cells (which secrete antimicrobial peptides into the lumen), goblet
cells and neuroendocrine cells are present. In the large intestine, the unicellular epithe-
lium layer only contains crypts but no villi and therefore is relatively flat. Furthermore,
Paneth cells are absent; however, the large intestine does contain more goblet cells than
the small intestine [Peterson and Artis, 2014].
The mucosal barrier
Goblet cells constitutively secrete highly glycosylated mucins (e.g. MUC2) into the
lumen, together forming a thick layer called ’mucus’. Whereas the mucus of the murine
small intestine only has one layer, the mucus of both murine and human large intestine
consists of two distinct layers [Gustafsson et al., 2012]. Studies performed in the
murine system demonstrated that the outer layer is inhabited by a distinctive microbial
population of commensal bacteria, whereas the inner layer is nearly sterile [Li et al.,
2015]. Additionally, the outer layer contains soluble IgA, which is constantly secreted by
LP plasma cells. The mucus thus represents the first important barrier between luminal
bacteria and LP immune cells [Johansson et al., 2013]. In accordance, MUC2-deficient
mice are known to spontaneously develop colitis [Van der Sluis et al., 2006].
The most efficient mucosal barrier however is provided by the epithelial cell membrane,
which is impenetrable to most hydrophilic solutes in the absence of specific transporters.
In conformity, epithelial layer damage induced by toxins as secreted by the pathogenic
bacterium Clostridium difficile [Riegler et al., 1995] is associated with a pronounced bar-
rier loss. With an intact epithelial cell layer, however, the paracellular pathway between
epithelial cells is controlled by tight and adherens junctions [Diamond, 1977; Turner,
2009]. The selective permeability of tight junctions is known to be regulated by cy-
3
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tokines, such as tumor necrosis factor (TNF)-α and interferon (IFN)-γ and dysregulated
expression of these cytokines is linked to diseases associated with barrier dysfunction
such as IBD [Baert et al., 1999].
Beneath the mucosal barrier provided by mucus and the epithelial layer, the LP hosts a
variety of immune cells which will be described in detail in the following section.
1.2. Immune cells in the lamina propria during
homeostasis
Resident LP cells include immune cells such as dendritic cells, macrophages, T cells, B
cells, eosinophils, mast cells and stromal cells such as fibroblasts [Mowat and Agace,
2014]. Intestinal immune cells in contrast to their relatives of the peripheral blood
are generally understood to have a decreased activation ability, a characteristic that is
thought to aid in the maintenance of intestinal homeostasis.
1.2.1. Lymphocytes
Lymphocytes constitute one of the largest populations of immune cells in the intestinal
mucosa. They consist of T cells, B cells, and innate lymphoid cells. Like all other
intestinal immune cells, lymphocytes are confined to the mucosa under homeostatic
conditions. A notable exception is a population of CD8+ intraepithelial lymphocytes,
which are located at the basement membrane between enterocytes.
Findings of our group and others could show that the ability of T lymphocytes to mount
an adaptive immune response is seriously compromised under homeostatic conditions.
Activation of T cells through the T cell receptor (TCR) are strongly inhibited by
several local mechanisms, keeping the LP T cells in a hyporesponsive state [Sido et al.,
2008, 2000; Qiao et al., 1991, 1993; Pirzer et al., 1990; De Maria et al., 1993]. At the
same time, LP T cells sensitively respond to CD2 ligation, an antigen-independent
pathway of T cell activation [Meuer et al., 1984; Hunig et al., 1987; Braunstein et al.,
2008], or CD28 co-stimulation, producing significantly higher amounts of cytokines than
4
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peripheral blood lymphocytes [Liu et al., 2001; Boirivant et al., 1996]. This specialised
differentiation state of LP T cells likely contributes to the maintenance of intestinal
homeostasis by preventing a chronic inflammatory response to the large number of
antigens present in close proximity in the gut lumen.
Unlike most healthy tissues, the normal LP contains large numbers of IgA producing
plasma cells. A small fraction of plasma cells produce IgM. Through the constant se-
cretion of IgA into the gut lumen, plasma cells contribute to the mucosal barrier by
protecting the epithelium from pathogens [Brandtzaeg and Johansen, 2005].
1.2.2. Myeloid cells
There are several different cell types of non-lymphoid immune cells localized in the in-
testinal LP such as DCs, macrophages, eosinophils and mast cells. One focus of this
study is the characterization of an inflammatory response in macrophages. This popu-
lation will therefore be described in detail in this section.
Macrophages
In mice, the large intestine contains one of the largest pools of mononuclear phagocytes
in the body with macrophages representing one of the most abundant fraction of
leukocytes in the healthy intestinal LP [Lee et al., 1985; Mowat and Agace, 2014].
Human intestinal tissue resident macrophages are - in contrast to murine macrophages
- not able to proliferate and their life span is currently unknown [Smythies et al., 2006;
Jenkins et al., 2011]. In mice, Bain et al. [2014] could show, that macrophages are
constantly replenished by circulating monocytes every three to four days.
Interestingly, in both humans and mice, their abundance seems to correlate with the
increase of the bacterial load in the lumen from proximal to distal gastrointestinal
tract and thus, macrophages are found to be most prominent represented in the colon
[Nagashima et al., 1996; Denning et al., 2011; Sekirov et al., 2010]. Especially in the
human colon, CD68+ macrophages have been shown to be localized directly beneath
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the epithelial surface and thereby are in very close proximity to the massive load of
bacterial antigens in the lumen [Mahida et al., 1989].
Under homeostatic conditions, intestinal macrophages have been shown to be hypore-
sponsive towards pathogen-associated molecular pattern (PAMP) stimulation, which is
thought to be achieved by their relatively low expression of pattern recognition receptors,
Fc and complement receptors compared to the expression in peripheral blood mononu-
clear cells (PBMC). Among other potential factors, this anergic phenotype is thought
to evolve by TGF-β mediated downregulation of nuclear factor (NF)-κ B proteins in
bone-marrow derived, pro-inflammatory macrophages previously recruited from the pe-
riphery via locally produced IL-8 and TGF-β [Smythies et al., 2010, 2005; Qiao et al.,
1996; Hausmann et al., 2002]. This hyporesponsive phenotype is generally thought to
contribute to the maintenance of homeostasis.
1.3. Intestinal inflammation
As described in the last sections, in the past many studies have established mechanisms
such as the mucosal barrier and the hyporesponsive phenotype of LP immune cells as
key factors in the maintenance of intestinal homeostasis despite the close proximity of
immune cells and microbiota as well as dietary antigens in the gut. In contrast, little is
known about the ability of the intestine to mount an immediate inflammatory response
i.e. after pathogenic infection as well as the factors that - under certain conditions -
lead to the perseverance of inflammation and culminate in the manifestation of chronic
inflammatory bowel diseases (IBD).
Acute intestinal inflammation is most often caused by infection with enteric pathogens
and can lead to clinical symptoms such as bloody diarrhoea, abdominal pain and
fever. Most of these enteric infections are ’self-limited’ and require little or no medical
attention, although they can be fatal in some cases. Morphologically, the mucosa of
these patients often shows an acute or mixed inflammatory immune cell infiltration
into the LP. At their onset, acute and chronic inflammation histologically share many
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common features. However, in contrast to patients with later-stage IBD, the mucosa
of patients with acute self-limiting colitis normally shows an intact crypt architecture,
although the surface epithelium is often damaged [Lamps, 2015].
Chronic inflammatory bowel diseases (IBD) comprise two clinical phenotypes: Ulcera-
tive colitis (UC) and Crohn’s Disease (CD). These two diseases have a pattern of chronic
relapsing and remitting intestinal inflammation, whose pathogenesis has been shown to
be closely associated with a mucosal barrier defect and infiltration of LP immune cells
[Pastorelli et al., 2013]. Whereas UC is normally limited to the colon and rectum with in-
flammatory infiltrates being confined to the mucosa, the manifestation of CD can occur in
the whole gastrointestinal tract, although ileum and colon are most frequently involved.
Additionally, inflammation in CD can extend throughout the intestinal wall. Clinically,
both UC and CD patients among other symptoms suffer from severe diarrhoea, bloody
stools, ulcers as well as fibrosis, the latter being more prominent but not exclusively
present in CD patients [Hendrickson et al., 2002; Gordon et al., 2014]. In accordance
with the resembling disease presentation of both phenotypes, a global gene expression
analysis showed that gene expression patterns in chronic inflamed mucosa compared to
healthy mucosa are remarkably similar between CD and UC [Granlund et al., 2013].
Although knowledge regarding the pathogenesis of IBD is limited, an aberrant reac-
tion of the intestinal immune system to luminal antigens and barrier dysfunctions have
been implicated. Moreover, a statistical enrichment of single-nucleotide polymorphisms
(SNPs) in patients has been associated with IBD. Many of the detected loci were asso-
ciated with both disease types. Interestingly, risk alleles at two CD loci, PTPN22 and
NOD2, show protective effects in UC and may reflect some of the biological differences
between both diseases [Jostins et al., 2012].
Given the little insight into the etiology of IBD, treatment for IBD patients is mostly
symptomatic. It includes lifestyle alterations, medical management and surgical inter-
ventions. In addition to the administration of broad anti-inflammatory medication, an
antibody against TNF-α is able to restore the epithelial barrier in IBD with highest
efficiency in CD patients. However, after an initial success in treating the symptoms
of IBD, some patients develop anti-drug antibodies and require increasing doses or the
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switch to a different TNF-α antibody [Scott and Lichtenstein, 2016].
As of today, IBDs are incurable diseases. To develop more suitable treatment options,
investigations to enhance our understanding of the origins of intestinal inflammation is
essential.
1.3.1. Models to study intestinal inflammation
Currently, more than 70 distinct genetically engineered mouse models exist in which
intestinal inflammation develops spontaneously [Mizoguchi et al., 2016]. Additionally,
several murine models employ chemical agents to induce experimental colitis. The most
widely used model employing a chemical agent is probably the dextran sodium sulphate
(DSS) - induced colitis model. Here, the uptake of 3-10 % DSS via the drinking water
leads to extensive epithelial damage in the colon within six to ten days. The developed
symptoms imitate to some extent the symptoms of UC, including diarrhoea, rectal
bleeding and weight loss [Okayasu et al., 1990]. Another chemically induced colitis
model, the TNBS model, mimics some of the symptoms of CD. In this model, intrarectal
administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS), a substance which renders
self-proteins immunogenic to the immune system by haptenation, causes a massive mu-
cosal inflammation involving a dense infiltration of T cells and macrophages throughout
the entire wall of the large intestine. This is accompanied by progressive weight loss,
bloody diarrhea, rectal prolapse and large bowel wall thickening [Neurath et al., 2000].
TNBS-induced colitis is also used to study fibrosis [Loeuillard et al., 2014].
In addition to the murine models described above, several groups have successfully
established "humanized mice" by establishing a human microbiome in germ-free mice
[Rongvaux et al., 2014].
In comparison to the huge availability of murine models, intestinal models of the hu-
man system are scarce. Most human studies focus on the analysis of chronic stages of
intestinal inflammation comparing biological processes as occurring in normal mucosa
with those occurring at relapsed or remitting stages of IBD. Tissue of acute /self-limiting
intestinal inflammation is usually not available, as neither endoscopy nor surgery is re-
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quired as part of the diagnostic procedure or treatment follow-up, respectively.
The study of acute intestinal inflammation is mainly performed in vitro employing ep-
ithelial cell lines or ex vivo by the isolation of intestinal LP cells through the removal
of the epithelial layer via treatment with the Ca2+-chelator ethylenediaminetetraacetic
acid (EDTA) and subsequent enzymatic digestion of mucosal tissue [Rogler et al., 1998].
Rarely, organ cultures are employed for the study of intestinal inflammatory responses.
Mahida et al. [1997] developed a model to study the migratory behaviour of intestinal
immune cells after epithelial barrier defects. In this model, mucosa resectates were
denuded of the epithelium by treatment with EDTA in order to mimic epithelial damage
occurring in vivo. After culture of the remaining mucosa, lymphocytes, macrophages
and eosinophils migrated out of the LP via tunnels of the extracellular matrix.
1.3.2. Macrophages in intestinal inflammation
Given the focus of this thesis, the knowledge regarding intestinal macrophages in in-
testinal inflammation, based on murine and human models, will be summarized in this
section.
Despite the hyporesponsive, CD14low phenotype, that intestinal macrophages display
under homeostatic conditions, they have been implicated to play an important role in
intestinal inflammation: For one, CD patients show a strong mucosal infiltration of
CD14hi macrophages [Autschbach et al., 2002]. Moreover, intestinal macrophages in
patients with acute inflammation (acute appendicitis and acute diverticulitis) as well as
IBD patients have been shown to express increased levels of TREM-1. This increased
TREM-1 expression by macrophages in IBD patients has been further linked to an
enhanced secretion of pro-inflammatory cytokines such as TNF, IL-6, IL-8, IL-1β as
well as the chemokine CCL2, thus further demonstrating the impact of these cells on
intestinal inflammation [Schenk et al., 2007].
In mice as well as humans, it has been proposed, that during intestinal inflammation,
PBMC are recruited to the intestinal inflammatory site [Bain et al., 2014; Thiesen et al.,
2014]. However, whether (and if so, how) previously anergic tissue resident macrophages
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are able to differentiate into the observed proinflammatory phenotype in inflammation
or if the inflammatory response is entirely mediated by fully responsive recruited PBMC
is still unclear.
In addition to their proinflammatory role, intestinal macrophages have also been im-
plicated in anti-inflammatory processes such as tissue remodelling and wound heal-
ing [Kühl et al., 2015]. Expression of MMP2, which takes part in the breakdown of
the extracellular matrix (ECM), has been shown to be expressed in tissue resident
macrophages and is increased in the mucosa of fibrotic CD patients [Kirkegaard et al.,
2004; Bailey et al., 2012]. Moreover, mannose receptor CD206 expressing wound-healing
macrophages are increased in the injured mucosa of UC patients [Martinez et al., 2013;
Cosin-Roger et al., 2013].
In accordance with the differential role of macrophages in intestinal inflammation, it
should be noted, that in contrast to the earlier M1/M2 dogma of macrophages, which
distinguished them into an either distinct pro- (M1) or anti-inflammatory (M2) type,
recent work showed that macrophages display a great extent of plasticity and their phe-
notype can vary greatly dependent on stimuli and milieu [Xue et al., 2014].
1.4. Protein synthesis in inflammation
A coordinated and dynamic regulation of gene and protein expression levels is essential
for the induction and resolution of a healthy inflammatory response. For instance, the
activation of PRRs in response to microbial infection triggers signalling cascades and
consequent activation of certain transcription factors, culminating in the differential
regulation of hundreds of genes involved in antimicrobial defense, phagocytosis, cell
migration, tissue repair and the regulation of adaptive immunity [Carpenter et al.,
2014]. Defects in these control mechanisms may result in a failure to resolve the
inflammatory response and thus contribute to the development and progression into
chronic inflammatory diseases [Mazumder et al., 2010].
The following section first gives an overview of the knowledge regarding regulation of
protein synthesis in inflammation in general, before explicitly focusing on regulation of
protein synthesis in the intestine in subsection 1.4.2.
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Regulation of gene expression at the level of translation offers several benefits over
transcriptional control: Post-transcriptional regulation can be rapidly activated based
on existing mRNAs without the need of prior transcription. Additionally, it can be
quickly reversed by e.g. phosphorylation events that lead to the activation or deacti-
vation of specific regulatory factors. There are several post-transcriptional regulation
pathways regulating gene expression in innate immunity such as mRNA splicing,
mRNA polyadenylation, mRNA stability and protein translation - all of which have
been shown to be implicated in regulating the strength and duration of inflammatory
processes. Upon bacterial challenge in vitro, almost one fifth of genes that are expressed
in dendritic cells undergo alternative splicing, some of them known to participate in
antimicrobial defense [Rodrigues et al., 2013]. Furthermore, when human monocytes
are stimulated with the toll like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) and
IFN-γ, the polyadenylation machinery favours proximal poly(A) site use in terminal
exons that contain two or more poly(A) sites. This leads to a global shortening of key
regulatory elements such as microRNA target sites and stability mediating AU-rich
elements [Sandberg et al., 2008].
Eukaryotic protein translation is generally cap-dependent and involves the following
steps: Initiation, elongation, termination and ribosomal degradation. The rate-limiting
step of translation is the initiation step and thus makes it a sensitive and efficient anchor
point for regulation. In accordance, most known regulatory mechanisms control the
initiation step, in which the small ribosome subunit is recruited to the 5’ end of mRNA,
causing the assembly of the complete ribosome that subsequently begins polypeptide
synthesis. The recruitment of the small ribosome subunit depends on the assembly of
the eukaryotic translation initiation factor 4F (eIF4F) complex at the 5’ cap structure of
mRNA. This complex consists of the three initiation factors eIF4F, eIF4G and eIF4A.
To achieve eIF4F complex assembly, eIF4E binds to the 5’ cap of mRNA and then
recruits eIF4G and eIF4A. The inhibitory 4E-binding protein 1 (4E-BP1) controls eIF4F
complex assembly by inhibiting the binding of eIF4G to eIF4E. Phosphorylation of 4E-
BP1 leads to its dissociation from eIF4E, thus allowing the recruitment of eIF4G and
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eIF4A [Pestova et al., 2001]. The phosphorylation of 4E-BP1 is known to be regulated
by the mTOR pathway.
1.4.1. The mTOR pathway
The mammalian target of rapamycin (mTOR) pathway is known to upregulate anabolic
processes such as protein and lipid synthesis while inhibiting autophagy. It thus repre-
sents a key regulator of cell size and proliferation. Its dysregulation has been implicated
in the pathogenesis of several diseases including diabetes, fibrosis and cancer [Ma and
Blenis, 2009; Laplante and Sabatini, 2012].
Several findings implicate a role of mTOR in innate immunity: TLR ligands have been
shown to activate mTOR in human monocytes, macrophages and DCs. After LPS
stimulation, murine macrophages and DCs massively increase protein synthesis, a process
that is largely dependent on the PI3K-mTORC1 pathway [Lelouard et al., 2007; Ivanov
and Roy, 2013].
mTOR is an atypical serine/threonine protein kinase and a member of the phosphoinosi-
tide 3-kinase (PI3K)-related kinase family. Together with several proteins mTOR forms
two distinct complexes, known as mTORC1 (see Figure 1.2) and mTORC2. mTORC1
contains mTOR, raptor (regulatory associated protein of mTOR) as well as LST8 (lethal
with SEC13 protein 8) and has been shown to directly regulate translation in mammals
via its two main downstream targets 4E-BP1 and the 40S ribosomal protein S6 kinases
(S6Ks) [Jacinto and Hall, 2003].
mTORC1 exhibits phosphotransferase activity that is activated by the GTP-bound form
of the small G protein RHEB (Ras homologue enriched in brain) after translocation of
mTOR to the lysosome in response to amino acids. Activated mTOR can also be found
in the cytoplasm, nucleus and mitochondrium, although the functional significance of
these localisations are still under investigation [Betz and Hall, 2013]. RHEB itself is
negatively regulated by a tumor suppressor heterodimer of tuberous sclerosis 1 (TSC1)
and 2 (TSC2), which converts RHEB into its inactive GDP-bound form.
mTORC1 was shown to be regulated by several pathways as the PI3K-AKT, Ras-ERK
(extracellular signal-regulated kinase) and Wnt signaling pathway by the inibition of the
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Figure 1.2.: mTORC1 signaling. GEF, guanine nucleotide-exchange factor; HIF1α,
hypoxia-inducible factor 1α; IRS1, insulin receptor substrate 1; NF1, neu-
rofibromin 1; PDK1, phosphoinositide-dependent kinase 1; PtdIns, phos-
phatidylinositol; PTEN, phosphatase and tensin homologue; REDD1, pro-
tein regulated in development and DNA damage response 1 (also known as
DDIT4) [Ma and Blenis, 2009]
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TSC1-TSC2 complex [Shaw and Cantley, 2006; Inoki et al., 2006].
Additionally, several factors are known to influence mTORC1 activity: Among others,
amino acids, glucose, insulin and growth factors are known to activate mTORC1. Fur-
thermore, mTORC1 can also be stimulated by cytokines such as TNF-α. It has been
recently shown, that the inhibitor of NF-κB kinase-β(IKKβ), a main downstream ki-
nase in the TNF-α signaling pathway, can activate mTORC1 via TSC1 inhibition by
phosphorylation [Lee et al., 2007].
In contrast, hypoxia is known to negatively regulate mTORC1 activity. Moreover,
mTORC1 is suggested to sense an inadequate supply of cellular energy and suppress the
energy-consuming protein synthesis under starvation conditions. Recent studies have
proposed the AMP-activated protein kinase (AMPK) as one of the ’energy sensors’ for
mTORC1 that leads to mTOR deactivation under conditions that increase intracellular
levels of AMP to limit ATP-consuming functions of the cell [Hahn-Windgassen et al.,
2005; Gwinn et al., 2008] .
The mTORC2 complex contains mTOR, LST8, rictor (rapamycin independent compan-
ion of mTOR) and SIN1 (stress-activated protein kinase-interacting protein 1). Similar
to mTORC1, it can be activated by growth factors and PI3K/Akt signaling. Function-
ally, mTORC2 is involved in cytoskeletal organization and - through the activation of
the kinases SGK1 and Akt - in the regulation of cell survival and proliferation [Ma and
Blenis, 2009].
Apart from its well described impact on the regulation of eIF4F assembly, mTOR on
the one hand is known to stimulate the translation of ’eIF4E-sensitive’ mRNA through
mechanisms that yet remain elusive. On the other hand, mTOR controls the expression
of so-called TOP mRNAs. These mRNAs have a terminal oligopyrimidine (TOP) tract
at their 5’ end and are very sensitive towards mTOR inhibitors [Nandagopal and Roux,
2015].
There are several inhibitors available for studying downstream effector functions of
mTOR. mTOR was originally named after its sensivity towards the antifungal com-
pound rapamycin that led to its original detection. Rapamycin (synonym: sirolimus)
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shows anti-proliferative and immunosuppressive characteristics [Chang et al., 1991] and
is clinically i.e. utilized as base therapy in the prophylaxis of acute renal transplant
rejection [Groth et al., 1999]. Additionally, sirolimus-coated stents efficiently prevent
restenosis [Sousa et al., 2001, 2005].
On the molecular level, rapamycin is only able to inhibit mTORC1, whereas mTORC2
is insensitive to treatment with this drug (at least under short-term treatment). Ad-
ditionally, recent findings have demonstrated that rapamycin is not able to fully in-
hibit mTORC1 [Feldman et al., 2009]. In contrast, another mTOR inhibitor, Torin1,
which was used in this study, is able to inhibit both mTORC1 and mTORC2 activity
[Thoreen et al., 2012, 2009].
1.4.2. Protein synthesis in the intestine
As mentioned before, the intestinal immune cells of the LP are known to be hyporespon-
sive towards PAMPs under homeostatic conditions, thus the upregulation of protein
synthesis to bacterial stimuli under physiological conditions as described above seems
unlikely.
Currently, little is known about the regulation of protein synthesis in the human intes-
tine, regardless whether concerning the protein synthesis ratio compared to other organs
or changes occurring between homeostatic and inflamed mucosa. This lack of knowledge
is likely due to methodological difficulties in measuring protein synthesis tissue specifi-
cally. In rats, McNurlan et al. [1979] predicted the amount of protein synthesized in the
small intestine, utilizing a flooding technique involving a bolus of L-[1-13C]leucine. He
observed that the intestine makes up 14 % and the liver 12 % of total protein synthesis
of the whole body and found that protein synthesis rates of the small intestine was re-
duced 30 % after two days of starvation. Heys et al. [1992] were able to show via leucine
uptake, that daily protein synthesis rates in colorectal mucosa from IBD patients (with
five patients diagnosed with UC and one with CD) were raised 2.6 fold in comparison to
normal mucosa (N=10). In comparison, the levels in malignant colorectal cancer were
raised 2.3 fold and 3.9 fold in benign tumors of the rectum. Remarkably, protein synthe-
sis in the liver of IBD patients was raised 1.7 fold compared to benign diseases such as
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chronic cholecystitis or benign colonic tumors. Importantly, so far, no data is available
regarding the compartment-specific protein synthesis in the human colonic LP, neither
under homeostatic nor under inflammatory conditions.
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1.5. Aim of thesis
Inflammatory bowel diseases (IBD) define a group of chronic inflammatory diseases
of the intestinal tract that affect five million people worldwide. They are associated
with a mucosal barrier defect and the dysregulated, chronic activation of resident
lamina propria (LP) immune cells, that under homeostatic conditions have a high
tolerance towards bacterial and dietary antigens. However, little is known about
the molecular mechanisms underlying the onset of the initial acute inflammatory
response in LP cells. A better understanding of these initial processes will help to
determine the factors that eventually lead to a chronic manifestation of the inflammation.
To study early intestinal inflammation, I employed the ’loss of epithelial layer’ (LEL)
model, a human organ culture model, in which an EDTA-mediated barrier defect in
colonic mucosa is associated with the activation of resident LP cells.
In this thesis, I sought to understand the molecular mechanisms underlying the initiation
of acute intestinal inflammation in resident LP cells by the following concept:
(1) Characterization of the inflammatory response of LP cells as induced in the LEL
model by conducting global gene expression analysis and subsequent validation of
the physiological relevance of the inflammatory response.
(2) Identification of biological processes involved in the initiation of an inflammatory
response in LP cells by performing bioinformatic analysis of the obtained global
gene expression profiles.
(3) Evaluation of global translation levels in LP cells in the LEL model in situ.
(4) Investigation of the mTOR pathway with regard to its role in the observed induction
of protein synthesis.
(5) Examination of the contribution of the mTOR pathway to the induction of inflam-
matory effector molecules in LP cells.
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2.1. Tissue samples
Patient material was obtained in collaboration with the departments of surgery at the
University Hospital Heidelberg, the hospital Salem in Heidelberg as well as the St. Vin-
centius Hospital in Speyer. Gut specimen were derived from patients undergoing resec-
tion due to localized colon cancer. Colonic mucosa, localized near the resection margin
and declared as healthy by a pathologist, was dissected from the surgical specimen and
immediately subjected to the experimental procedures. Exclusion criteria for this study
were the presence of multiple metastasis, diabetes, IBD, diverticulitis/diverticulosis or
previous chemo- or radiotherapy treatment. Biopsies were obtained from patients under-
going routine colonoscopy. All human studies were approved by the ethics committee of
the University of Heidelberg (ethical votes S-024/2003 and S-390/2015) and performed
in accordance with the principles laid down in the Declaration of Helsinki. Written in-
formed consent was obtained from the patients. Patients taking part in this study had
an average age of 72 ± 8.11 years.
2.2. The LEL model
The dissected mucosa (see section 2.1) was washed for 1.5 h using RPMI/ABXmedium at
4°C under constant shaking with changes of medium every 20 min at 4°C (for composition
of all used solutions in this section, see Table 2.1). Mucosa was then washed once
in ice-cold HBSS/ABX for 10 min. Mucus was removed via treatment with 1 mM
1,4-dithiothreitol (DTT, Roche AG, Karlsruhe) dissolved in HBSS/ABX for 15 min
followed by washing the explant with HBSS/ABX twice for 5 min each. The epithelial
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Component Company Conc. Volume Solution
1 2 3
RPMI 1640 Medium Life Technologies,
Paisley, UK
- 500 ml x x
HBSS w/o Ca2+,
Mg+
Life Technologies - 500 ml x
Penicillin / Strepto-
mycin
Life Technologies 10000 IE/ml 5 ml x x x
Fungizone Life Technologies 250 µg/ml 5 ml x x x
Ciprobay Bayer Pharma AG,
Berlin, DE
2 mg/ml 2,5 ml x x x
Gentamicin Life Technologies 50 mg/ml 500 µl x x x
Cotrim Ratiopharm GmbH,
Ulm, DE
96 mg/ml 500 µl x x x
Fetal Calf Serum
(FCS)
Pan Biotech GmbH,
Aidenbach, DE
100% 50 ml x
L-Glutamine Life Technologies 200 mM 5 ml x
Table 2.1.: Composition of media and salt solutions in the LEL model. Solution 1 is
stated as RPMI/ABX, solution 2 as HBSS/ABX and solution 3 as RP-
MI/ABX + 10 % FCS in the text.
layer was subsequently removed by treating the explant three times with 0.7 mM EDTA
(Merck KGaA, Darmstadt, pH 7.3 - 7.35, dissolved in HBSS/ABX) for 30 min each
with intermittent 10 min HBSS/ABX washing steps at 37°C under constant shaking.
After washing for four times 10 min each with HBSS/ABX, the tissue was transfered
to medium consisting of RPMI/ABX + 10 % FCS for 12 h over night at 37°C. For an
image depicting the main steps of the LEL model, see Figure 3.1 on page 36.
At specific time points, size standardized tissue punches were collected from mucosa as
described in Table 2.2.
2.2.1. Inhibitors
For experiments with inhibitors, the LEL model was performed using small jars. After 20
min of washing, standardized 0.8 cm punches were made and distributed into jars (max
four punches were put into one jar) containing 7 ml of the appropriate solution (same
19
2. Material and Methods
ID DTT EDTA Add. treatment before collection t collection
TM 0 h - - - 0 h
TM 2 h x - 10 min HBSS/ABX 2 h
LEL - M 3 h x 1 x 10 min HBSS/ABX 3 h
LEL - M 4 h x 2 x 10 min HBSS/ABX 4 h
LEL - M 5 h x 3 x 2 x 10 min HBSS/ABX 5 h
TM 5 h - - RPMI/ABX + 10% FCS (37°C) 5 h
LEL - M 17 h x 3 x RPMI/ABX + 10% FCS (37°C) 17 h
TM 17 h - - RPMI/ABX + 10% FCS (37°C) 17 h
Table 2.2.: Samples collected at different time points during the LEL model. At indicated
time point of collection, samples were either flash frozen in liquid nitrogen
and stored at -80°C, transferred to 4% formalin or subjected to additional
treatment (see subsection 2.2.2). TM: Total mucosa; LEL-M: Loss of epithe-
lial layer - mucosa.
as described in the standard protocol) with or without addition of specified inhibitors.
Torin1 (Merck KGaA, Darmstadt) was employed at a concentration of 250 nM or 1
µM. Cycloheximide (Merck KGaA) was used at concentrations 10 µg/ml or 100 µg/ml.
Inhibitors were present at all times during performance of the LEL model.
2.2.2. Detection of protein synthesis in situ via Click-It®
technology
A way to study protein synthesis in situ is the so called Click-It® technology (Life Tech-
nologies), where the alkyne analog of puromycin, Ortho-Propargyl-Puromycin (OPP) is
rapidly incorporated into newly synthesized proteins by binding covalently to nascent
polypeptide chains, a reaction which can subsequently be detected by a copper(1)-
catalyzed azide-alkyne cycloaddition [Liu et al., 2012]. The technology has so far only
been used in animal models and in this thesis was established for the human system by
utilizing the LEL model.
Briefly, at specified time points (see Table 2.2), tissue samples were incubated with 20 µM
OPP in RPMI/ABX medium + 10% FCS at 37°C for 30 min (or RPMI/ABX medium +
10% FCS w/o OPP as a control). Tissue samples were then rinsed briefly in HBSS/ABX
and transferred immediately to 4 % PBS-buffered methanol-free formalin for subsequent
preparation of formalin fixed-paraffin embedded (FFPE) samples and sectioning (see
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section 2.6). For subsequent slide preparation followed by immunofluorescent detection
of OPP incorporation, see subsection 2.7.2.
2.3. Sample collection for gene expression analysis
2.3.1. Laser-capture microdissection
A powerful method to isolate specific areas from heterogeneous tissue, such as the in-
testinal mucosa, is laser-capture microdissection (LMD) of tissue sections transferred to
1.0 PEN (D) MembraneSlides (Carl Zeiss, Oberkochen, Germany). After specifying the
desired area on the section using a microscope linked to a computer, a connected laser
melts the membrane of the selected area and with a single laser impulse catapults it
into a collection tube for subsequent lysis and RNA isolation. Using this approach, the
lamina propria was isolated from the mucosa at four time points throughout the LEL
model: TM 0 h, TM 5 h, LEL-M 5 h and LEL-M 17 h (see Table 2.2).
For global gene expression analysis, following preparation of 12 µm cryosections at -25°C,
sections were directly covered with DTT (1 mg/ml) and incubated in solution for 5 min.
Slides were then transfered to a cuvette containing 100 % EtOH (-25°C).
Immediately before LMD using a PALM MicroBeam LMD (Carl Zeiss), sections were
counterstained at 4°C by successively immersing slides in cuvettes containing Cresyl Vi-
olet acetate (Sigma-Aldrich, Munich, Germany; 0.1 % in EtOH, 15 s), 100 % EtOH
(10 s, two changes) and xylene (10 s). Slides were then incubated in another change of
xylene for 5 min. Finally, slides were allowed to air-dry for 5 min.
LMD was performed for 1 h using the 10 x magnification of the microscope. For sub-
sequent lysis, 50 µl of RLT buffer from the Qiagen RNeasy Kit including DTT (20 mM
in 1 ml) and glycogen (1.14 %) were added to the tube containing the LMD sample
and then vortexed vigorously for 30 s followed by a 5 min incubation step and repeated
vortexing. The lysates were then stored in -80°C until RNA isolation.
Samples prepared for nCounter experiments were obtained similarly as described above,
however, 8 µm cryosections were made in order to better detect underlying epithelial
cells and prevent epithelial contamination observed in the WG-DASL Assay. Slides were
21
2. Material and Methods
immersed in 4°C acetone instead of xylene to allow protein isolation (data not shown in
thesis).
2.3.2. RNA isolation
RNA Isolation of LMD samples was performed using the RNeasy Kit (Qiagen N.V.,
Venlo, NL) following the manufacturer’s instructions for microdissected cryosections
with minor changes.
Briefly, LMD samples in RLT buffer were placed in a 37°C heatblock until thawed. RNA
was precipitated by adding 1 Vol 70 % EtOH to the LMD sample. The precipitated RNA
of the thoroughly resuspended sample was then bound to the membrane of a RNeasy
MinElute Spin column by centrifugation for 15 s at 8,000 g at room temperature (if not
stated otherwise, these configurations were used for all further steps). Samples with a
total volume exceeding column capacity (700 µl) were pooled by repeating precipitation
and binding steps reusing the same RNeasy MinElute Spin Column. Flowthrough was
discarded after each step in the protocol until elution. After a washing step with 350
µl RW1 buffer, residual DNA was removed by a DNase treatment (10 µl DNase + 70
µl RDD buffer), which was terminated after 15 min by adding 350 µl RW1 buffer and
a consequent centrifugation step. Chaotropic salts were removed by the addition of 500
µl RPE buffer. After centrifugation, 500 µl 80% EtOH were added to the column and
centrifuged for 2 min at 8,000 g. The column was then allowed to air-dry by centrifuging
with an open lid for 5 min at 16,000 g. RNA was finally eluted from the RNeasy
MinElute Spin column by adding 12 µl of RNase-free water directly to the center of the
spin column membrane. After centrifugation for 1 min at 16,000 g, the elute was again
added to the membrane to increase the RNA harvest and eluted again by centrifuging
for 4 min at 16,000 g. The RNA eluate was stored at -80°C after taking a separate
aliquot for evaluation of RNA integrity.
2.3.3. RIN evaluation
RNA quality was analyzed via a 2100 bioanalyzer (Agilent Technologies Inc., Santa
Clara, USA) using the RNA integrity number (RIN) software tool as indicator for the
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intactness of the RNA. A RIN of 10 equals totally intact and a RIN of 0 totally degraded
RNA [Schroeder et al., 2006]. To qualify for downstream experiments, the RIN had to
be at least 3. For a representative example of electropherograms of bioanalyzer analysis
from samples obtained at different time points during the course of one experiment,
please see page A-4 in the appendix.
2.4. Gene expression analysis
2.4.1. WG-DASL Assay
Global gene expression analysis of samples microdissected at the timepoints TM 0 h,
LEL-M 5 h and LEL-M 17 h during the LEL model was performed using the Whole-
Genome cDNA-mediated Annealing, Selection, extension, and Ligation (WG-DASL)
Assay (Illumina, San Diego, CA, USA). In this assay, after conversion of total RNA
to cDNA using biotinylated oligo (dT) and random nonamer primers, the biotinylated
cDNA is annealed to the DASL Assay Pool probe groups. The probe sets consist of
an upstream and a downstream oligo, each containing a gene-specific sequence and a
universal PCR primer sequence at its 5’ or 3’ end, respectively. After the hybridization
of the upstream oligo to the targeted cDNA site, it extends and ligates to its correspond-
ing downstream oligo to create a PCR template which can be amplified with universal
PCR primers. For the final analysis of gene expression, the resulting PCR products
are hybridized to the HumanHT-12 v4 Expression BeadChip [April et al., 2009]. The
probe groups of the WG-DASL Assay only span 50 base pairs (bp), which makes this
assay compatible with partially degraded RNA. For further details to the assay, please
see Table 2.3. Sample RNA concentrations were adjusted to the sample with the lowest
RNA amount according to bioanalyzer evaluation. The analysis was performed by the
Genomics and Proteomics Core Facility of the German Cancer Research Center (DKFZ),
Heidelberg, Germany.
23
2. Material and Methods
2.4.2. nCounter Assay
The nCounter Assay from Nanostring was chosen as method of choice for validation
of the WG-DASL Assay using the prebuilt Immunology Panel which consists of 594
genes, as it was the most appropriate available panel based on the focus of this thesis.
In this assay, the RNA target molecule is directly hybridized with a reporter probe
that carries a universal fluorescent barcode and a capture probe that contains a biotin
moiety which immobilizes the hybridized complex on a cartridge for subsequent data
collection [Reis et al., 2011; Veldman-Jones et al., 2015]. As the WG-DASL Assay,
this method is compatible with partially degraded RNA because of the short probe
span of 50 bp. However, in contrast to the WG-DASL Assay, the nCounter analysis
requires no cDNA synthesis or preamplification, thus providing quantitiative information
of transcript levels. For more details on the nCounter Assay and a direct comparison to
the WG-DASL Assay, see Table 2.3.
Samples collected at the time points TM 0 h, TM 5 h, LEL-M 5 h and LEL-M 17
h were adjusted to the sample with the lowest RNA amount according to bioanalyzer
evaluation before submission to the assay. The analysis was performed by the nCounter
Core Facility of the Institute of Human Genetics in Heidelberg, Germany.
WG-DASL nCounter
(Illumina) (Nanostring)
Analyzed genes ∼ 29.000 594 (Immunology Panel)
Compatibility with degraded RNA yes yes
Probe length 50 bp 50 bp
Minimum RNA input 200 ng 100 ng
cDNA synthesis yes no
Preamplification yes no
Hybridization on Chip solution-based
Fold Change Sensitivity 1.5-2 1.67
Table 2.3.: Comparison of the WG-DASL (Illumina) and nCounter (Nanostring) Assay.
[April et al., 2009; Reis et al., 2011]
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2.5. Bioinformatic analysis on gene expression data
The normalization, calculation of differentially expressed genes and heatmap generation
of the WG-DASL Assay data was performed by Maria Dinkelacker of the Bioinformatic
Division of the DKFZ. She continued to support the author in all other bioinformatic
analyses described in this section (which were performed by the author). If not stated
otherwise, all bioinformatic analyses were performed in R version 3.2.3 [R Core Team,
2015]. For base operations and plots, the packages dplyr v0.4.3 [Wickham and Francois,
2015], ggplot2 v2.0.0 [Wickham, 2009] and data.table v1.9.6 [Dowle et al., 2015] were
used.
2.5.1. Normalization WG-DASL Assay
Rawdata was preprocessed with genome studio V2011.1 from Illumina and then read
into R. Subsequent analysis of data was performed using the following packages: Biobase
v2.30.0 [Huber et al., 2015], limma v3.26.5 [Ritchie et al., 2015], lumi v2.18.0 [Du et al.,
2008] with database lumiHumanAll.db1.22.0. Annotation of data was performed us-
ing nuID1 from the limma package. After background correction (using the method
’normexp’), a quantile normalization was performed and values were log2 transformed.
Boxplots before and after normalization can be found on page A-5 in the appendix.
2.5.2. Normalization nCounter Assay
nCounter Assay normalization was performed using the package NanoStringNorm 1.1.21
[Waggott et al., 2012]. As in total, two cartridges from two different lots were run, a
Lot-to-Lot calibration was performed during normalization of raw data according to the
recommendation of the Nanostring tech support team (see Table 2.4). The resulting
normalized counts were log2 transformed. Besides static plots that were part of the
NanoStringNorm package (data not shown), boxplots of expression values indicated the
legitimation of this approach (see page A-7 in the appendix).
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Normalization via SOP Accounts for Option ’NanoStringNorm’
package
1. Positive controls y Technical variation geo.mean
2. Calibration of cartridges n Lot-to-Lot variation -
3. Negative controls y Background noise mean.2sd
4. Housekeeping genes y RNA input variation housekeeping.geo.mean
Table 2.4.: Worfklow normalization nCounter via ’NanoStringNorm’ package [Wag-
gott et al., 2012]. Raw data of both cartridges was used as initial input
and normalized together. Calibration was performed by first calculating the
gene-wise geometric mean of the 1st cartridge (geomean1) and 2nd cartridge
(geomean2). The calibration factor was defined as geomean1/geomean2 and
multiplied with each positive control normalized gene count of the 2nd car-
tridge. Housekeeping genes ABCF1, ALAS1, G6PD, RPL19, TBP were se-
lected based on lowest % CV and a low, medium or high gene expression as
recommended. Options chosen within the package were the default option-
s/methods as recommended by Nanostring and package developers [Wag-
gott et al., 2012]. SOP: Standard operation procedure for normalization of
nCounter Assays; y: yes; n: no
2.5.3. Heatmaps
Heatmaps for expression data of both WG-DASL and nCounter Assay were generated
using the package Heatplus v2.16.0 [Ploner, 2012] after performing z-score transforma-
tion. Samples were sorted by highest variance and clustering calculated using Eucledian
distance metrics. For the WG-DASL Assay, only the 1000 genes with the highest
variance were plotted.
2.5.4. Analysis of differential gene expression and inter-assay
comparisons
For both WG-DASL and nCounter assays, differential expression was calculated by the
test implemented in the limma package and P values adjusted for multiple testing by the
method of Benjamini and Hochberg [1995]. Differential expressed genes for observations
LEL-M 5 h vs. TM 0 h (Obs.1), LEL-M 17 h vs. TM 0 h (Obs.2), LEL-M 17 h vs.
LEL-M 5h (Obs.3) as well as TM 5 h vs. TM 0 h (nCounter Assay only, Obs.4) were
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defined as having an adj.P.Val below 0.05 and a log 2 fold change (logFC) ≥ |1|.
Venn diagrams
To create Venn diagrams, the package VennDiagram v1.6.16 was used [Chen, 2012].
For optimal comparison of WG-DASL and nCounter data, only genes present in both
datasets (mapped by Gene symbol annotation) were included in the analysis (565 genes).
Comparison of WG-DASL Assay and UC vs. NC dataset
For comparison between the LEL model (WG-DASL Assay) and UC vs. NC (normal
colon) data set [Granlund et al., 2013], genes were mapped by EntrezID annotation (the
only annotation present for the UC vs. NC dataset) which led to an overlap of 18,047
genes. Within these common genes, a cut off of an adj.P.Val of < 0.01 and a logFC ≥ |1|
was applied for both datasets to obtain lists of the differentially regulated genes. Sub-
sequently, lists were generated, which contained the overlaps of up- and downregulated
genes between both assays.
In collaboration with Maria Dinkelacker, random sampling of the same number of over-
lapping genes from all available genes on either array were generated for 1000 replications,
and an empirical P value for the number of genes in the intersection was calculated. As
no single random replicate had the same or a higher number of genes in the intersection
of both data sets, the P value was given as P.Val < 0.001.
Comparison of WG-DASL Assay with IBD associated SNP loci
For detection of IBD associated SNP loci [Jostins et al., 2012] near keygenes that were
upregulated in the LEL model but not in UC patient data, again a cut off of an adj.P.Val
< 0.01 and a logFC ≥ |1| for both datasets was applied. Comparison analysis was done
based on Gene ID annotation. Prior to analysis, the UC vs. NC dataset was Gene ID
annotated by using the package mygene v1.6.0 [Mark et al., 2014].
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2.5.5. Ingenuity Pathway Analysis
Pathway analysis of the WG-DASL Assay was performed with the software Ingenuity
Pathway Analysis (IPA, Qiagen) using content version 26127183. For analysis, the val-
ues for Obs.1, 2 and 3, as calculated in subsection 2.5.4, including adj.P.Val, logFC
and average expression were uploaded into IPA. All datasets were then filtered for an
adj.P.Val < 0.05 and a logFC ≥ |1|, after which a core analysis was performed with each
filtered dataset. Data from the subunits ’Canonical Pathways’, ’Diseases & Functions’
and ’Upstream Analysis’ was then further analyzed in R. For all subunits, data related
to ’Cancer’, ’Disease’ or ’Development’ was filtered out. Cut-offs were set to an adj.P.Val
< 0.05 and a z-score ≥ |2|.
2.6. Preparation of FFPE samples and sectioning
Samples as obtained at time points indicated in Table 2.2 were subsequently transferred
to histology cassettes and fixed after an user-optimized short-fixation perfusion protocol
with solutions and times as stated in Table 2.5. A rotary microtome (Leica, Nussloch)
was used to subsequently prepare 2 µm tissue sections.
Solution Incubation time
4 % formalin (in PBS) 24 h
70 % EtOH ≤ 48 h
95 % EtOH 20 min
abs. EtOH 20 min
abs. EtOH/ abs. Acetone (1:1) 20 min
abs. Acetone 30 min
Paraffin (65 °C) 40 min
Table 2.5.: Short-fixation perfusion protocol. 4 % PBS-buffered methanol-free formalin
was prepared from a 16 % stock solution (Life Technologies). Apart from
incubation in paraffin, all steps were performed at room temperature. After
procedure as described in this table, tissue samples were placed into with
molten paraffin filled metal molds and orientated as desired after which the
mold was placed on a cold plate. Paraffin blocks were then stored at 4°C.
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2.7. Immunfluorescence imaging
2.7.1. Antibodies
Detailed information to primary and secondary antibodies used for immunofluorescence
staining can be found in Table 2.6.
Antigen Clone Species Company Dilution
4E-BP1-p (Thr37/46) 236B4 rIgG Cell Signaling 1:1600
anti-active Caspase 3 polyclonal rIgG Abcam 1:20
CD14 SP192 rIgG Abcam 1:50
CD3 SP7 rIgG DCS 1:50
CD68 EBM11 mIgG1 Dako 1:50
CD68 (FFPE) PG-M1 mIgG3 Dako 1:50
IgA polyclonal rIgG Dako 1:1000
mTOR 7C10 rIgG Cell Signaling 1:50
mTOR-p (Ser2448) 49F9 rIgG Cell Signaling 1:50
RPS6 5G10 rIgG Cell Signaling 1:50
RPS6-p (Ser235/236) D57.2.2E rIgG Cell Signaling 1:400
Directed against Host Label Company Dilution
mouse sheep Biotin Amersham 1:600
mouse donkey AF488 Jackson ImmunoRes. 1:800
rabbit donkey Biotin Jackson ImmunoRes. 1:800
rabbit donkey AF488 Jackson ImmunoRes. 1:800
biotin - SA-Cy3 Jackson ImmunoRes. 1:1000
Table 2.6.: Primary and secondary antibodies used in immunofluorescence experiments.
All primary antibodies were directed against human antigens. Company in-
formations: Cell Signaling (Cambridge, UK), Abcam (Cambridge, UK), Dako
(Glostrup, Denmark), Jackson ImmunoResearch Laboratories, Inc. (West
Grove, PA, USA), Amersham plc (Little Chalfont, UK). AF: Alexa Fluor,
SA: Streptavidin.
2.7.2. FFPE sections
Tissue sections on slides were deparaffinized and rehydrated by immersing them into
xylene (two changes), 100 % EtOH (two changes), 95 % EtOH, 75 % EtOH and H2O
(two changes) for 5 min each. Subsequently, heat mediated antigen retrieval was per-
formed by incubating the slides in citrate buffer pH 6 (DCS diagnostics GmbH&Co.KG)
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at 120°C in a pressure cooker for 5 min. Slides were then rinsed in H2O. To block the
ability of eosinophils to bind fluorochromes and thus generating a false-positive signal,
sections were incubated with 0.1 g Chromotrope2R (Sigma-Aldrich) in 1% phenol for 1
h [Floyd et al., 1983; Patterson et al., 1989]. Subsequently, they were permeabilized and
blocked by incubating them with an antibody diluent (DCS diagnostics GmBH&Co.KG)
for 10 min.
For Click-It® detection, sections were at this point incubated with the Click-It®
Reaction Cocktail (including Alexa Fluor 647 picocyl azide) for 30 min at room
temperature.
The sections were then incubated with a primary antibody for 1 h or with antibody
diluent as a negative control. The sections were subsequently stained with the appro-
priate secondary antibodies, either labeled with biotin or a fluorochrome, for 30 min.
Subsequently, the sections were incubated with SA-Cy3 (1:1000) and nuclear mask stain
(1:2000, Life Technologies) for 30 min. The slides were then mounted with cover slips us-
ing ProLong Diamond AntiFade Mountant (Life Technologies). In between steps, slides
were washed with Tris-buffered saline (TBS).
2.7.3. Frozen sections
After generation of 8 µm sections, slides were immediately immersed in a -20°C cold
methanol-acetone (1:1) solution and incubated for 1 min in order to preserve phospho-
rylation of proteins in cryo sections. The slides were then transferred to TBS. Endoge-
nous biotin was blocked with the Avidin/Biotin Blocking Kit (Vector Laboratories Inc,
Burlingame, CA, USA). Slides were then permeabilized and blocked by incubating them
with an antibody diluent (DCS diagnostics GmBH&Co.KG) for 10 min. The primary
antibody was incubated over night at 4°C and additionally for 1 h at room temperature.
All other steps were performed as described for FFPE sections.
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2.7.4. PBMC
Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque (GE
Healthcare) density gradient centrifugation. After resuspension in RPMI medium +
10 % FCS (+ Penicillin/ Streptomycin and L-Glutamine (see Table 2.1); from now on
referred to as RPMI/PS + 10 % FCS), 4 * 105 cells/well were transferred to Poly-
L-Lysin coated LapTek Chambers (Corning, Kaiserslautern, Germany) and allowed to
adhere and regain resting conditions for 24 h at 37°C in a CO2 incubator. 30 min prior
to assessment of protein synthesis by OPP treatment (20 µM), the medium in two wells
was exchanged to HBSS/ABX and 0.7 mM EDTA in HBSS/ABX, respectively, while
100 µg/ml cycloheximide was added to a third well as a negative control for protein
synthesis. In the case of the wells that received prior HBSS or EDTA treatment and one
additional well, OPP treatment was performed diluted in RPMI/ABX + 10 % FCS to
mimic conditions as employed in the LEL model, whereas the other wells were incubated
in RPMI/PS + 10 % FCS. As a background control, OPP was omitted in one additional
well. After incubation with OPP for 30 min, cells were fixed using 4% methanol-free
PBS buffered formalin for 12 min at 37°C. Cells were then permeabilized with 0.25 %
Triton X-100 (Sigma-Aldrich) for 10 min. OPP Click-It® detection, nuclear stain and
mounting (after removal of chamber) was performed as described in subsection 2.7.2,
except for using phosphate-buffered saline (PBS) as a washing buffer.
2.7.5. Semi-quantification of the OPP Click-It® images
Semi-quantitative analysis of OPP Click-It® positive cells was performed using ImageJ
1.50e with a self-written macro (for complete script, see page A-8 in the appendix).
After selecting the image of the time point with the strongest fluorescent OPP Click-
It® signal, the lamina propria was manually selected and all other areas removed by
the function ’clear outside’. An optimal minimal pixel threshold was then set for the
AF647 (Click-It®) channel, so that after conversion into a binary image in combination
with the function ’watershed’, distinction of single cells was still possible. With the
’measure particles’ function, OPP Click-It® positive cells were defined by having a pixel
area size of 10-200 pixel (edges were excluded) and added to the region of interest (ROI)
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manager. To confirm that the selection contained actual cells (and as such contained
nuclei), an overlay of the selection with the DAPI channel was performed. Subsequently,
the intensity of OPP Click-It® positive cells in the original AF647 channel was measured
using the elements in the ROI manager. This resulted in a min, max, mean intensity
and the sum of intensity for each measured cell. To quantify the overall cell number, the
function ’Find Maxima’ was applied to the DAPI channel with a noise tolerance of 450
(edges were excluded). The threshold defined for the image with the apparently most
intense OPP Click-It® positive cells was used for all other analyzed images. To identify
the OPP Click-It® intensity of specific cell populations, the threshold for the channel
containing the cell population specific stain was defined. Subsequently, the resulting
selection was overlaid over the AF647 (OPP Click-It®) channel. Further quantification
was performed as described above.
2.8. Flow cytometry analysis of emigrated LP cells
Flow cytometric analysis was performed in collaboration with Dr. Anne-Kristin
Heninger, who established the protocol and performed all steps after permeabilization
as well as the analysis of collected data. Emigrated lamina propria cells, treated with
250 nM Torin1, 1 µM Torin1 or 10 µg/ml cycloheximide during the LEL-model were at
LEL-M 17 h analyzed for the presence of phosphorylated proteins by flow cytometry.
As a control, untreated, unstimulated PBMC, stained immediately after isolation from
peripheral venous blood by density centrifugation over Ficoll-Hypaque, were used.
In order to determine the phosphorylation state of mTOR downstream targets in a
cell-type specific manner, fluorochrome labelled antibodies recognizing (1) the B cell
markers CD19 or CD20 (2) the myeloid cell markers CD14, CD33 or CD66b (see
Table 2.7 on page 34) were added to the culture and incubated at 37°C for 20 min.
Subsequently, cells were fixed at 37°C for 12 min by adding pre-warmed 4% PFA/PBS
to the culture medium at a ratio of 1:1 for a final concentration of 2% PFA in the
culture. Immediately after fixation, cells were harvested, washed 1x in FACS buffer
(25 mM NaN3, 50 mM EDTA, 4 mM NaHCO3, 1% FCS in PBS) and 1x in PBS,
permeabilized (-20°C BD Biosciences Phosflow Perm Buffer III) for 30 min on ice and
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stored at -20°C until further processing.
Permeabilized cells were washed 3x with FACS buffer and divided into two tubes/ con-
dition. One tube was stained with phospho-4E-BP1Thr37/46 and phospho-RPS6Ser235/236
and the other tube was stained with phospho-mTORSer2448 and phospho-AktSer473 for
60 min at room temperature. Fluorochrome-labelled antibodies recognizing the pan-
leukocyte marker CD45, the T cell-specific receptor CD3 or the myeloid marker HLA-DR
were added simultaneously (see Table 2.7). The secondary antibody donkey anti-rabbit
AF488 (see Table 2.6) was used at 1:200 to label phospho-mTORSer2448 in a subsequent
staining step for 20 min on ice. After staining, cells were washed with FACS buffer and
acquired on a BD LSRFortessa flow cytometer equipped with FACS Diva 8 software.
Doublets and clumps were excluded based on SSC-A vs. SSC-W and FSC-A vs. FSC-H
plots. An unstained control was used to detect auto-fluorescence. At least 50,000 gated
events were acquired for each sample and analyzed using FlowJo 2 software version 10.0.8
(TreeStar, Inc., Ashland, USA). Expression of suface receptors and phosphorylation state
of mTOR downstream targets as well as mTORSer2448 was assessed by determining the
MFI of relevant fluorochromes. A FMO (fluorescence minus one) control was used to
determine the background MFI in the absence of the phospho-specific antibody. Lam-
ina propria myeloid cells were identified as CD45+ lineage− (i.e. CD3/19/20/66b−),
CD33+HLA-DR+ cells. Within the LP myeloid cell population, CD14+ macrophages
were distinguished from CD14− dendritic cells.
2.9. Luminex® multiplex analysis
For Luminex® multiplex analysis, size standardized punches, collected at indicated time-
points, were incubated in RPMI/ABX medium + 10% FCS with or without inhibitors
for 1 h (12 h for LEL-M 17 h) at 37°C. Supernatants were collected and after cell re-
moval by centrifugation flash frozen in liquid nitrogen and stored at -80°C until analysis.
Luminex® multiplex analysis was performed using customized screening assays (for an-
alytes CCL19, CCL2, CCL22, CD14, CD163, CXCL1, CXCL8, ICAM-1, IL-18, M-CSF,
MIF, MMP12) or high-sensitivity performing assays (for analytes IL-1β, IL-6, TNF-
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Antigen Clone Label Company Dilution
CD19 HIB19 APC-H7 BD Biosciences 1:5.5
CD20 L27 APC-H7 BD Biosciences 1:5.5
CD14 MφP9 V450 BD Biosciences 1:5.5
CD33 P67.6 PE BD Biosciences 1:3
CD66b 80H3 APC-AF750 Beckman Coulter 1:5.5
4E-BP1-p (Thr37/46) 236B4 AF647 Cell Signaling 1:50
RPS6-p (Ser235/236) D57.2.2E AF488 Cell Signaling 1:25
mTOR-p (Ser2448) 49F9 - Cell Signaling 1:50
Akt-p (Ser473) M89-61 AF700 BD Biosciences 1:10
CD45 HI30 AF700 BioLegend 1:56
CD3 SK7 PerCP BD Biosciences 1:16
HLA-DR G46-6 V500 BD Biosciences 1:25
Table 2.7.: Antibodies used for surface stain in flow cytometry analysis of emigrated
LPMC and PBMC. All primary antibodies were directed against human
antigens. Company information: BD Biosciences (Heidelberg, Germany),
Beckman Coulter (Brea, CA, USA).
α, VEGF) from R&D systems (Minneapolis, MN, USA) and a Bio-Rad Luminex 100
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). The Luminex® multiplex analysis
itself was performed in collaboration with Dr. Niels Halama, National Center for Tumor
Diseases (NCT), Heidelberg.
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3.1. The loss of epithelial layer (LEL) model
Epithelial layer damage represents an early hallmark of acute and chronic intestinal
inflammation and has been shown to coincide with the induction of an inflammatory
response in resident lamina propria (LP) cells. However, little information is available
regarding molecular mechanisms driving the activation of the normally hyporesponsive
phenotype of LP immune cells.
Recent work from our group introduced the loss of epithelial layer (LEL) model (Fig-
ure 3.1) as a helpful tool to study molecular mechanisms underlying an acute inflam-
matory response in the intestine. Initial observations indicated that release of mucus
and epithelial cells from normal human colonic mucosa by DTT and EDTA treatment
resulted in the upregulation of transcript levels of inflammatory markers such as IL6,
IL8, IL1B, TNFA, INFG, IL23A and CCL2 in resident LP cells.
To determine, whether these initially analyzed inflammation markers correspond to the
initiation of a global inflammatory response and to further investigate the dimensions
and details of this event, global gene expression analysis was performed employing mu-
cosa samples taken at different time points during the LEL model.
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Figure 3.1.: The loss of epithelial layer (LEL) model. Healthy total mucosa (TM) from
patients undergoing surgery for colon cancer is dissected from the surgical
specimen (TM 0 h) and submitted to extensive washing. Mucus is removed
by DTT treatment (TM 2 h). Subsequently, the mucosa is subjected to
three consecutive 0.7 mM EDTA treatments with intermittent washing steps
(LEL-M = 3 h, 4 h, 5 h), leading to the detachment of the epithelial layer
from the underlying LP. After LEL, cells migrate out of the LP. The LEL is
followed by a 12 h culture (LEL-M 17 h). For detailed information regarding
tissue sample collection, see Table 2.2 on page 20. Image of model was
created based on Mowat and Agace [2014].
3.2. Global gene expression analysis indicates the
initiation of an inﬂammatory response in the
LEL model
With the objective of investigating mechanisms associated with the induction of in-
ﬂammation speciﬁcally in LP cells, laser-capture microdissection (LMD) was employed
to isolate the latter cell population from total mucosa prior to culturing (TM 0 h),
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after LEL (LEL-M 5 h) as well as after 12 h of subsequent culture (LEL-M 17 h, see
Figure 3.1).
To assess homeostatic gene expression levels in order to subsequently determine differ-
ential gene expression under inflammatory conditions, most approaches as input either
use (1) entire biopsies or (2) LP cells isolated via EDTA treatment and subsequent
enzymatic digestion from normal, uninflamed TM. However, method (1) includes all
layers of the mucosa and the LP cells from method (2) express inflammatory markers
that are not detected under homeostatic conditions in situ (unpublished data). Taken
these findings into consideration, LMD, a superior method to accurately assess the
resting state of LP cells and their subsequent activation after onset of inflammation,
was chosen for the first time.
After LMD and RNA isolation, all tissue samples showed signs of degradation with a
RNA integrity number (RIN) ranging between 3.5 and 7 (for representative electrophero-
grams of RNA quality assessment, see page A-4 in the appendix). Given the low RNA
integrity, samples were analyzed using the whole genome cDNA-mediated Annealing, Se-
lection, extension and Ligation (WG-DASL) assay from Illumina, an array-based method
that allows the expression profiling of partially degraded RNA by using probe-groups
that only span 50 bps.
For further details regarding the WG-DASL Assay and its bioinformatic normalization,
see subsection 2.4.1 on page 23 and 2.5.1 on page 25, respectively.
Hierarchical clustering analysis of the quantile normalized microarray data sets demon-
strated a clear distinction between TM and LEL-M samples by two separate clusters and
a further distinction between LEL-M samples by a subcluster of LEL-M 17 h samples
(Figure 3.2). The color distribution in the heatmap of the same figure, indicating the
relative gene expression, is very similar between replicates of one time point. These
results demonstrate the reproducibility of the gene expression results obtained in the
four replicate experiments.
After defining significantly differentially regulated genes by an absolute log 2 fold change
(logFC) ≥ 1 and an Benjamini-Hochberg adj.P.Val < 0.05, 2171 genes were differentially
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Figure 3.2.: Expression profile of WG-DASL gene expression data. Shown is a heatmap
based on z-score transformed expression values of the top 1000 genes (sorted
by highest variance of the WG-DASL Assay dataset for the time points
TM 0 h, LEL-M 5 h and LEL-M 17 h). Columns have been reordered
by hierarchical clustering (complete linkage, Euclidean distance metrics).
Colors indicate z-score values as shown in the scale legend. Shown data
was obtained in four independent experiments (R1-R4) with tissue samples
collected at different time points within one experiment being obtained from
the same specimen.
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expressed for Observation (Obs.)1: LEL-M 5 h vs. TM 0 h, whereas 3100 genes were
differentially regulated for Obs. 2: LEL-M 17 h vs. TM 0 h. Both observations
showed a similar ratio of upregulated vs. downregulated genes (having a small tendency
towards downregulated genes). Notably, only 178 genes were differentially expressed
for Obs. 3: LEL-M 17 h vs. LEL-M 5 h, indicating a rapid upregulation of most
differentially regulated genes immediately after LEL. An overview over numbers of up-
and downregulated genes between time points is given in Table 3.1.
Obs.1 Obs.2 Obs.3
Direction LEL-M (5 h) LEL-M (17 h) LEL-M (17 h)
adj.P.Val of vs. vs. vs.
cut-off regulation TM (0 h) TM (0 h) LEL-M (5 h)
0.05 ↑ 1046 1525 110
↓ 1125 1575 68
0.01 ↑ 380 741 3
↓ 517 916 0
Table 3.1.: Differential gene expression in the LEL model (WG-DASL Assay). Num-
bers indicate the absolute quantities of genes with an logFC ≥ |1| and an
Benjamini-Hochberg adj.P.Val < 0.05 (0.01) for indicated observations.
↑: upregulated, ↓: downregulated.
As could be expected from previous qRT-PCR experiments of our group, inflammatory
genes such as CSF3, IL6, CXCL2 and IL8 were among the top upregulated genes,
with the expression of all four genes being significantly increased for both Obs.1 and
2. Additionally, the upregulation of other inflammatory genes such as MMP10, IRF7,
IL11, IL22, IL24, SERPINA3, CCL21 and CXCL2 indicated the initiation of a global
inflammatory response (Figure 3.3).
Overall, for the limited number of genes shown in Figure 3.3, the expression of many
genes was significantly differentially regulated for both observations, while only gene
RERGL was solely significant for Obs.1. However, several genes were only significantly
differentially expressed for Obs.2 (i.e. IL11, IL22, MME (also known as MMP12 ),
MMP3, IL24 ), thus showing a progression of the inflammatory response over the course
of the LEL model.
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At least some of these downregulated genes represent epithelium specific genes such
as Kreatin 20 (KRT20) and Polymeric immunoglobulin receptor (PIGR), reflecting a
degree of epithelial cell contamination of the microdissected LP compartment (page A-6
in the appendix). This was not preventable, as emerging crypts are not always
morphologically distinguishable from the LP in a given tissue section.
The full lists of all up- and downregulated genes for Obs.1, 2 and 3 of the WG-DASL
Assay can be found on pages A-22 ff. in the appendix.
In summary, the results of the microarray analysis showed the upregulation of expression
of genes involved in the initiation of an inflammatory response in the LEL model imme-
diately after the loss of the epithelial layer (LEL-M 5 h). This inflammatory response is
still present at LEL-M 17 h. Furthermore, the differential regulation of certain genes for
Obs.2 but not Obs.1 indicate a progression of the inflammatory response from LEL-M
5 h to LEL-M 17 h.
3.3. Validation of global gene expression data by
quantitative gene expression analysis using the
nCounter system
Before taking further analysis steps, the microarray results were validated via nCounter
technology (Nanostring, Seattle, WA, USA) by using the Human Immunology v2 kit,
consisting of 594 immunology-related human genes and 15 internal reference genes. At
the time of analysis, this kit among other predefined nCounter gene expression codesets
comprised the most comprehensive set of immune system associated genes.
In contrast to the WG-DASL Assay, the nCounter technology does not include a
preamplification step and thus can be seen as a more quantitative approach. As
the nCounter system like the WG-DASL Assay uses probes that only span 50 bps,
this technology is compatible with partially degraded RNA. For more details to the
nCounter Assay and a detailed comparison to the WG-DASL Assay, see subsection 2.4.2
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Figure 3.3.: Top 50 upregulated genes in the LEL model (WG-DASL Assay). Blue
dots indicate that the upregulation of the associated gene was significant
(adj.P.Val < 0.05) for both observations (Obs.1: LEL-M 5 h vs. TM 0 h,
Obs.2: LEL-M 17 h vs. 0 h), while red dots indicate significance only for
Obs.1 and green dots for Obs.2, respectively. Where two logFC values are
too close to each other to produce two readable gene names, only one gene
name is indicated randomly.
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on page 24.
Again, LP samples were collected by LMD at time points TM 0 h, TM 5 h, LEL-M
5 h and LEL-M 17 h. Samples were obtained by four independent experiments. TM
5 h was included in the nCounter Assay as a control for time-dependent, but LEL
independent upregulation of genes. This timepoint was omitted in the WG-DASL
Assay in favor of analyzing four replicates for each of the three time points investigated,
as the WG-DASL Assay has a capacity of 12 samples per run and possesses a limited
inter-assay quantification ability (due to its preamplification step).
For details regarding normalization of the nCounter Assay, see subsection 2.5.2 on
page 25.
In accordance with the WG-DASL Assay, hierarchical cluster analysis of the obtained
nCounter expression data sets demonstrated a clear distinction between TM and
LEL-M samples by two separate clusters as well as between LEL-M samples by two
second level clusters (Figure 3.4). In contrast to this differentiation, the similarity
of gene expression between TM time points was shown by their absent distinction
from each other. These results, together with the color distribution in the heatmap,
demonstrate the reproducibility of the nCounter gene expression results obtained in the
four independent experiments.
Table 3.2 shows the absolute numbers of significantly differentially regulated genes
(logFC ≥ |1|, adj.P.Val < 0.05): For Obs.1, 248 genes were differentially expressed.
This number decreased to 225 for Obs.2. Obs.3 yielded 87 differentially expressed
genes. Notably, in total mucosa, following 5 h of culture (TM 5 h) when com-
pared to TM prior to culturing (TM 0 h), the expression of only two genes, the
chemokine family members CXCR4 (logFC = 2.12) and PPBP (also known as CXCL7,
logFC = -2), changed significantly. In accordance with the high resemblance of the
gene expression profile between TM 0 h and TM 5 h, there was a high amount of
similarity of differentially expressed genes for Obs.1 and LEL-M 5 h vs. TM 5 h (Obs.4).
Many of the top upregulated genes in the nCounter Assay as i.e. IL6, IL8, CXCL2
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Figure 3.4.: Expression profile of nCounter gene expression data. Shown is a heatmap
based on z-score transformed expression values of all 579 genes of the
nCounter dataset for the time points TM 0 h, TM 5 h, LEL-M 5 h and
LEL-M 17 h. Columns have been reordered by hierarchical clustering (com-
plete linkage, Euclidean distance metrics). Colors indicate z-score values as
shown in the scale legend. Shown data was obtained in four independent
experiments (R1-R4), with tissue samples collected at different time points
within one experiment being obtained from the same specimen.
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Figure 3.5.: Top 50 differentially regulated genes in the LEL model (nCounter Assay).
Blue dots indicate that the upregulation of the associated gene was signif-
icant (adj.P.Val < 0.05) for both observations (Obs.1: LEL-M 5 h vs. TM
0 h, Obs.2: LEL-M 17 h vs. 0 h), while red dots indicate significance only
for Obs.1 and green dots for Obs.2, respectively. Where two or more logFC
values were too close to each other to produce readable gene names, only
one gene name is indicated randomly.
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Obs.1 Obs. 2 Obs.3 Obs.4
Direction LEL-M (5 h) LEL-M (17 h) LEL-M (17 h) LEL-M (5 h)
adj.P.Val of vs. vs. vs. vs.
cut-off regulation TM (0 h) TM (0 h) LEL-M (5 h) TM (5 h)
0.05 ↑ 93 95 47 78
↓ 155 130 40 141
0.01 ↑ 68 74 11 57
↓ 123 93 4 88
Table 3.2.: Differential gene expression in the LEL model (nCounter Assay). Numbers
indicate the absolute quantities of significantly differentially regulated genes
for indicated time point comparisons. logFC ≥ |1|, Benjamini-Hochberg
adj.P.Val as indicated. ↑: upregulated, ↓: downregulated.
and ICAM4 were also among the top upregulated genes of the WG-DASL Assay (see
Figure 3.5 and Figure 3.3). The full lists of all significantly differentially expressed
genes for Obs.1, 2 and 4 can be found on pages A-37 ff. in the appendix.
A comparison between both assays based on 565 common genes revealed a strong
overlap between assays (Figure 3.6). For Obs.1, 71 % of upregulated genes in the
WG-DASL Assay were also upregulated in the nCounter Assay, which increased to 96
% for downregulated genes. For Obs.2, this corresponded to an overlap of 80 % for
upregulated and 89 % for downregulated genes, respectively. Importantly, except gene
ATP-binding cassette sub-family B member 1 (ABCB1 ), which was downregulated
in the nCounter Assay, but upregulated in the WG-DASL Assay for Obs.1, no genes
were regulated in opposite directions between assays. A list of the genes that were
unidirectionally regulated in both assays can be found on page A-52 and A-53 in the ap-
pendix. Notably and in line with the results of the WG-DASL Assay (Figure 3.3), most
overlapping genes present for Obs.1 were also present for Obs.2, whereas overlapping
genes for Obs.2 had a tendency to be differentially expressed only for that observation.
In summary, based on 565 common genes, the high overlap in up- and downregulated
genes detected in the two different assays validated the initiation of the inflammatory
response and furthermore the characteristics (based on differentially regulated genes) of
this response in the LEL model at onset of inflammation.
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Figure 3.6.: Gene expression overlap between WG-DASL and nCounter Assay. Upregu-
lated (↑) and downregulated (↓) genes were defined by an logFC ≥ |1| and
an adj.P.Val < 0.05. The comparison includes only the common 565 genes
between assays (mapped by Gene ID annotation); (A) Obs.1, LEL-M 5 h
vs. TM 0 h: In total, 16% and 43 % of common genes were differentially
regulated in the WG-DASL and nCounter Assay, respectively. (B) Obs.2,
LEL-M 17 h vs. TM 0 h: In total, 23% and 40 % of common genes were
differentially regulated in the WG-DASL and nCounter Assay, respectively.
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3.4. The LEL model reflects inflammatory processes
as observed in intestinal inflammation in vivo
Following validation of the results of the WG-DASL Assay, I next determined whether
the LEL model reflects inflammatory processes as observed in intestinal inflammation
in vivo. For that purpose, the WG-DASL data sets of differentially regulated genes in
the LEL model were compared to a published analysis. In this publication, mucosa
samples from ulcerative colitis (UC) patients were compared to healthy mucosa samples
[Granlund et al., 2013].
The published analysis consists of several datasets, comparing colonic mucosa samples
from 20 healthy controls (NC, normal colon) and 37 patients with active UC. It has
to be taken into consideration, that in contrast to the LMD LP samples collected
during the LEL model, the samples of this analysis consisted of total mucosa. To
be able to compare the datasets, genes analyzed in both datasets were matched via
EntrezID annotation (being the only annotation given for the UC vs. NC dataset). This
procedure resulted in 18,047 common genes. Out of these common genes, a total of 733
genes were significantly differentially regulated in the WG-DASL Assay for Obs.1 with
an increase to 1310 genes for Obs.2, whereas 725 genes were differentially regulated in
the UC vs. NC dataset (adj.P.Val < 0.01).
The comparison of the expression of the common genes revealed a partial overlap
between the UC dataset and the LEL model, as can be seen in Figure 3.7. Based on
the differentially regulated genes in the LEL model, there was an 12 % overlap between
datasets in the upregulated genes for both Obs.1 and Obs.2, whereas the overlap in
downregulated genes decreased from 26 % to 21% for Obs.1 to Obs.2. Notably, 16
genes (4 % of 434 genes) that were downregulated in the LEL model for Obs.1, were
upregulated in the UC dataset, a number that increased to 31 (4 % of 736 genes) for
Obs.2, whereas no genes were upregulated in the WG-DASL Assay, but downregulated
in the UC vs. NC data set for Obs.1 and only 3 genes 0.4 % for Obs.2. A table with
all overlapping or differing genes can be found on pages A-54 to A-56 in the appendix.
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Generating 1000 random lists to exclude a false-positive overlap based on coincidence,
the overlap between both datasets was significant with an adj.P.Val of < 0.001, thus
indicating the physiological relevance of the LEL model.
Based on the assumption, that the LEL model reflects a ’normal’ acute inflammatory
response in contrast to the pathological chronic response seen in IBD patients, I next
compared genes that were near single-nucleotide polymorphisms (SNP) associated with
IBD as predicted by genome wide association studies (GWAS, Jostins et al. [2012])
with the WG-DASL dataset. For Obs.1, I found 16 and for Obs.2 27 genes that were
upregulated in the LEL model, but not in the UC vs. NC dataset [Granlund et al.,
2013]. A table of all identified genes and their corresponding SNPs can be found on
page A-57 in the appendix.
In summary, on a gene expression level, the LEL model partially reflects inflammatory
processes as observed in chronic intestinal inflammation in vivo.
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Figure 3.7.: Gene expression overlap between the LEL model and UC vs. NC dataset.
Overlap of upregulated (↑) and downregulated (↓) genes is based on 18,047
common genes between WG-DASL Assay (LEL model) and UC vs. NC
dataset [Granlund et al., 2013] for (A) Obs.1 (B) Obs.2. Cut offs: LogFC
≥ |1|; adj.P.Val < 0.01. NC: normal colon; UC: Ulcerative colitis
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3.5. Bioinformatic analysis indicates an initiation of
protein synthesis at the onset of inflammation in
the LEL model
In order to search for potential biological processes as well as upstream regulators
associated with the induction of an intestinal inflammatory response in the LEL model,
I next analyzed the WG-DASL data using the software Ingenuity Pathway Analysis
(IPA), a well known tool for pathway analysis. Further details regarding data input
and analysis can be found in subsection 2.5.5 on page 28.
As expected, many of the identified canonical pathways and biological functions
predicted to be activated were related to inflammation as i.e. ’IL-6 Signaling’, ’Acute
Phase Response Signaling’, ’IL-8 Signaling’ or ’Leukocyte Extravasation Signaling’
(Table 3.3), ’adhesion of blood cells’, ’stimulation of cells’ and ’chemotaxis’ (Table 3.4).
IPA also allows the prediction of upstream regulators and their activation state.
This analysis is based on (1) the overlap of differentially expressed genes in the
dataset with known target molecules of the particular upstream regulator and (2) the
differential expression of these target molecules in the dataset, respectively. In order
to be predicted as an upstream regulator, the gene encoding the upstream regulator
does not have to be differentially expressed in the dataset itself. The molecule types
with the highest predicted numbers of upstream regulators for both Obs.1 and Obs.2
were ’transcription regulator’, ’cytokine’, ’kinase’, ’other’ and ’growth factor’ (Table 3.5).
In search for potential mechanisms underlying intestinal inflammation, I observed that
predicted pathways such as ’FGF signaling’ or ’PI3K/Akt signaling’ are involved in
translational control. This finding was supported by predicted biological functions as
’cell proliferation’, known to depend on ongoing protein synthesis and ’phosphorylation
of protein’, a function that is known to positively control the activation state of many
translation regulators. Among predicted upstream regulators, the predominance of
activated growth factors as well as kinases involved in translation such as EIF2AK2
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and EIF2AK3 pointed toward the upregulation of translation. In contrast, known
translation inhibitors such as microRNAs were consistently predicted to be inhibited.
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Obs.1 Obs.2
LEL-M 5 h vs. LEL-M 17 h vs.
TM 0 h TM 0 h
Biological Function z-score adj.P.Val z-score adj.P.Val
1 cell survival 3.46 6.3E-11 2.91 2.8E-17
2 function of blood cells 3.16 4.9E-10 2.35 5.1E-19
3 survival of organism 3.06 8.1E-15 2.04 4.6E-22
4 function of leukocytes 3.02 2.6E-11 1.95 1.5E-19
5 cell viability 2.98 6.3E-11 2.78 7.5E-18
6 adhesion of blood cells 2.96 1.3E-06
7 stimulation of cells 2.90 1.2E-08 2.52 9.1E-16
8 function of phagocytes 2.68 1.3E-08 1.88 4.3E-17
9 homeostasis of blood cells 2.40 7.0E-09 2.79 2.1E-12
10 homeostasis of leukocytes 2.39 1.0E-08 2.72 2.9E-12
11 cellular homeostasis 2.39 1.9E-19 3.08 1.2E-21
12 Lymphocyte homeostasis 2.39 7.3E-09 2.72 1.4E-12
13 function of mononuclear leukocytes 2.38 3.1E-07
14 recruitment of cells 2.38 1.3E-10 2.03 2.4E-20
15 cell movement 2.21 1.1E-21 2.10 4.8E-39
16 invasion of cells 2.01 2.0E-14 2.94 1.5E-26
17 chemotaxis 1.89 6.4E-11 2.28 1.5E-20
18 homing of cells 1.87 8.3E-12 2.25 1.1E-21
19 chemotaxis of cells 1.77 1.7E-10 2.08 1.2E-19
20 cell movement of muscle cells 1.74 1.4E-07 2.44 1.3E-10
21 proliferation of cells 1.70 1.8E-24 2.11 5.4E-47
22 binding of DNA 1.65 2.8E-08 2.49 3.6E-10
23 ion homeostasis of cells 1.49 2.6E-09 2.07 7.3E-11
24 organization of cytoplasm 2.73 9.9E-11
25 organization of cytoskeleton 2.67 1.8E-10
26 growth of plasma membrane projections 2.37 7.8E-10
27 function of antigen presenting cells 2.25 1.8E-13
28 phosphorylation of protein 2.22 1.6E-11
29 adhesion of connective tissue cells 2.04 4.9E-10
1 organismal death -5.73 1.6E-15 -5.52 1.4E-23
2 morbidity or mortality -5.30 4.3E-16 -5.30 1.4E-24
3 Edema -2.86 6.8E-11 -2.66 5.1E-12
4 oxidation of fatty acid -2.24 1.3E-07
5 oxidation of lipid -2.17 1.2E-08
Table 3.4.: IPA Biological Functions in the LEL model (WG-DASL Assay). Shown are
IPA annotated biological functions with an absolute z-score of ≥ 2 (in at least
one observation) and a Fisher’s exact T-test adjusted P Value < 0.05. Rank
in table was defined by z-score in Obs.1 and secondly in Obs.2. A list with
all significantly enriched biological functions for all observations w/o z-score
cut-off can be found on page A-62 ff. in the appendix.
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LEL-M 5 h LEL-M 17 h LEL-M 17 h
vs. vs. vs.
TM 0 h TM 0 h LEL-M 5 h
Molecule Type All + - All + - All + -
1 complex 20 19 1 23 20 3 1 1 0
2 cytokine 43 42 1 47 45 2 6 5 1
3 enzyme 19 12 7 18 12 6 0 0 0
4 g-protein coupled receptor 6 6 0 6 6 0 0 0 0
5 group 31 28 3 32 29 3 3 3 0
6 growth factor 27 27 0 22 21 1 1 1 0
7 ion channel 3 1 2 4 2 2 0 0 0
8 kinase 40 38 2 44 42 2 1 1 0
9 ligand-dependent nuclear receptor 3 1 2 2 1 1 1 1 0
10 mature microRNA 1 0 1 4 0 4 0 0 0
11 microRNA 6 0 6 4 0 4 0 0 0
12 other 28 24 4 38 29 9 1 1 0
13 peptidase 4 4 0 7 7 0 0 0 0
14 phosphatase 5 1 4 4 1 3 0 0 0
15 transcription regulator 63 46 17 76 53 23 1 1 0
16 translation regulator 0 0 0 1 1 0 0 0 0
17 transmembrane receptor 26 23 3 29 25 4 2 1 1
18 transporter 4 3 1 5 4 1 1 0 1
Table 3.5.: IPA Upstream Regulator prediction in the LEL model (WG-DASL Assay).
Shown is the summary of the numbers of predicted upstream regulators (cat-
egorized by molecule type and observation) that had an absolute z-score ≥ 2
and a Fisher’s exact T-test adjusted P.Val. < 0.05. A full list of members of
the molecule type and their predicted activation can be found on page A-67
ff. in the appendix. +: upstream regulators predicted to be activated; -:
upstream regulators predicted to be inhibited.
3.6. Protein synthesis is rapidly upregulated at the
onset of intestinal inflammation
Given (1) the bioinformatic prediction of an upregulation of protein synthesis in the
LEL model and (2) lack of information on the regulation of protein synthesis in LP
cells in intestinal inflammation, I next investigated whether protein synthesis was
upregulated in the LEL model at the onset of inflammation.
One way to study protein synthesis in situ is the so called Click-It® technology,
where the alkyne analog of puromycin, Ortho-Propargyl-Puromycin (OPP), is rapidly
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incorporated into newly synthesized proteins by binding covalently to nascent polypep-
tide chains, a reaction which can subsequently be detected by a copper(1)-catalyzed
azide-alkyne cycloaddition. This method has so far only been applied in cell culture
experiments and animal models and was in the context of this thesis established for
human intestinal tissue. Please note, that if not specifically indicated otherwise, all
immunohistochemical stainings in this thesis were performed on formalin fixed paraffin
embedded (FFPE) tissue sections.
Remarkably, no OPP uptake and thereby protein synthesis was detectable in either
untreated total mucosa (0, 5 or 17 h) or DTT treated mucosa (TM 2 h) under the
experimental conditions employed (Figure 3.8). In contrast to TM mucosa, LEL
mucosa showed high levels of protein synthesis, which were visible immediately after
the first EDTA treatment (LEL-M 3 h), where approx. 5 % of all LP cells were OPP+,
increased to approx. 20 % at LEL-M 5 h and to 25 % at LEL-M 17 h. For details to
semi-quantitative analysis of OPP+ cells, see subsection 2.7.5 on page 31.
It is important to mention that in PBMCs, while they showed constitutive levels of
protein synthesis without the need for stimulation, treatment with EDTA did not lead
to an upregulation of protein synthesis (see page A-16 in the appendix). Additionally,
while tissue samples were routinely incubated in RPMI medium for OPP treatment,
incubation of LEL-M 5 h samples in HBSS, to rule out starvation effects, led to similar
results (data not shown).
To further exclude that the lack of protein synthesis as seen in TM 0 h samples was
caused by side-effects of surgery, Click-It® technology was performed on colon biopsies
from patients undergoing colonoscopy for colon cancer screening. In line with the
findings in TM 0 h samples, no constitutive protein synthesis was detected in these
samples (data not shown).
In order to identify the cell types showing enhanced protein synthesis in the LEL model,
immunohistochemical analysis was performed. This revealed that CD68+ macrophages
were among OPP+ cells (Figure 3.10). Remarkably, IgA+ cells were the cell population
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that did show the most intense OPP signal, while there was no protein synthesis
detectable in CD3+ T cells (see page A-17 and A-18 in the appendix). Other cell
populations were not investigated.
In summary, these findings show that the induction of the inflammatory response in the
LEL model was associated with the rapid upregulation of protein synthesis in LP cells
including macrophages and IgA+ cells.
3.7. The mTOR pathway is upregulated in
CD68+OPP+ macrophages at the onset of
inflammation
Regulation of protein synthesis is commonly associated with mTOR. The previously
performed IPA analysis identified upstream and downstream members of the mTOR
pathway in the top list of predicted pathways (PI3K/AKT signaling, see Table 3.3) and
predicted upstream regulators (EIF4E, see page A-9 in the appendix). To investigate
the role of the mTOR pathway in the LEL model, I first examined the expression of
mTOR via immunofluorescence. Indeed, mTOR was found to be strongly expressed
in CD68+OPP+ macrophages over the whole duration of the LEL model (Figure 3.9).
Given the high intensity of the mTOR signal in macrophages, all other cells appeared
mTOR− under the employed settings. Immunofluorescent staining of frozen sections
showed that CD68+ macrophages did express phospho-mTORSer2448 throughout the
model (see page A-13 in the appendix).
Interestingly, both mTOR and phospho-mTORSer2448 are concentrated in granular
structures in LP cells under homeostatic conditions (TM 0h). However, following LEL,
mTOR remained localized in these granular structures, although a distinct reduction
of these structures was observed, while phospho-mTORSer2448 revealed a more diffuse,
cytoplasmic staining pattern. Investigations to further characterize the subcellular
localization of mTOR, which has been tightly linked to its activation status [Betz and
Hall, 2013], are ongoing.
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In accordance with mTOR expression, ribosomal protein S6 (RPS6), a known mTORC1
downstream target, was expressed constitutively throughout the LEL model (see
page A-16 in the appendix). Phosphorylation of RPS6Ser235/236 however was only
upregulated after induction of inflammation by LEL, having its strongest expression
at LEL-M 4 h and showed a partial overlap with the OPP Click-It® signal. Among
cells that were strongly positive for phospho-RPS6Ser235/236 were also CD68+OPP+
macrophages (Figure 3.10).
In line with phosphorylation of RPS6Ser235/236, phospho-AktSer473 expression in cryo
sections was only detectable after the onset of inflammation, but not in homeostatic,
total mucosa (see page A-14 in the appendix).
Taken together, the results indicated that the upregulation of protein synthesis is asso-
ciated with the upregulation of the mTOR pathway at the onset of inflammation.
Figure 3.8. (preceding page): Mucosal protein synthesis in the LEL model. Rate of pro-
tein synthesis was determined via OPP Click-It® technol-
ogy. Results shown are from one representative experiment
out of three independent experiments. (A) Percentage of
OPP+ LP cells (red, left y-axis) and their pixel intensities
shown as a Tukey boxplot (right y-axis) as determined by
semi-automated particle analysis (for details see subsec-
tion 2.7.5 on page 31). A total of 1710 (± 351) cells were
analyzed on average (using two images from distant section
regions). All images were taken with the same microscope
settings using a 20x objective. (B) Immunofluorescent im-
ages used for semi-quantification of protein synthesis rates
(one of two analyzed images) is shown per time point).
*TH, Minimum pixel threshold for analysis
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Figure 3.9.: mTOR expression in CD68+ macrophages and its correlation to protein syn-
thesis in the LEL model. Rate of protein synthesis was determined via OPP
Click-It® technology. Results shown are from one representative experiment
out of three independent experiments.
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3.8. Upregulation of protein synthesis in CD68+
macrophages at the onset of inflammation is
controlled by mTORC1
Given the parallel upregulation of both protein synthesis and activation of the mTOR
downstream targets at the onset of inflammation, I next wanted to determine if the
protein synthesis was actually controlled by the mTOR pathway. The LEL model was
therefore performed in the presence of the mTORC1/2 inhibitor Torin1. The translation
elongation inhibitor cycloheximide was employed as a control. 250 nM Torin1 were able
to partially inhibit protein synthesis as indicated by a reduced OPP incorporation into
these cells as well as by an approx. 30 % decrease in overall percentage of OPP+ cells
(Figure 3.11).
Importantly, Torin1 significantly inhibited protein translation in CD68+ macrophages
but not in IgA+ cells (see Figure 3.12 as well as page A-17 in the appendix). As expected,
RPS6 phosphorylationSer235/236 was inhibited in LP cells including CD68+ macrophages
following Torin1 treatment, confirming that this phosphorylation event is regulated by
the mTOR kinase in the experimental system employed (Figure 3.12). In contrast,
overall RPS6 expression levels were not much affected by treatment with this inhibitor,
indicating that the decrease in RPS6Ser235/236 phosphorylation was not a consequence of
weaker RPS6 expression itself (see page A-16 in the appendix).
In summary, these findings suggest that the observed upregulation of protein synthesis at
the onset of inflammation is partially controlled by the activation of the mTOR pathway.
Figure 3.10. (preceding page): mTORC1 target phospho-RPS6 expression in CD68+
macrophages and its correlation to protein synthesis in
the LEL model. Rate of protein synthesis was evaluated
via OPP Click-It® technology. Results shown are from
one representative experiment out of three independent
experiments.
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Figure 3.11.: Impact of mTOR on regulation of protein synthesis in the LEL model.
The LEL model was performed in the absence or constant presence of
the mTORC1/2 inhibitor Torin1 (250 nM) or cycloheximide (100 µg/ml).
The rate of protein synthesis was evaluated at indicated time points via
OPP Click-It® technology. Results shown are from one representative
experiment out of three independent experiments. (A) Percentage of OPP+
LP cells (red, left y-axis) and their pixel intensities shown as a Tukey
boxplot (right y-axis). A small percentage of false-positive cells (indicated
by negative controls w/o OPP) was subtracted as background. Remaining
percentage of OPP+ cells in timepoint TM 5 h was only 0.36% and therefore
not plotted on boxplot. On average, 1690 (± 297) cells were analyzed per
time point. (B) Immunofluorescent images used for semi-quantification
(one of two analyzed images is shown per time point). The corresponding
negative controls can be found on page A-19 in the appendix.
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Figure 3.12.: Association of upregulation of protein synthesis with RPS6Ser235/236 phos-
phorylation in the LEL model. Rate of protein synthesis was determined
via OPP Click-It® technology). Specified inhibitors (250 nM Torin1 and
100 µg/ml cycloheximide) were present at all times. Results shown are
from one representative experiment out of three independent experiments.
(A) Semi-quantification of OPP intensity in CD68+ macrophages shown as
a Tukey boxplot. On average, 827 (± 194) cells were analyzed per time
point. (B) Immunofluorescent images used for semi-quantification.
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3.9. mTORC downstream targets are upregulated in
myeloid cells following their emigration out of
the lamina propria
In the recent sections, the impact of mTOR on the upregulation of protein synthesis in
LP cells including macrophages after the onset of inflammation was demonstrated in
situ. Mahida et al. [1997] showed that the loss of the epithelial layer is associated with a
massive emigration of macrophages, eosinophils, B cells as well as T cells out of the LP.
In addition, previous work from our group was able to show, that in the LEL model,
these emigrated cells show the induction of inflammatory markers [Szikszai et al., 2015].
In this section, the activation state of the mTOR pathway in mononuclear cells that
emigrated out of the LP (LPMCs) during the 12 h organ culture following LEL (LEL-M
5 - 17 h) was analyzed.
To this end, the phosphorylation levels of these emigrated intestinal LPMCs for
the downstream targets RPS6Ser235/236 (mTORC1), 4E-BP1Thr37/46 (mTORC1) and
AKTSer473 (mTORC2) as well as mTORSer2448 itself were investigated. Due to the
previously described methodological inability to isolate LPMCs from total mucosa
samples without their activation, nonstimulated allogeneic PBMCs were utilized to
define a basal phosphorylation level of the investigated targets (Figure 3.13).
Of the investigated CD45+ cell populations, LP myleoid cells (CD33+HLA-DR+)
showed the highest expression levels for phospho-mTORSer2448 as well as mTORC1
downstream targets. Notably, CD14− vs. CD14+ expression levels within the myeloid
cell population were slightly higher for both mTORC1 downstream targets, while they
were decreased for phospho-AKTSer473 expression (Figure 3.13).
CD19+CD20+ B cells did show an intermediate expression for phospho-mTORSer2448 as
well as mTORC1 downstream targets, while CD3+ T cells showed the lowest expression
for all targets investigated. LP B cells did on average express the highest levels of
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mTORC2 target phospho-AKTSer473 among investigated cell populations (Figure 3.13).
In comparison to PBMCs, the LPMCs expression levels of the investigated targets
showed differences based on cell population (Figure 3.13):
In CD33+HLA-DR+CD14+ myeloid cells, the expression of phospho-RPS6Ser235/236 was
on average nearly five fold higher in LPMCs compared to PBMCs, while phospho-
AKTSer473 expression was increased nearly three fold on average.
In CD19+CD20+ B cells, phospho-RPS6Ser235/236 expression was four fold higher in
LPMCs vs. PBMCs, while 4E-BP1Thr37/46 phosphorylation was three fold higher.
Remarkably, phospho-AKTSer473 was expressed seven fold higher in CD19+CD20+
LPMCs than PBMCs. There was no evident difference regarding the expression of
phospho-mTORSer2448 based on cell origin.
Notably, there were no reproducible differences between PBMCs and LPMCs phospho-
rylation levels in CD3+ T cells for any of the targets investigated.
In summary, the observed phosphorylation levels of mTORC downstream targets in
LPMCs vs. PBMCs indicated the activation of the mTOR pathway in myeloid as well
as B cells, while this was not evident for T cells. Note, however, that there are several
distinct phosphorylation sites for the investigated targets which were not investigated.
To determine the responsiveness of the different LP cell populations towards mTOR
inhibition, the phosphorylation state of the downstream targets after the constant
presence of 250 nM or 1 µM Torin1 throughout the LEL model was investigated
(Figure 3.14). As in in situ experiments, cycloheximide was used as a control; however,
given the longer presence of the inhibitors compared to previous experiments, 10
µg/ml instead of 100 µg/ml cycloheximide were employed to prevent the induction of
apoptosis. Please note, that 10 µg/ml were still sufficient to suppress protein synthesis
at LEL-M 5 h in situ (data not shown).
Expression of the phosphorylation state of mTOR downstream targets as well as mTOR
itself was investigated as in Figure 3.13. As can be seen in Figure 3.14, the lower dose
of Torin1 (250 nM) was already within the saturation area, as the higher dose could not
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Figure 3.13.: Expression of mTOR downstream targets in emigrated LPMCs in the LEL
model. LPMCs were isolated at LEL-M 17 h. As a comparison, allogeneic
PBMCs from healthy donors were stained for same markers as LPMCs
(red). CD19+CD20+ cells were identified using a common fluorochrome
channel. Shown are the results of four independent experiments. The line
indicates the median of the replicates.
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increase the effects seen on any of the investigated downstream targets. The calculated
percentages below are therefore referring to the effects of the lower dose. Note, that
there was no reproducible effect of Torin1 on phospho-mTORSer2448 expression in any
of the investigated cell populations.
CD33+HLA-DR+ myeloid cells were the cell population which was most responsive
towards Torin1 mediated mTOR inhibition: Phospho-RPS6Ser235/236 expression was
decreased by an average of 80 %, while the expression of phospho-4E-BP1Thr37/46 was
even reduced by 90 % in the presence of Torin1. While there was no difference in re-
sponsiveness in the investigated myeloid subpopulations towards mTORC1 downstream
targets, phospho-AKTSer473 expression was decreased by 47 % in CD14+, but by only
35 % in CD14− myeloid cells.
In CD19+CD20+ B cells, the expression of the two investigated mTORC1 targets
showed a similar decrease of 68-69 % on average. The reduction of phospho-AKTSer473
expression in the presence of Torin1 varied to some extent with an average decrease of
40 %.
Finally, CD3+ T cells did show the lowest response towards Torin1 mediated mTORC1
inhibition with a 25 % decrease of phospho-RPS6Ser235/236 expression, although Torin1
was able to decrease the expression of phospho-4E-BP1Thr37/46 by 77 %. Phospho-
AKTSer473 expression in this cell population was not affected by Torin1.
Taken together, the results showed that Torin1 mediated inhibition had most impact on
mTORC1 targets and that the myeloid cell population overall was the cell population
most affected by this inhibition. These findings were in line with the ability of Torin1
to suppress overall phospho-RPS6Ser235/236 expression in situ. Furthermore, the high
responsiveness of the myeloid cell compartment in comparison to the other investigated
cell populations stands in accordance with the high expression of mTOR solely in CD68+
cells in situ.
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Figure 3.14.: Effect of mTOR inhibition on emigrated LPMCs in the LEL model. LPMCs
were isolated at LEL-M 17 h. Indicated inhibitors were present at all times
during the performance of the LEL model. CD19+CD20+ cells were iden-
tified using a common fluorochrome channel. Shown are the results of
four independent experiments. Absolute MFI expression values of LPMCs
in the absence of an inhibitor of the same experiments are shown in Fig-
ure 3.13 and were set as 100 % expression in this figure. The line indicates
the median of the replicates.
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3.10. mTOR differentially regulates the secretion of
inflammatory mediators during the initiation of
an inflammatory response in the LEL model
Finally, to determine the functional impact of mTOR pathway activity on inflammtory
effector functions of LP cells, the effect of Torin1 exposure on secretion of inflammatory
cytokines and chemokines was analyzed. For this purpose, the LEL model was performed
in the absence or presence of 250 nM Torin1 or 10 µg/ml cycloheximide. Supernatants
were collected after 12 h of organ culture (LEL-M 17 h) and subjected to Luminex®
multiplex analysis. Cytokines were selected for analysis based on the upregulation of
corresponding genes in the LEL model. In addition, the secretion levels of IL-18 and
MIF, cytokines constitutively expressed in the LP and secreted upon stimulation, were
investigated. As shown in Figure 3.15, Torin1 treatment resulted in a 26 % - 58 % inhi-
bition of all chemokines investigated except for IL-8, which together with the cytokines
IL-6, IL-1β and ICAM-1 provided inconclusive results. IL-18 and VEGF secretion levels
were both decreased by approx. 50 % upon Torin1 treatment. In contrast, M-CSF and
MIF secretion levels were upregulated by 10 % and 30% , respectively, after exposure
to Torin1. The mTOR inhibitor did not affect the secretion levels of CD14, CD163 and
MMP12 (see page A-21 in the appendix).
In summary, these results demonstrate that mTOR controls the secretion of chemokines
during the initiation of the inflammatory response in the LEL model. However, the
upregulation of two pro-inflammatory cytokines after Torin1 treatment suggest that the
mTOR pathway has an bidirectional role in the mediation of the inflammatory response
in the LEL model.
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Figure 3.15.: Impact of mTOR on the secretion of soluble factors after the onset of in-
testinal inflammation in the LEL model. At LEL-M 5 h, defined tissue
punches were incubated for 12 hours. Supernatants were then subjected to
Luminex® multiplex analysis. Graphs show relative expression values with
LEL-M 17 h without inhibitor set to 100 %. Inhibitors (250 nM Torin1, 10
µg/ml cycloheximide) were present throughout the model. The line indi-
cates the median of the replicates. The corresponding absolute expression
values can be found on page A-20 in the appendix.)
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Inflammation is commonly defined as an adaptive response to infection or tissue damage
and is thought of having evolved in order to ultimately restore homeostasis [Medzhitov,
2008]. However, if this acute inflammatory response is not able to eliminate the ini-
tial cause of inflammation, i.e. because of genetic variants in the host or the severity
of inflammation, the initially controlled inflammation persists in a then uncontrolled,
pathological and chronic manner. In order to deepen our understanding of chronic
inflammatory diseases such as IBD, it is essential to understand the mechanisms of
the inflammatory response at its early time points as well as the reasons why in some
individuals the acute inflammatory response fails to restore homeostasis and thus be-
comes chronic. In the intestine, where immune cells such as myeloid cells are known to
be hyporesponsive under homeostatic conditions, appropriate experimental models for
studying early inflammatory events in these cells are limited and thus little is known as
to why and how these cells undergo activation.
In this thesis, I sought to understand the early molecular mechanisms underlying the
activation of lamina propria (LP) cells, in particular immune cells, in an acute intestinal
inflammation. To address this, first, the LEL model was validated as a physiological
appropriate and relevant acute inflammation model by global gene expression analysis
in comparison to existing IBD patient data. Second, the inflammatory response as ini-
tiated by the LEL model was characterized by the identification of canonical pathways,
biological functions and potential upstream regulators by means of Ingenuity Pathway
Analysis. Third, a rapid increase in protein synthesis was identified as an initial in-
flammatory process in LP immune cells and it was shown that this phenomenon was
associated with the upregulation of the mTOR pathway. Fourth, by employing func-
tional studies, it was demonstrated that the increased protein synthesis was partially
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mediated by an upregulation of the mTOR pathway in LP cells, in particular myeloid
cells. Finally, the investigation of the contribution of the mTOR pathway to the induc-
tion of the inflammatory response in these cells led to the observation of a bifunctional
role of mTOR with both pro- and anti-inflammatory aspects.
4.1. The LEL model as a tool to study initial
intestinal inflammation
Currently, the regulation of intestinal inflammatory events is mostly studied employing
murine models. Models in the murine system possess a common genetic and environmen-
tal background between subjects and offer a broad spectrum of experimental approaches.
Yet, the immune systems of mouse and man are clearly dissimilar, both in general and
particular with regard to the intestine [Gibbons and Spencer, 2011; Mestas and Hughes,
2004; Zschaler et al., 2014]. Human studies are often limited to first isolating cells and
then stimulating them ex vivo, which takes these cells out of their natural environment.
In this thesis, a human organ culture model, the LEL model, was characterized as a tool
to study the process of early acute inflammation in LP (immune) cells of the human
intestinal mucosa.
To investigate, whether earlier results of our group regarding the upregulation of pro-
inflammatory cytokines in the LEL model reflected the initation of a global inflammatory
response, first, global gene expression analysis from LP cells isolated by laser-capture
microdissection (LMD) was performed. The data generated represents the first global
gene expression analysis of LP samples existing under homeostatic (and uninflamed)
conditions in situ. All published gene expression data of intestinal cells so far were
either derived from total mucosa or LPMCs isolated not only by enzymatic digestion
but also release of epithelial cells by EDTA treatment [Rogler et al., 1998]. In line
with the results of this thesis, LPMCs isolated by the former protocol from healthy
mucosa express inflammation-associated molecules (e.g. CD14, CD86), which are not
expressed by these cells under homeostatic conditions in situ (Rugtveit et al. [1997] and
unpublished data). These findings indicate that these cells do not remain in a resting
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state upon using such isolation methods.
The induction of a global intestinal inflammatory response in the LEL model
The global gene expression analysis in accordance with the markers investigated previ-
ously, showed the induction of a global inflammatory response after loss of the epithelial
layer (LEL-M 5 h and 17 h), evident by the following findings:
(1) Pro-inflammatory genes were upregulated, i.e. IL6, IL8, ATF3 (Activating Tran-
scription Factor 3), CXCL2, CCL21 and CSF3 [Gruys et al., 2005].
(2) Many pro-inflammatory pathways and functions were predicted to be activated
(pathways: ’IL-1 Signaling’, ’IL-6 Signaling’, ’IL-8 Signaling’, ’Acute Phase Response
Signaling’, ’Leukocyte Extravasation Signaling’, ’B Cell Activating Factor Signal-
ing’ and ’LPS/IL-1 Mediated Inhibition of RXR Function’,...; Biological Functions:
’function of blood cells’, ’stimulation of cells’, ’function of leukocytes’,’adhesion of
blood cells’, ’invasion of cells’, ’chemotaxis’, ’function of antigen presenting cells’,...).
(3) Pro-inflammatory cytokines among predicted upstream regulators were predicted
to be activated, while anti-inflammatory cytokines such as IL1RN and IL10 were
predicted to be inhibited.
The inflammatory response as observed in the LEL model was very similar between
observations (Obs.1: LEL-M 5 h vs. TM 0 h; Obs.2: LEL-M 17 h vs. TM 0 h; Obs.3:
LEL-M 17 h vs. LEL-M 5 h), although there also existed differences: Genes, whose
expression was highly upregulated for Obs.1, but to a lower extent for Obs.2, mainly
included early response mediators as the IFN-γ regulator IRF7 (known to be repressed
by nonphosphorlyated 4E-BP1, [Colina et al., 2008]) and NR4A1 (nuclear receptor
subfamily 4, Group A, Member 1). NR4A1 (also known as NUR77) encodes a protein
involved in TLR-IL1R signalling by interacting with TRAF6. Variants of the NR4A1
gene resulting in lower protein expression are associated with a higher risk for IBD.
Accordingly, deficiency in NUR77/NR4A1 expression increases the susceptibility of
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mice to DSS-colitis [Wu et al., 2016].
In contrast, several anti-inflammatory mediators were upregulated solely for Obs.2, one
of which is the IL1 receptor antagonist IL1RN (also known as IL1RA). The importance
of the anti-inflammatory role of IL1RN has been indicated in intestinal inflammation
by the spontaneous development of colitis in Rag2−/−Il1rn−/− mice [Akitsu et al., 2014].
The role of IL1RN, which was upregulated in the UC vs. NC dataset of Granlund et al.
[2013], in human chronic intestinal inflammation is less clear, as several studies came
to contradicting conclusions regarding the association of IL1RN mutations with IBD
depending on the ethnic background in the group investigated [Craggs et al., 2001;
Daryani et al., 2015; Lopez-Hernandez et al., 2015; Mittal et al., 2005]. Remarkably,
IL1RN was predicted to be an inhibited upstream regulator by IPA, indicating potential
posttranscriptional regulation of its expression.
The physiological relevance of the LEL model
The comparison of the gene expression data as obtained in the LEL model with the
Granlund et al. [2013] analysis of gene expression data from UC vs. NC mucosa revealed
a significant overlap (adj.P.Val < 0.001) between both data sets and thus supports the
physiological relevance of the LEL model (see Figure 3.7 on page 49).
A complete overlap could not be expected, due to the following reasons:
(1) The LEL model reflects the earliest stages of acute intestinal inflammation, whereas
UC mucosa usually represents chronic stages.
(2) UC patients receive anti-inflammatory treatment that affects their gene expression
levels.
(3) The UC vs. NC datasets are based on gene expression profiling of biopsies consisting
of total mucosa, but not on the compartment-specific analysis of LP.
(4) Recruitment of immune cells from the peripheral blood to the LP cannot occur in
the LEL model.
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(5) The inflammatory response in UC patients may be dysregulated due to genetic
variants identified to be linked to IBD by GWAS studies [Jostins et al., 2012].
The clinical relevance of genes observed to be differentially regulated in the LEL model
vs. UC needs to be further explored, in particular with regard to initial mucosal
inflammatory processes. Notably, a potential involvement of some of these genes in
human intestinal inflammation in vivo is suggested by the fact that they have been
prioritized as key genes linked to IBD susceptibility loci as identified by a GWAS
[Jostins et al., 2012]. One of these genes, which has not been characterized in UC
before and may hence be interesting for further investigations is FOSL1, a mem-
ber of the AP1 family of transcription factors. Its overexpression in mice was shown
to have a beneficial effect on DSS-induced colitis [Karin et al., 1997; Takada et al., 2010].
Additional evidence for the physiological relevance of the LEL model exists since many
of the upregulated pathways observed here are also associated with IBD pathogenesis
such as ’IL-8 signaling’, ’HMGB1 Signaling’, ’Wnt/Ca+ pathway’ [Mazzucchelli et al.,
1994; Hu et al., 2015; Serafino et al., 2014].
Reflection on the potential of the LEL model to study intestinal inflammation
The potential of the LEL model lies within its possibility to study molecular mechanisms
underlying the initiation of an inflammatory response in human LP cells during the
very first hours. In particular, it allows to study the switch from a hyporesponsive to
an inflammatory state in resident LP cells.
While the initiation of inflammation with the treatment of EDTA is obviously artificial,
the duration of the EDTA treatment itself is short (3x 30 min with intermittent
washing) and inflammation is initiated rapidly.
EDTA as a calcium chelator leads to the detachment of the epithelial layer by removing
the tight junctions of the epithelium. Thus, in contrast to DSS-induced colitis, where
epithelial cells undergo necrosis, the epithelial cells themselves remain intact. As they
are removed by washing steps in between EDTA treatments and because of the high
volume/tissue ratio of the employed solutions, the influence of potential secreted factors
75
4. Discussion
by the epithelium on LP cells is limited. Analysis of epithelial cells, isolated prior to
and after detachment, did not reveal major changes in gene expression levels (nCounter
Assay, data not shown), providing further evidence speaking against their impact on
the induction of the intestinal inflammation as observed in the LEL model. Studies
regarding the protein expression levels of the epithelium in the LEL model should be
undertaken in the future.
The possibility of EDTA causing the inflammatory response in the LEL model
cannot be completely ruled out. However, the treatment of PBMCs with EDTA
does not lead to increased levels of investigated cytokines IL6, IL8, IL1B and IL23A
[Schröder-Braunstein et al., 2014]. Additionally, protein synthesis, as detected via
OPP Click-It® technology, was not increased in EDTA treated PBMCs vs. HBSS
treated PBMCs (see Figure A.12 on page A-16 in the appendix). Also, being a
calcium chelator, EDTA rather leads to a decreased inflammatory response as calcium
is needed for the activation of many inflammatory pathways i.e. the complement system.
Difficulties of the LEL model consist - as in all human models - of variances between
individuals based on different genetic and environmental backgrounds, as well as age
differences. Furthermore, in comparison to murine models, the possibilities of performing
functional studies in the LEL model are limited, although possible, as was shown in this
thesis.
Importantly, as the LEL model is an ex vivo organ culture model, investigations are
focused on resident LP cells, since a recruitment of cells from the circulation is not
possible. There is an ongoing debate, whether resident LP cells are capable of mounting
an inflammatory response or if this event is mediated completely by the recruitment
of circulatory immune cells [Mowat and Agace, 2014]. Utilizing the LEL model, here
it was demonstrated that a vigorous inflammatory response indeed can be initiated in
human resident LP cells. This finding was not totally unexpected, given that these cells
function as the first line of defense.
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Experimental and bioinformatic challenges and considerations
During LMD sample collection, the RNA in the LP samples was partially degraded as
indicated by a RNA integrity number (RIN) < 7. LMD is a time consuming process,
a factor that negatively affects RNA integrity. Even RNA isolation of whole tissue
sections immediately after their preparation without prior LMD did not result in
enhanced RNA quality (data not shown), leading to the conclusion that the RNA
in the tissue was already degraded prior to sectioning. LP consists of loose tissue,
making it more vulnerable to RNA degradation by extracellular RNases in comparison
to the epithelium, where the RIN remained above 7 even after LMD (data not shown).
Alternatively, the observed RNA degradation could represent side-effects of surgery. To
my knowledge, there are no publications available that specifically address LP RNA
quality, although two recent publications showed the tendency to RNA degradation in
total colonic mucosa tissue even if mucosal samples were flash frozen immediately after
resection [Heumuller-Klug et al., 2015; Bao et al., 2013].
Fortunately, the low RNA quality had no effect on the reliability of the WG-DASL
Assay, as this assay allows the analysis of partially degraded RNA and is even com-
patible with RNA isolated from FFPE tissue, which is undergoing a much more severe
degradation than the flash frozen samples used in this thesis.
Among the top downregulated genes in the WG-DASL and nCounter Assay, there
were also known epithelium associated genes as KRT20 and PIGR [Uhlen et al., 2015],
indicating epithelial contamination in the LP samples. This was most likely caused by
morphologically not distinguishable layers of evolving crypts beneath the microdissected
LP. The downregulated genes were still included in the pathway analysis of IPA in order
to gain a broader spectrum of potentially involved pathways and an indication towards
their activation state. As many genes are expressed in both epithelium and LP, it was
not possible to filter out epithelium-specific genes.
Regarding the robustness of the predicted results of the pathway analysis, a main lim-
itation in general is that the prediction is limited to known pathways and the extent
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of findings in the background database. Pathways involving hotspot research areas as
cancer - filtered out in my analysis - have a higher chance of being detected in contrast
to research areas that do not receive such broad attention or are difficult to access due to
i.e. methodological reasons. Finally, if pathways involved in similar biological processes
regulate overlapping sets of genes, they will both be detected and thus can lead to ’false-
positive’ conclusions. Finally, IPA is based on transcription levels only and remains a
bioinformatic analysis.
4.2. The rapid upregulation of protein synthesis in
the LEL model
In line with the high level of upregulation of gene expression at the onset of inflammation
in the LEL model, the majority of predicted transcription factors known to positively
regulate transcription, were predicted to be activated.
Interestingly, among upregulated genes, not many were explicitly associated with
active translation. However, many of the predicted pathways, functions and upstream
regulators were in some way or other associated with upregulated protein synthesis,
thus indicating potential regulation of translation factors on a post-transcriptional
level. For pathways, these were ’HMGB1 Signaling’, ’FGF Signaling’, ’PI3K/AKT
Signaling’. Functions relying on anabolic events predicted to be activated were ’cell
survival’ and ’proliferation of cells’, while functions involved in catabolism as ’oxidation
of fatty acid’ and ’oxidation of lipid’ were predicted to be inhibited. In line with these
results, miRNAs among predicted upstream regulators were uniformly presumed to be
inhibited. Additionally, the only predicted translation factor, EIF4E, was presumed to
be activated. Furthermore, many of the kinases predicted to be activated are actually
involved in protein synthesis and ’phosphorylation of protein’ was predicted as an
activated function for Obs.2.
In accordance with this indicated potential regulation of protein synthesis on a post-
transcriptional level, preliminary mass spectrometry results of LMD LP samples showed
an enrichment in proteins which have RNA binding capacity (data not shown).
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In this study, it was shown for the first time that - under the experimental conditions
employed - constitutive protein synthesis in both LP and epithelium in total human
colonic mucosa is low under homeostatic conditions by utilizing OPP Click-It®
technology. In comparison, PBMCs showed a high level of constitutive protein synthesis
without prior stimulation in the same experimental setting (see Figure A.12 on
page A-16 in the appendix). In contrast, the observed ability of resident LP cells to
rapidly upregulate protein synthesis after LEL demonstrated that these cells despite
their anergic state under homeostatic conditions, are able to rapidly mount a vigorous
response at the onset of inflammation.
In humans, protein synthesis under inflammatory conditions in the human intestine has
so far only been investigated in total mucosa of IBD patients, but not specifically in the
LP and under acute inflammatory conditions. Recently, Liu et al. [2012] introduced
the in this thesis utilized OPP Click-It® technology. In accordance with the findings
observed in this thesis, Liu et al. [2012] found no active protein synthesis in the LP in
the small intestine of rats under homeostatic conditions. In contrast to the findings of
this thesis, the group found positively stained OPP Click-It® positive cells in the same
intestinal region within crypts and at the base of intestinal villi. However, in addition
to investigating a different intestinal region in a different organism, they injected 100
µl of 20 mM OPP intraperitoneally and incubated for 1 h before tissue harvesting,
whereas here, a 1000 fold lower dose (20 µM) was employed with an incubation period
of only 30 min. It is therefore possible that ongoing protein synthesis in the epithelium
in human TM samples investigated in this thesis was below the detection limit. The
inability to detect protein synthesis in the epithelium in the conducted experiments,
despite the known high turnover rates in this compartment [Lipkin et al., 1963], sets the
relative level of initiated protein synthesis in the LP after LEL into a new perspective.
In accordance with the observation of this thesis, Liu et al. [2012] after investigating
protein expression in rat liver, kidney and spleen, found the highest expression in
hepatocytes and spleen, whereas protein synthesis in the homeostatic small intestine
was comparatively low.
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The possibility of several other factors being responsible for both lack of protein
synthesis under homeostatic conditions as well as its induction after LEL by EDTA
treatment were ruled out by a series of control experiments.
(1) The positive correlation between the observed OPP Click-It® signal and level of pro-
tein synthesis was demonstrated by the ability of the translation elongation inhibitor
cycloheximide to almost completely suppress it.
(2) Side-effects of surgery were ruled out by the absence of detectable protein synthesis in
biopsies taken from healthy individuals undergoing a routine endoscopic procedure.
(3) ’Starvation-nutrition’ induced protein synthesis, caused by the necessary soberness
of patients before medical procedure and the subsequent presence of nutrition during
OPP treatment performed in RPMI medium, were excluded by the following control
experiments: On the one hand, TM punches failed to exhibit an OPP Click-It®
signal after incubation in either HBSS or RPMI medium for 3 h. On the other hand,
an induction of protein synthesis was detectable, even if OPP treatment of the sample
at LEL-M 5 h was performed in HBSS instead of RPMI medium. Accordingly,
previous studies have shown that the intestine is not very sensitive to short term
starvation [Adegoke et al., 1999].
(4) EDTA itself as the inducer of protein synthesis rather than the LEL caused by the
EDTA treatment was ruled out by the lack of significant difference in the achieved
OPP Click-It® signal in PBMCs following their incubation in either EDTA/HBSS,
HBSS or RPMI medium, respectively.
4.3. The mTOR pathway
mTOR is known to represent a master regulator of both transcription and translation.
Whereas the pathway itself with an activation z-score of 1.3 for Obs.2 was not among
the predicted activated pathways in IPA and the majority of its known members
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not differentially regulated in the LEL model, there was substantial evidence for an
involvement of the mTOR pathway in the LEL model on the level of gene expression:
mTOR is known to phosphorylate and inactivate translation inhibitor 4E-BP1 upon its
activation. Accordingly, 4E-BP1 target IRF7 was among the top 50 upregulated genes
for Obs.1 in the LEL model [Colina et al., 2008]. Furthermore, expression of translation
initiator EIF4E, known to bind to and be inhibited by hypophosphorylated 4E-BP1,
was induced after the onset of inflammation and among predicted activated upstream
regulators.
Finally, RERGL, a paralog of RHEB and the only gene significant for Obs.1, but not
Obs.2 among the top 50 upregulated genes, encodes a protein that is required for
mTORC1 activation on the lysosomal membrane [Kim et al., 2008].
Furthermore, the induction of the mTOR pathway in the LEL model was sug-
gested by the predicted activation of (1) mTOR activating upstream pathways
’PI3K/AKT’, ’Protein Kinase A’, ’HMGB1’ and ’iNOS’ signaling [Nobukuni et al., 2005;
de Joussineau et al., 2014; Yang et al., 2012; Lopez-Rivera et al., 2014] and (2) posi-
tively regulated mTOR downstream pathways such as ’FGF’ and ’WNT’ signaling [Mat-
suo et al., 2007; Inoki et al., 2006].
Finally, the serine kinase IKBKB, a major downstream target of the TNF-α signaling
pathway and activator of mTOR signaling kinase activity (through suppression of the
mTOR inhibitor TSC1 [Lee et al., 2007]), is the predicted top upstream regulator among
the group kinases for both Obs.1 and Obs.2.
4.3.1. The activation of the mTOR pathway in the LEL model
CD68+ macrophages - under the employed conditions - exclusively and strongly express
mTOR throughout the LEL model. This is in line with the results of Latella et al. [2013],
who showed the expression of total mTOR at the apical border of the murine colonic
LP in healthy control mice, an area almost exclusively populated by macrophages, thus
confirming my results both regarding cell type specificity and constitutive expression of
mTOR. Accordingly, the importance of mTOR signaling in myeloid cells in inflamma-
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tory processes has been shown by several studies [Schmitz et al., 2008; Weichhart et al.,
2008; Byles et al., 2013].
mTOR localization in macrophages
The subcellular localization of mTOR has been tightly associated with its activity,
with a lysosomal localization being required for its activation by phosphorylation [Betz
and Hall, 2013]. Interestingly, immunohistological analysis demonstrated that mTOR
as well as phospho-mTORSer2448 are concentrated in granular structures in LP cells,
in particular CD68+ macrophages, under homeostatic conditions (TM 0 h). Following
LEL, mTOR remained localized in granular structures, although a distinct reduction
of these structures was observed, while phospho-mTORSer2448 revealed a more diffuse,
cytoplasmic staining pattern. In line with this finding, mTOR, after phosphorylation
on the lysosomal membrane, has been shown to translocate to the cytoplasm where it
apparently retains activity [Rosner and Hengstschläger, 2012; Zhou et al., 2015; Betz
and Hall, 2013]. Ser2448 represents one of four currently known phosphorylation sites
of mTOR, whose exact function still remains to be defined [Chiang and Abraham, 2005;
Acosta-Jaquez et al., 2009]. Phosphorylation of mTORSer2448 has been shown to be
mediated by the p70S6 kinase, a downstream target of mTOR. However, mTORSer2448
phosphorylation in emigrated LPMCs was not significantly inhibited in the presence of
the mTORC1/2 inhibitor Torin1, suggesting that it may be regulated independently of
mTOR activity. Further studies are needed to fully characterize the mTOR subcellular
localization in LP cells in the LEL model, which may provide crucial information on the
regulation of mTOR activation and function under homeostatic and inflamed conditions
in these cells.
Upregulation of the mTOR pathway in myeloid cells
An upregulation of the mTORC1 complex at the onset of inflammation in the LEL
model was indicated by an increased phosphorylation of the mTORC1 downstream
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target RPS6Ser235/236 in both Obs.1 and Obs.2. This upregulation of RPS6 phospho-
rylation was almost completely inhibited in the presence of the mTORC1/2 inhibitor
Torin1, clearly indicating that this phosphorylation event is controlled by mTOR in
LP cells. Among phospho-RPS6+ cells, as observed in LEL-M tissue in situ, were also
CD68+ macrophages. In line with this result, RPS6Ser235/236 phosphorylation levels
were also increased in emigrated macrophages when compared to PBMC. Both findings
consistently point toward the activation of the mTOR pathway during the initiation
of an inflammatory response in this cell population. Importantly, many macrophages
revealed a simultaneous upregulation of phospho-RPS6Ser235/236 and protein synthesis
at LEL-M 5 h and 17 h when compared to TM 0 h. The participation of the mTOR
pathway activation in the upregulation of protein synthesis in this cell population was
demonstrated by Torin1 treatment, which not only almost completely prevented the
upregulation of RPS6Ser235/236 phosphorylation in macrophages in situ and following
emigration out of the LP, but also partially inhibited protein synthesis in situ.
Although flow cytometric analysis showed that the mTORC1 downstream target
4E-BP1Thr37/46 phosphorylation, especially in myeloid cells, was sensitive to Torin1
inhibition, it also revealed the similarity of 4E-BP1Thr37/46 phosphorylation levels
between emigrated LPMCs and PBMCs. This finding stands in contrast with the
increase in RPS6Ser235/236 phosphorylation in emigrated LPMCs vs. PBMCs. The
phosphorylation state of 4E-BP1Thr37/46 could not be investigated in situ due to the
inability to detect a specific signal in neither FFPE nor cryo sections, which might -
besides the lack of a suitable antibody for this technique - be due to the kinetics of
4E-BP1Thr37/46 phosphorylation. As therefore the expression of phospho-4E-BP1Thr37/46
levels in resting LPMCs in situ are currently unknown, they may or may not correspond
to the detected phosphorylation levels in PBMCs. A finding in favor of the latter is
the detected constitutive protein synthesis in resting PBMCs in contrast to its lack in
resting LP cells. Furthermore, the strong upregulation of IRF7 expression, known to be
repressed by active, non-phosphorylated 4E-BP1 in mice [Colina et al., 2008], indicated
the induction of 4E-BP1 phosphorylation at the onset of inflammation in the LEL model.
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In line with an activation of the mTORC2 complex in LP macrophages during the initia-
tion of an intestinal inflammatory response, phosphorylation of AKTSer473 was increased
in the latter cell population in situ as well as in emigrated HLA-DR+CD33+CD14+
LPMCs vs. PBMCs. Further experiments are necessary to understand the observed
differences of sensitivity towards Torin1 mediated AKTSer473 dephosphorylation in
CD14+ vs. CD14− cells.
The mTOR pathway is upregulated in B Cells, but not in T cells in the LEL
model
Previous experiments from our group and others already showed that resident LP T
cells are hardly activated in both the LEL model or intestinal inflammation [Sido et al.,
2008, 2000; Qiao et al., 1991, 1993; Pirzer et al., 1990; De Maria et al., 1993]. In line
with these results, none of the investigated mTOR downstream targets were highly
expressed in emigrated CD3+ LPMCs or upregulated in comparison to CD3+ PBMCs,
suggesting that the mTOR pathway is not upregulated in this cell population at the
onset of inflammation under the conditions employed.
Although the IgA+ cell population showed the strongest induction of protein synthesis
at the onset of inflammation and B cells have been implicated in mTOR dependent
activation [Limon and Fruman, 2012], CD19+CD20+ emigrated LPMCs vs. PBMCs
did, in comparison to macrophages, only show a moderate upregulation of either of the
two mTORC1 downstream targets investigated. It has at this point to be taken into
consideration that this cell population was identified using one common fluorescence
channel for both CD19+ and CD20+. The indicated activation of the mTORC2 pathway
by the induction of AKTSer473 phosphorylation has to be further investigated due to
the heterogeneity of results. Interestingly, although RPS6Ser235/236 phosphorylation was
efficiently decreased by Torin1 both in emigrated CD19+CD20+ LPMCs as well as in
IgA+ cells in situ (the latter cell type was identified based on morphology), protein
synthesis was only efficiently (and still incompletely) inhibited in CD68+ cells, but not
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in IgA+ cells. These results suggest that the observed protein synthesis in IgA+ cells are
controlled by a mTOR independent mechanism.
The upregulation of protein synthesis and mTORC1 downstream targets in both B and
T lymphocytes in situ at the onset of inflammation are currently under investigation.
mTOR independent regulation of protein synthesis
As described above, Torin1 was not able to completely inhibit protein synthesis in
macrophages and not at all in IgA+ cells. This was not based on a dose dependent
effect, as an increased inhibitor dose was unable to enhance any of the seen mTOR
downstream target inhibition effects in any of the investigated cell populations. The
findings therefore suggest the presence of other mTOR-independent control mechanisms
of protein synthesis at the onset of inflammation in the LEL model.
Publications regarding mTOR independent translation are scarce and many mTOR
independent pathways through other mechanisms are still dependent on the phosphory-
lation of the RPS6 upstream regulator S6K. However, some studies suggest mTOR-S6K
independent translation via PKCβII-RACK1 interaction, PRR16/Largen, or direct
activation of EIF4G [Grosso et al., 2008; Yamamoto et al., 2014; Norton and Layman,
2006]. In accordance, PKCs were among the upstream regulators predicted to be highly
activated in IPA analysis for both observations. However, further investigations are
necessary to positively identify these Torin1 independent mechanisms of translational
control in macrophages, IgA+ cells and possibly other cell populations in the LEL model.
Taken together, these findings indicate that mTOR pathway activity is upregulated
during the initiation of an inflammatory response in LP macrophages. Furthermore,
evidence is provided that the mTOR pathway is also activated in LP cells of the B cell
lineage.
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4.3.2. The mTOR mediated control of the inflammatory
response
In order to define the contribution of mTOR pathway activation to the induction of
inflammatory effector functions in LP cells, the impact of Torin1 on the secretion of a
panel of inflammatory mediators, which were shown to be upregulated during the onset
of inflammation in the LEL model, were investigated.
Despite the presence of Torin1 throughout the performance of the model, the influence
of the inhibitor on almost all studied parameters was only detectable at time point
LEL-M 17 h. One reason for this phenomenon could simply be the low mediator
concentrations that were detected for most parameters at LEL-M 5 h (data not shown),
where the supernatant was collected after 1 h, whereas for time point LEL-M 17 h, the
supernatant was collected after 12 h. Overall, there were high quantitative variances
between the different patient samples regarding total expression levels and response
to inhibitor treatment - a characteristic feature of studies performed in the human
system. Remarkably, among parameters analyzed, the investigated chemokines were
the group that was most sensitive towards Torin1 mediated mTOR inhibition. Apart
from chemokine ligand 19 (CCL19), which was only moderately upregulated at LEL-M
17 h vs. TM 0 h, all tested chemokines were strongly upregulated after 17 h culture
without inhibitor and inhibited in the presence of Torin1.
The control of chemokine secretion by mTOR
Chemokines are important mediators in early inflammation and known to attract leuko-
cytes towards the site of injury/inflammation, a process that has been shown to be
important in the intestinal inflammatory response [MacDermott et al., 1998].
The monocyte chemoattractant protein-1 (MCP-1)/CCL2 is known to recruit mono-
cytes, memory T cells, and dendritic cells to the site of inflammation. MCP-1 has
been found to be highly expressed in LP macrophages of IBD patients and its secretion
from monocytes has recently been shown to be sensitive towards mTOR inhibition by
rapamycin [Grimm et al., 1996; Lin et al., 2014].
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CCL19 together with its receptor CCR7, are highly upregulated on gene expression level
in the LEL model both in situ (CCL19: Obs.2 only, CCR7: Obs.1 and Obs.2) as well as
in emigrated myeloid cells vs. myeloid PBMCs (unpublished microarray and qRT-PCR
data). It has been implicated to be expressed via intestinal DCs in CD patients, where
it is thought to promote the development of autoreactive T cells [Middel et al., 2006].
The sensitivity of CCL19 secretion in primary cells towards mTOR inhibition is shown
in this thesis for the first time.
CCL22, also known as macrophage-derived chemokine (MDC) is mainly expressed by
macrophages, mast cells and DCs [Yamashita and Kuroda, 2002]. The importance
of CCL22 in barrier-defect mediated inflammation was indicated by Hashimoto et al.
[2006], who showed that CCL22 production by monocyte derived DC reflects the disease
activity of patients with atopic dermatitis.
CCL22 was upregulated on gene expression level in the LEL model both in situ
(nCounter Assay, both observations) as well as in emigrated myeloid cells vs. PBMCs
(unpublished microarray data). In line with these results, Guenaltay et al. [2015] were
able to show increased CCL22 gene expression levels in the colon of patients with
microscopic colitis. In contrast, CCL2 was not among upregulated genes in the UC
patient datasets from Granlund et al. [2013]. Its upregulation in LP cells on protein
level in the context of intestinal inflammation as well as its regulation by mTOR is
shown in this thesis for the first time.
Finally, CXCL1, a chemoattractant for neutrophils, which so far had no known associa-
tion with mTOR and was not considered to be involved in the pathogenesis of IBD, was
also upregulated in the LEL model on mRNA level in situ. Interestingly, murine Cxcl1
expression is strongly upregulated in whole colon samples of mice following Clostridium
difficile infection [McDermott et al., 2016].
In summary, I was able to show that the mTOR pathway controls the secretion of
several chemokines at the onset of inflammation as observed in the LEL model. If this
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observation reflects a mTOR pathway mediated control of the recruitment of leukocytes
in vivo, remains to be examined in appropriate animal models.
The mTOR mediated decrease of IL-18 and VEGF secretion
In addition to its effect on chemokine secretion, Torin1 treatment did also increase the
levels of inflammasome controlled cytokine IL-18 and the angiogenetic molecule VEGF
in the LEL model.
Elevated IL-18 levels [Williams et al., 2015] as well as SNP loci in IL-18 or IL-18 related
molecules in IBD patiens [Jostins et al., 2012] have suggested a role for IL-18 in the
pathology of IBD. Accordingly, it has been recently discussed as a potential target for
IBD treatment [Kanai et al., 2013]. In line with my results, Ko et al. [2008] were able to
decrease LPS-induced IL-18 secretion levels in rat DCs via rapamycin. In this thesis, I
was able to establish a link between the mTOR pathway and IL-18 secretion in intestinal
inflammation for the first time.
mTOR mediated inhibition of the secretion of pro-inflammatory cytokines
In contrast to the above described inhibition of the secretion of several inflammatory
mediators, Torin1 treatment did increase MIF as well as M-CSF secretion levels.
The pro-inflammatory macrophage migration factor (MIF) is known to be constitutively
expressed in homeostatic epithelial cells, macrophages as well as various other cell types
that reside in the LP [Maaser et al., 2002; Yang et al., 2015; Calandra et al., 1994]. MIF
polymorphisms have been associated with IBD susceptibility and MIF levels have been
shown to be increased in UC, but not CD patients [Yang et al., 2015; Murakami et al.,
2001]. Although MIF secretion levels are reduced at LEL-M 5 h vs. TM 0 h in the LEL
model, this might be related to the absence of epithelium after LEL or a depletion of MIF
pools immediately after onset of inflammation (LEL-M 3 h) and has to be investigated
further. However, MIF has been indicated to act upstream of mTOR by activating
the mTOR inhibitor AMPK in fibroblasts in the ischaemic heart [Miller et al., 2008] -
a finding that together with the demonstrated mTOR activation in the LEL model is
in line with the observed decrease of MIF secretion at LEL-M 5 h vs. TM 0 h. The
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increased MIF secretion levels in the presence of Torin1 indicated a negative control by
the mTOR pathway. However, whether MIF is also a downstream target of mTOR or
controlled through feedback mechanisms, has to be further investigated. The results
indicate that mTOR also displays an anti-inflammatory role in the induction of the
inflammatory response by repression of pro-inflammatory cytokines at least in the LEL
model.
4.3.3. Reflections on potential other effector functions controlled
by the mTOR pathway during the initiation of intestinal
inflammation: Tissue remodelling
Macrophages represent the first line of defense in the intestinal LP and as such play
an important part in mediating inflammatory responses. Importantly, in the context
of inflammation, macrophages are known to be crucial regulators of tissue remodeling
including fibrogenesis [Kühl et al., 2015] - a process involved in wound healing as well as
tissue remodelling and known to be regulated by mTOR through TGF-β [Gao et al.,
2013]. Several lines of evidence support the notion that this process is rapidly induced
by LP cells during the initiation of an inflammatory reponse in the LEL model:
(1) MMPs 1, 2, 3, 10 and 12 were extensively upregulated on gene expression level.
They are known regulators of tissue remodelling processes by breakdown of excessive
ECM and suggested to be involved in the pathogenesis of IBD [Kirkegaard et al.,
2004; Kofla-Dlubacz et al., 2012; Wiercinska-Drapalo et al., 2003]. In line with this
finding, preliminary mass spectrometry results indicated an enrichment of ECM
proteins after onset of inflammation.
(2) Both TGFB1 and TGFB2 were upregulated on gene expression level during the
whole time course of the model.
(3) TGF-β has been shown to induce the differentiation of human lung fibroblasts into
myofibroblasts [Kulkarni et al., 2011], a process known to be suppressed by PPAR-
γ signaling (a pathway predicted to be inhibited by IPA in the LEL model), while
TGF-β itself activates PI3K/AKT signaling (predicted to be activated by IPA),
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ultimately inducing AKTSer473 phosphorylation. AKTSer473 phosphorylation is in-
creased in macrophages both in situ as well as in emigrated CD33+HLA-DR+CD14+
cells following the initiation of the inflammatory response. Importantly, another re-
search group indicated that TGF-β mediated fibrogenesis in these cells could be
inhibited by rapamycin [Gao et al., 2013].
(4) Further signs of tissue remodeling and fibrogenesis in the LEL model included the
upregulation of angiogenetic factors such as VEGF on both mRNA and protein
level. In accordance with regulation of fibrogenesis by mTOR, VEGF was among
the molecules that were inhibited by Torin1.
4.4. Clinical aspects of the findings
A limited number of studies employing mTOR inhibitors for the treatment of IBD
have shown mixed results: In a pediatric IBD study with 11 UC and 3 CD patients,
the use of the mTOR inhibitor sirolimus (rapamycin) did lead to clinical remission of
45% (5) of UC (with additional 18 % (2) showing clinical response) and all CD patients
(3). Mucosal healing was achieved in 45 % (5) of UC and 67% (2) of CD patients
[Mutalib et al., 2014]. Additionally, in two different case studies, two CD patients
had a marked improvement after treatment with sirolimus or everolimus, respectively
[Massey et al., 2008; Dumortier et al., 2008]. In contrast, in a different CD study,
mTOR inhibition by everolimus failed to show any clinical benefit of this drug regarding
maintenance of steroid-free remission when compared to standard azathioprine therapy
or placebo [Reinisch et al., 2008]. Similarly, murine studies analyzing the effect of
mTOR inhibition on intestinal inflammation showed contradicting results, ranging from
repression of epithelial cell regeneration to amelioration of inflammation [Guan et al.,
2015; Yin et al., 2013; Sun et al., 2012].
These heterogeneous observations suggest that effects of mTOR inhibition in IBD
might be essentially depending on the degree of inflammation, the concentration of
the inhibitor administered, the genetic background, etc.. Notably, when interpreting
these results regarding the role of mTOR in intestinal inflammation, one has to keep
90
4. Discussion
in mind that all described studies use rapamycin, which is unable to inhibit mTORC1
completely and is insensitive towards mTORC2 inhibition.
Interestingly, many of the predicted key genes linked to SNPs that are associated with
IBD by GWAS are involved in the IP3 pathway [Jostins et al., 2012]. These key genes
mainly encode phosphatases, which mediate the degradation of IP3, thus regulating the
activity of the PI3K-mTOR axis. Genetic variants leading to an alteration of the mTOR
pathway may not unlikely contribute to the development of IBD through dysregulation
of i.e. leukocyte recruitment. Furthermore, genetically determined overactivation of
mTOR activity during inflammation may potentially predispose to the development of
fibrosis, which represents a common complication of IBD [Rieder and Fiocchi, 2008;
Gordon et al., 2014].
In order to collect evidence for a contribution of the mTOR pathway to the induction of
tissue remodeling and fibrogenesis during the initiation of an inflammatory response and
- hence - potentially to fibrosis in chronic inflammation, the effect of mTOR inhibitors on
the expression of mediators promoting these molecular processes will be tested in the LEL
model in the future. Importantly, a causal relationship between these processes would
support a potential benefit of mTOR inhibitors for the treatment of fibrotic events in
IBD; such a therapeutic option has been discussed but neither preclinically nor clinically
tested yet [Siegmund, 2015].
4.5. Conclusions and proposed model
Taken together, in this thesis, the LEL model was established as a physiologically
relevant system to study the initiation of an inflammatory response in human LP cells.
Global gene expression showed the induction of a strong inflammatory response in this
cell population and that this inflammatory response has a significant overlap with UC
patient data. For the first time it was shown here that the mTOR pathway at least
in part mediates this initial inflammatory process by controlling the upregulation of
translation. Furthermore, this mTOR controlled process is predominantly mediated by
macrophage activity. Finally, the induction of chemokine secretion in LP cells could
91
4. Discussion
be linked to mTOR activity. The findings of this thesis thus adds a number of novel
aspects to our still limited understanding of initial events in intestinal inflammation
and indentify the mTOR signaling pathway as a potential therapeutic target for IBD.
Based on the present findings and data published by others, the following potential
model is proposed (Figure 4.1): a mucosal barrier defect - as caused by epithelial
layer damage - leads to the rapid induction of a pro-inflammatory response in resident
LP cells including macrophages. This event is associated with the upregulation
of mRNA and protein synthesis, a process partially regulated by mTOR. mTOR
controlled pro-inflammatory chemokine secretion as well as angiogenesis lead to the
recruitment and subsequent infiltration of circulating leukocytes into the LP. In parallel,
fibrogenesis, a process known to be regulated by mTOR, is induced to limit both
area and time of exposure of LP cells to luminal microbiota. After resolution of the
inflammation, homeostasis is restored. Dysregulation of the mTOR pathway - i.e. by
genetic alterations - might lead to a perseverance of the inflammatory response and the
manifestation of chronic inflammation and fibrosis as seen in IBD.
Low levels of gene and 
protein expression
Chronic inflammation
Induction of an inflammatory response 
in immune LP cells
Homeostasis
mTOR mTOR mTOR mTOR?
Dysregulation of the mTOR pathway?
Early inflammation
LP immune cells possess a 
hyporesponsive phenotype
Immune 
modulationꜛ
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Fibro-
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Figure 4.1.: Proposed model.
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Figure A.1.: RNA integrity in the LEL model. Representative RNA electropherograms
derived from tissue samples of one patient, produced by Agilent Bioanalyzer.
Analyzed RNA was isolated from LMD LP samples at different time points
during the LEL model. RIN: RNA Integrity Number.
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Figure A.2.: WG-DASL gene expression boxplots (raw and quantile normalized). For
more details to normalization, see subsection 2.5.1 on page 25.
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Figure A.3.: WG-DASL Assay Top 50 downregulated genes for observations LEL-M 5
h vs. TM 0 h (Obs.1) and LEL-M 17 h vs. 0 h (Obs.2). Blue dots indi-
cate prediction of the transcription factor was significant (adj.P.Val < 0.05)
for both observations, while red dots indicate significance of prediction for
Obs.1 and green dots for Obs.2 only, respectively. Where logFC values were
to close to each other to produce readable names, only one gene name is
given at random.
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Figure A.4.: nCounter Assay gene expression boxplots (raw, calibrated and normalized).
Top boxplots show log2 counter values of raw data, boxplots in the middle
show values after Lot-to-Lot calibration of Cartridge 2, boxplots at the
bottom show log2FC calibrated data after normalization with housekeeping
genes. For more details to normalization, see subsection 2.5.2 on page 25.
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1 rename ( "Al l " ) ;
2 selectWindow ( "Al l " ) ;
3 run ( "Set Sca l e . . . " , " d i s t ance=0 known=0 p i x e l=1 uni t=p i x e l " ) ;
4 run ( "Make Composite" ) ;
5 run ( "Dupl icate . . . " , " dup l i c a t e " ) ;
6 setToo l ( "polygon" ) ;
7 waitForUser ( " S e l e c t lamina propr ia , then pr e s s ok ! " )
8 run ( "Clear Outside " ) ;
9 run ( " Sp l i t Channels " ) ;
10 selectWindow ( "C2−All−1" ) ;
11 run ( "Dupl icate . . . " , " " ) ;
12 run ( "Threshold . . . " ) ;
13 setThresho ld (410, 4095) ;
14 // Change to appropr ia t e thresho ld , i f nece s sa ry !
15 waitForUser ( "Threshold ok?" )
16 run ( "Convert to Mask" ) ;
17 run ( "Watershed" ) ;
18 run ( "Set Measurements . . . " , " area mean min in t e g r a t ed r e d i r e c t=None decimal=3" ) ;
19 run ( "Analyze P a r t i c l e s . . . " , " s i z e =10−200 exc lude add" ) ;
20 selectWindow ( "C2−All−1" ) ;
21 roiManager ( "Show None" ) ;
22 roiManager ( "Show Al l " ) ;
23 roiManager ( "Measure" ) ;
24 selectWindow ( "C1−All−1" ) ;
25 run ( "Grays" ) ;
26 run ( "Find Maxima . . . " , " no i s e=450 output=[Point S e l e c t i o n ] exc lude " ) ;
27 run ( "Find Maxima . . . " , " no i s e=450 output=Count exc lude " ) ;
28 St r ing . copyResults ( ) ;
29 // d i s p l a y s histogram :
30 // run (" D i s t r i bu t i on . . . " , "parameter=RawIntDen or=10 and=0−0") ;
31 waitForUser ( "Ready to c l o s e everyth ing ?" )
32 while ( nImages>0) {
33 selectImage ( nImages ) ;
34 close ( ) ;
35 }
36 selectWindow ( "Resu l t s " ) ;
37 run ( "Close " ) ;
38 selectWindow ( "ROI Manager" ) ;
39 run ( "Close " ) ;
Figure A.5.: Script for ImageJ macro used for semi-quantitative analysis of protein syn-
thesis in the LEL model. Macro was written in the IJ1 macro language.
For further details, see subsection 2.7.5 on page 31.
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Figure A.6.: Activation of upstream transcription and translation factors in the LEL
model as predicted by IPA. The only significant translation regulator was
EIF4E. Blue dots indicate prediction of the transcription factor was sig-
nificant (adj.P.Val < 0.05) for both observations, while red dots indicate
significance of prediction for LEL-M 5 h vs. TM 0 h (Obs.1) and green
dots for LEL-M 17 h vs. TM 0 h (Obs.2) only, respectively. Where z-score
values were to close to each other to produce a readable name, only one
name is given at random.
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Figure A.7.: Activation of upstream regulator cytokines in the LEL model as predicted
by IPA. Blue dots indicate that prediction of cytokine was significant
(adj.P.Val < 0.05) for both observations, while red dots indicate signifi-
cance of prediction for LEL-M 5 h vs. TM 0 h (Obs.1) and green dots for
LEL-M 17 h vs. TM 0 h (Obs.2) only, respectively. Where z-score values
were to close to each other to produce a readable name, only one name is
given at random.
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Figure A.8.: Activation of upstream regulator kinases in the LEL model as predicted by
IPA. Blue dots indicate prediction of the kinase was significant (adj.P.Val <
0.05) for both observations, while red dots indicate significance of prediction
for LEL-M 5 h vs. TM 0 h (Obs.1) and green dots for LEL-M 17 h vs. TM
0 h (Obs.2) only, respectively. Where z-score values were to close to each
other to produce a readable name, only one name is given at random.
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Figure A.9.: Activation of upstream regulator growth factors in the LEL model as pre-
dicted. Blue dots indicate prediction of the growth factor was significant
(adj.P.Val < 0.05) for both observations, while red dots indicate significance
of prediction for LEL-M 5 h vs. TM 0 h (Obs.1) and green dots for LEL-M
17 h vs. TM 0 h (Obs.2) only, respectively . Where z-score values were to
close to each other to produce a readable name, only one name is given at
random.
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Figure A.10.: Phospho-mTORSer2448 expression in the LEL model. Immunofluorescent
staining was performed using frozen sections. White arrows indicate
phospho-mTOR+CD68+ macrophages. For staining procedure, see sub-
section 2.7.3 on page 30.
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Figure A.11.: Phospho-AKTSer473 expression in the LEL model. Immunofluorescent
staining was performed using frozen sections. White arrows indicate
phospho-AKT+CD68+ macrophages. For staining procedure, see subsec-
tion 2.7.3 on page 30.
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Figure A.12. (preceding page): Constitutive protein synthesis in PBMC evaluated by
Click-It® technology. For details to procedure, see sub-
section 2.7.4 on page 31. Briefly, PBMC were obtained
by Ficoll-Hypaque density gradient centrifugation. Cells
were transferred to Poly-L-Lysin coated LapTek cham-
ber slides and allow to adhere and regain resting con-
ditions for 24 h at 37°C. 30 min prior to assessment of
protein synthesis by OPP treatment (30 min, 20 µM), the
medium in two wells was exchanged for HBSS/ABX and
0.7 mM EDTA in HBSS/ABX, respectively, while 100
µg/ml cycloheximide was added to a third well as a nega-
tive control for protein synthesis. (A) Semi-quantitative
analysis of protein synthesis. For details to procedure,
see section 2.7.5 on page 31 (B) Immunofluorescent im-
ages used for quantification. CH: cycloheximide; RP-
MI/PS: RPMI medium containing only Penicilin/Strep-
tomycin; HBSS/ABX: HBSS with several antibiotics as
used in LEL model (see table 2.1 on page 19)
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Figure A.13.: RPS6 expression in the LEL model in presence/absence of inhibitors. Rate
of protein synthesis was determined via OPP Click-It® technology. Speci-
fied inhibitors (250 nM Torin-1 and 100 µg/ml cycloheximide) were present
at all times during the performance of the LEL model. Results shown are
from one representative experiment out of three independent experiments.
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Figure A.14.: Protein synthesis in IgA+ cells in the LEL model. Rate of protein synthesis
was determined via OPP Click-It® technology. Specified inhibitors (250
nM Torin1 and 100 µg/ml cycloheximide) were present at all times during
the performance of the LEL model. Results shown are from one repre-
sentative experiment out of three independent experiments. (A) Semi-
quantification of OPP intensity in IgA+ macrophages shown as a Tukey
boxplot (see page 31). 2100 ± 531 cells were analyzed per time point. (B)
One of two immunofluorescent images used for quantification.
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Figure A.15.: Protein synthesis in CD3+ T cells in the LEL model. Rate of protein syn-
thesis was determined via OPP Click-It® technology). Results shown are
from one representative experiment out of two independent experiments.
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Figure A.16.: Impact of mTOR on regulation of protein synthesis in the LEL model:
Negative controls. Rate of protein synthesis was determined via OPP
Click-It® technology. Specified inhibitors (250 nM Torin1 and 100 µg/ml
cycloheximide) were present at all times during the performance of the
LEL model. The results represent one of three independent experiments.
As a small percentage of cells was false-positive (as indicated by nega-
tive controls w/o OPP), this percentage was subtracted as background.
On average, 1690 (± 297) cells were analyzed per time point. Shown are
the immunofluorescent images of negative controls used for quantification
(one of two analyzed images is shown per time point). The corresponding
images in the presence of OPP can be found in Figure 3.11 on page 62.
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Figure A.17.: Secretion of inflammatory mediators in the LEL model I. At indicated time
points, size standardized tissue punches were incubated in RPMI/ABX
medium for 1 h (12 h for LEL-M 17 h). Supernatants were then subjected
to Luminex® multiplex analysis. Inhibitors (250 nM Torin1, 10 µg/ml cy-
cloheximide) were present throughout the performance of the LEL model.
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Figure A.18.: Secretion of inflammatory mediators in the LEL model II. At indicated
time points, size standardized tissue punches were incubated in RP-
MI/ABX medium for 1 h (12 h for LEL-M 17 h). Supernatants were then
subjected to Luminex® multiplex analysis. Graphs show relative expres-
sion values with LEL-M 17 h without inhibitor set to 100 %. Inhibitors
(250 nM Torin1, 10 µg/ml cycloheximide) were present throughout the
performance of the LEL model.
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Table A.1.: WG-DASL Assay: Top 200
significantly upregulated genes
for observation LEL-M 5 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 CSF3 6.52 1.0E-04
2 IL6 5.85 1.8E-04
3 CSF3 5.62 1.1E-03
4 FAM71A 5.62 2.1E-04
5 MAFA 5.45 2.0E-03
6 RND1 5.39 9.3E-05
7 SERPINA3 4.88 5.9E-04
8 MAFF 4.81 4.3E-04
9 ADAMTS4 4.71 8.1E-04
10 EGR3 4.70 1.1E-04
11 AMPD3 4.66 1.6E-03
12 EGR3 4.62 6.4E-05
13 MOB4 4.58 9.8E-05
14 IL8 4.57 1.6E-03
15 CALCA 4.44 2.0E-04
16 CXCL2 4.39 1.1E-04
17 ARC 4.37 8.3E-04
18 IRF7 4.34 1.1E-03
19 TNFSF9 4.33 9.8E-05
20 HAS1 4.30 3.7E-03
21 GAP43 4.29 5.8E-03
22 C2CD4B 4.26 1.1E-04
23 ATF3 4.25 1.4E-03
24 DES 4.21 1.0E-03
25 UBC 4.18 1.4E-03
26 ULBP2 4.17 1.6E-04
27 MIR212 4.14 5.4E-04
28 ICAM4 4.12 2.0E-04
29 FOSL1 4.12 1.2E-04
30 SLC8A2 4.11 1.1E-03
31 ICAM4 4.10 2.3E-04
32 ABL2 4.06 7.3E-04
33 CCL21 4.06 8.3E-04
34 PCOLCE2 4.05 2.6E-02
35 MT1A 4.02 3.7E-02
Continued...
Gene logFC adj.P.Val
36 GFPT2 4.00 1.2E-04
37 DNAAF1 3.96 4.3E-04
38 SFRP2 3.96 1.8E-02
39 GEM 3.93 1.8E-03
40 MAFF 3.93 9.9E-04
41 NFKB2 3.93 1.0E-03
42 KRT24 3.89 8.2E-04
43 PPP2R4 3.87 9.7E-04
44 NR4A1 3.86 9.7E-03
45 RRAD 3.85 1.1E-04
46 RERGL 3.82 3.8E-02
47 MIR132 3.79 5.0E-03
48 C2orf40 3.79 5.4E-04
49 PI16 3.78 2.4E-02
50 RRAD 3.76 8.9E-04
51 ATF3 3.75 1.6E-03
52 SOCS3 3.75 1.1E-04
53 CHRDL1 3.74 3.7E-02
54 MAFF 3.66 2.1E-03
55 RGS16 3.65 5.0E-04
56 PCDH10 3.64 2.0E-04
57 RELT 3.59 8.4E-03
58 NR4A2 3.58 2.1E-03
59 CSF3 3.57 7.7E-03
60 NR4A1 3.53 3.7E-04
61 PTGIS 3.52 5.1E-04
62 MIR320A 3.52 7.3E-04
63 PMAIP1 3.49 4.4E-04
64 NR4A3 3.47 1.3E-03
65 PEG10 3.46 3.9E-04
66 SLC2A14 3.45 2.6E-04
67 SELE 3.44 6.2E-03
68 NANOS1 3.44 3.5E-03
69 UPP1 3.43 5.4E-03
70 FGF18 3.42 4.7E-04
71 CDH16 3.41 1.8E-02
72 LOC440570 3.41 9.9E-04
73 IL1B 3.37 2.2E-04
74 SPHK1 3.37 7.0E-03
75 CDK16 3.36 1.7E-03
76 DDIT3 3.35 5.3E-04
Continued...
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Table A.1.: WG-DASL Assay: Top 200
significantly upregulated genes
for observation LEL-M 5 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
77 MIR636 3.35 5.4E-04
78 MIR24-2 3.34 1.6E-04
79 TEX14 3.33 8.9E-03
80 G0S2 3.32 2.2E-03
81 NFKBIZ 3.31 4.7E-03
82 TNFRSF10D 3.27 1.3E-03
83 JPH2 3.26 3.7E-03
84 NR4A3 3.23 1.6E-03
85 SCN3B 3.22 1.0E-03
86 SLCO4A1 3.22 1.1E-03
87 CDH10 3.22 1.9E-03
88 SYT4 3.20 1.8E-02
89 MAFF 3.18 4.1E-04
90 CHRDL2 3.18 1.1E-03
91 UCN2 3.15 3.9E-04
92 SFRP1 3.14 1.4E-02
93 TSPYL2 3.13 3.0E-03
94 GREM1 3.12 1.0E-02
95 CD83 3.11 7.4E-04
96 KDM6B 3.09 6.7E-03
97 SOX17 3.08 3.2E-03
98 BDKRB1 3.08 1.4E-02
99 SFRP4 3.07 3.0E-03
100 GREM1 3.06 5.3E-03
101 MYC 3.03 1.0E-02
102 SBSPON 3.02 2.4E-02
103 S100A13 3.02 3.3E-03
104 MIR770 3.00 3.7E-04
105 ICAM1 3.00 1.1E-03
106 ING1 3.00 6.0E-03
107 NEFL 2.99 1.7E-02
108 RELN 2.99 8.1E-03
109 EIF4E 2.99 3.1E-03
110 MMP19 2.97 8.9E-04
Continued...
Gene logFC adj.P.Val
111 NFKB2 2.97 4.3E-04
112 NPAS4 2.96 2.0E-03
113 TNFAIP6 2.95 3.1E-03
114 PNRC1 2.95 1.7E-03
115 MMP19 2.94 1.0E-03
116 VASN 2.93 1.9E-03
117 HSPB8 2.92 1.2E-02
118 PI15 2.92 9.8E-03
119 IL8 2.92 9.5E-04
120 SPHK1 2.91 4.9E-03
121 SERPINE1 2.91 3.7E-04
122 CPXM2 2.90 2.0E-03
123 P2RX2 2.90 2.9E-02
124 NR4A3 2.90 2.2E-04
125 VIP 2.90 1.4E-02
126 CCL3 2.89 1.4E-03
127 DHDH 2.89 3.3E-03
128 CD83 2.89 3.2E-04
129 ULBP1 2.89 6.3E-03
130 C9orf47 2.88 1.5E-03
131 CCBE1 2.87 1.9E-03
132 NFATC1 2.86 1.6E-03
133 LSMEM1 2.86 1.3E-03
134 TUBB3 2.84 1.2E-03
135 PRRX1 2.83 1.3E-02
136 SMOC2 2.83 2.0E-02
137 DLL4 2.83 5.0E-03
138 AKAP12 2.82 2.2E-04
139 LINC00152 2.81 1.5E-03
140 CDKN1A 2.80 1.2E-02
141 TSPYL2 2.80 1.0E-02
142 CCDC19 2.79 3.5E-03
143 IL23A 2.78 1.5E-03
144 ARL4D 2.78 1.1E-02
145 RGAG4 2.78 1.2E-03
146 MIR92B 2.76 2.1E-03
147 DGKB 2.75 2.2E-02
148 IL1A 2.74 3.4E-03
149 NFATC1 2.73 1.1E-03
150 FAM222A 2.73 4.6E-03
151 DYRK3 2.72 3.4E-03
Continued...
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Table A.1.: WG-DASL Assay: Top 200
significantly upregulated genes
for observation LEL-M 5 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
152 PLAUR 2.71 1.1E-03
153 APCDD1L 2.71 3.3E-03
154 SOX2 2.70 2.5E-03
155 PRKAR1A 2.70 6.6E-03
156 TGFB1 2.70 8.9E-04
157 KIF1A 2.70 9.7E-03
158 MSX1 2.70 1.3E-02
159 SLC41A1 2.70 7.5E-03
160 ARID5A 2.69 3.1E-03
161 WISP2 2.69 4.0E-03
162 NCS1 2.69 4.8E-03
163 MAP1A 2.69 1.2E-02
164 DPP6 2.68 3.4E-02
165 CSF2 2.66 9.0E-03
166 HSPA2 2.64 9.8E-03
167 WTAP 2.64 3.1E-03
168 MMP16 2.63 3.7E-03
169 CADM3 2.63 6.3E-03
170 ACAN 2.62 9.0E-04
171 FDCSP 2.62 6.9E-03
172 FAXC 2.62 2.2E-03
173 GCH1 2.62 7.7E-03
174 PTPDC1 2.62 1.6E-02
175 PCDHA7 2.61 8.5E-03
176 NR4A3 2.61 1.0E-03
177 TNFSF14 2.61 4.3E-02
178 HAPLN3 2.60 1.7E-02
179 MEDAG 2.60 2.4E-02
180 C2orf66 2.60 1.2E-03
181 TNFRSF12A 2.59 1.0E-02
182 GRIK1 2.59 3.3E-03
183 RGMA 2.58 8.4E-03
184 PDLIM7 2.57 1.9E-03
185 SORBS1 2.56 1.3E-02
Continued...
Gene logFC adj.P.Val
186 RPL13P5 2.56 1.9E-02
187 FLT4 2.56 6.4E-03
188 HIST3H2A 2.55 3.9E-03
189 DUSP4 2.55 2.3E-02
190 PNCK 2.54 8.0E-03
191 CILP 2.54 4.6E-02
192 CYB5D1 2.53 1.4E-03
193 OSM 2.53 1.2E-02
194 MOGAT1 2.52 1.1E-03
195 FAP 2.52 1.7E-02
196 GPM6B 2.52 1.1E-02
197 PRPH 2.52 3.2E-02
198 C10orf10 2.51 1.1E-03
199 MIR645 2.51 2.1E-02
200 TUBB2B 2.50 3.3E-03
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Table A.2.: WG-DASL Assay: Top 200 sig-
nificantly downregulated genes
for observation LEL-M 5 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 TMIGD1 -6.33 1.8E-03
2 MS4A12 -6.21 1.3E-03
3 CEACAM7 -5.99 1.9E-03
4 SLC17A4 -5.95 6.4E-05
5 COL17A1 -5.87 6.4E-05
6 BTNL3 -5.84 2.9E-04
7 TMPRSS2 -5.72 4.3E-03
8 CD177 -5.57 1.6E-04
9 GGT6 -5.54 2.2E-04
10 KRT20 -5.53 2.3E-04
11 IGSF9 -5.46 6.4E-05
12 EDN3 -5.30 3.1E-03
13 CDH17 -5.27 1.1E-04
14 GCNT3 -5.19 1.9E-03
15 MARVELD3 -5.17 4.3E-04
16 MEP1A -5.17 1.1E-04
17 CDHR5 -5.12 2.5E-04
18 GUCA2B -5.06 1.9E-03
19 TUBAL3 -5.01 9.8E-04
20 SLC51B -4.91 3.1E-04
21 TMEM139 -4.91 1.3E-04
22 UGT2A3 -4.88 1.2E-04
23 CLCA4 -4.88 3.3E-03
24 ITGB6 -4.79 2.0E-03
25 PPP1R14D -4.79 1.1E-03
26 B3GALT5 -4.76 1.4E-04
27 BEST2 -4.76 1.2E-04
28 TFF1 -4.76 1.2E-04
29 C1orf210 -4.74 2.3E-04
30 FUT3 -4.74 3.8E-04
31 CLRN3 -4.73 1.0E-03
32 B3GALT5 -4.70 1.2E-04
33 A1CF -4.68 8.2E-03
34 HMGCS2 -4.65 4.3E-03
35 LRRC19 -4.64 1.2E-03
Continued...
Gene logFC adj.P.Val
36 GBA3 -4.63 5.7E-04
37 FABP1 -4.63 7.6E-04
38 BCAS1 -4.62 2.6E-04
39 TMEM45B -4.61 2.2E-04
40 CDHR5 -4.60 7.6E-04
41 DHRS9 -4.58 1.2E-04
42 CDHR2 -4.56 2.1E-03
43 NXPE4 -4.54 4.3E-04
44 EFNA2 -4.54 2.3E-04
45 PLA2G4F -4.51 1.7E-04
46 SCIN -4.50 2.4E-04
47 RAB25 -4.50 1.1E-04
48 C1orf116 -4.47 1.4E-03
49 SLC51A -4.46 5.3E-03
50 ZG16 -4.44 1.3E-03
51 CLDN8 -4.43 5.9E-04
52 GPR128 -4.42 1.3E-04
53 TRIM15 -4.42 9.6E-03
54 OTOP2 -4.39 2.1E-03
55 ANKS4B -4.39 2.2E-04
56 C1orf210 -4.37 7.6E-04
57 PPP1R14C -4.36 7.6E-04
58 CAPN13 -4.34 6.3E-04
59 CA7 -4.34 1.4E-03
60 TM4SF5 -4.29 5.3E-03
61 AQP8 -4.28 1.1E-03
62 CBLC -4.28 3.4E-04
63 F2RL1 -4.27 1.2E-04
64 CEACAM6 -4.27 4.6E-04
65 CA1 -4.27 2.4E-04
66 LOC389332 -4.26 1.6E-04
67 F2RL1 -4.26 1.2E-04
68 SULT1B1 -4.26 4.7E-04
69 NOX1 -4.25 3.5E-03
70 GDA -4.23 1.3E-04
71 C12orf36 -4.23 1.8E-02
72 NAT2 -4.22 1.2E-04
73 CLDN8 -4.22 1.9E-04
74 CTSE -4.21 3.9E-03
75 LRRC31 -4.19 4.1E-03
76 NR1I2 -4.19 4.3E-04
Continued...
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Table A.2.: WG-DASL Assay: Top 200 sig-
nificantly downregulated genes
for observation LEL-M 5 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
77 ISX -4.17 1.9E-03
78 CRB3 -4.15 1.2E-04
79 CD177 -4.14 6.3E-04
80 CEACAM5 -4.14 2.9E-03
81 C1orf106 -4.14 6.5E-03
82 BCL2L15 -4.13 1.1E-03
83 PDE6A -4.12 7.8E-04
84 GBA3 -4.12 4.6E-04
85 SRI -4.11 3.2E-04
86 BCAS1 -4.11 1.1E-04
87 CYP4F2 -4.10 1.2E-03
88 MT1H -4.09 1.2E-04
89 KRT19 -4.08 7.8E-04
90 SLC13A2 -4.08 1.3E-03
91 DEFB1 -4.08 1.1E-03
92 METTL7B -4.08 1.6E-04
93 SHD -4.06 2.3E-03
94 C10orf99 -4.06 8.1E-03
95 SI -4.03 5.0E-04
96 DSG2 -4.02 3.7E-04
97 MYO1A -4.02 1.6E-03
98 FXYD3 -4.00 7.6E-04
99 LOC100124692 -3.98 3.7E-04
100 A1CF -3.98 4.5E-04
101 MARVELD3 -3.97 7.7E-03
102 FOXA1 -3.97 3.1E-04
103 UGT1A6 -3.97 4.1E-03
104 PLS1 -3.95 1.1E-03
105 KRTAP13-2 -3.95 2.5E-04
106 FAM83E -3.94 8.8E-03
107 CLDN7 -3.94 2.1E-03
108 PTK6 -3.93 2.7E-04
109 MYO5B -3.93 8.6E-04
110 TJP3 -3.92 5.2E-03
Continued...
Gene logFC adj.P.Val
111 LRRC26 -3.92 1.4E-03
112 FFAR4 -3.92 1.5E-03
113 GPA33 -3.90 3.8E-04
114 HSD11B2 -3.88 2.9E-03
115 SERINC2 -3.87 2.3E-03
116 MB -3.86 1.1E-04
117 COL17A1 -3.86 1.1E-04
118 HKDC1 -3.85 3.1E-03
119 CEACAM1 -3.85 2.7E-04
120 PTGDR -3.84 4.2E-03
121 CDH1 -3.84 6.2E-04
122 NOX1 -3.82 1.2E-02
123 SGK2 -3.82 2.2E-04
124 MS4A8 -3.81 4.5E-03
125 PLS1 -3.81 4.7E-04
126 FXYD3 -3.80 2.7E-03
127 CKMT1B -3.80 1.9E-03
128 SPDEF -3.78 5.9E-03
129 NXPE1 -3.78 2.4E-03
130 PDZD3 -3.78 2.2E-04
131 CDX2 -3.77 1.2E-03
132 TMC5 -3.77 3.1E-04
133 TSPAN8 -3.76 6.0E-04
134 EPB41L4B -3.76 1.1E-03
135 ARL14 -3.75 3.1E-03
136 TMEM236 -3.73 3.2E-04
137 EPS8L3 -3.72 8.8E-03
138 TMEM171 -3.72 3.3E-03
139 BARX2 -3.72 3.2E-04
140 PTPRR -3.72 2.1E-04
141 MYO7B -3.71 8.8E-03
142 HHLA2 -3.71 7.5E-04
143 C9orf152 -3.71 1.1E-03
144 MYH14 -3.70 1.8E-04
145 REG4 -3.70 1.3E-02
146 HNF1B -3.70 2.7E-03
147 SLC35G1 -3.69 7.1E-04
148 PIGR -3.68 1.0E-02
149 ATP2C2 -3.68 3.4E-03
150 ESRP1 -3.68 9.4E-04
151 TBX10 -3.68 1.7E-03
Continued...
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Table A.2.: WG-DASL Assay: Top 200 sig-
nificantly downregulated genes
for observation LEL-M 5 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
152 GUCY2C -3.68 2.2E-03
153 PRAP1 -3.66 1.1E-02
154 SPINK1 -3.66 1.4E-02
155 EDN3 -3.65 1.1E-04
156 OVOL2 -3.65 1.2E-03
157 DHRS11 -3.65 1.0E-03
158 AP1M2 -3.64 5.6E-04
159 UGT1A8 -3.63 4.5E-03
160 ATOH1 -3.63 1.8E-03
161 AOC1 -3.62 2.0E-03
162 GPT -3.62 1.6E-03
163 HRCT1 -3.62 9.2E-03
164 MT1H -3.61 3.8E-04
165 LGALS4 -3.61 3.8E-03
166 WDR72 -3.61 3.4E-03
167 UGT1A7 -3.60 1.8E-03
168 TTLL6 -3.59 9.2E-04
169 PDZK1IP1 -3.58 2.1E-03
170 SCGB2A1 -3.58 1.2E-04
171 BCMO1 -3.58 1.4E-03
172 DSC2 -3.58 2.0E-04
173 ITPKA -3.57 2.3E-03
174 PTK6 -3.56 1.8E-02
175 TRIM15 -3.55 1.1E-02
176 MUC13 -3.53 1.0E-02
177 CA2 -3.53 3.4E-03
178 BTNL3 -3.52 8.9E-03
179 DMBT1 -3.51 4.6E-04
180 PRSS3 -3.50 1.4E-03
181 GUCA2A -3.50 1.4E-03
182 MUC2 -3.49 4.2E-03
183 FABP2 -3.48 1.6E-03
184 AKR1B10 -3.48 5.8E-03
185 PLA2G10 -3.47 7.7E-03
186 NR1I2 -3.47 5.5E-04
Continued...
Gene logFC adj.P.Val
187 STX19 -3.47 2.0E-03
188 HEPACAM2 -3.46 3.1E-02
189 ALPI -3.45 8.8E-03
190 SDCBP2 -3.44 1.1E-02
191 AGR3 -3.44 1.6E-03
192 CLIC5 -3.42 1.2E-04
193 XK -3.42 2.2E-04
194 TRIM31 -3.42 1.8E-03
195 SLC4A4 -3.42 2.3E-02
196 MYOM3 -3.41 5.4E-03
197 CAPN9 -3.41 5.9E-03
198 NXPE4 -3.41 2.0E-03
199 MARVELD3 -3.40 8.0E-03
200 NGEF -3.40 2.4E-03
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Table A.3.: WG-DASL Assay: Top 200
significantly upregulated genes
for observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 CSF3 7.26 4.4E-07
2 KIAA1199 7.07 2.5E-05
3 MMP10 6.94 3.1E-06
4 CSF3 6.68 3.1E-06
5 IL6 6.35 4.4E-06
6 IL8 5.78 9.3E-05
7 AMPD3 5.57 2.0E-05
8 IL24 5.21 4.9E-04
9 ADAMTS4 5.20 4.4E-05
10 SERPINA3 4.93 1.4E-04
11 NPTX1 4.92 2.0E-05
12 SLC8A2 4.89 3.0E-05
13 CXCL2 4.85 3.6E-06
14 MMP1 4.85 2.3E-05
15 MOB4 4.84 6.4E-04
16 IL1RN 4.83 1.3E-04
17 IL11 4.79 6.2E-05
18 MME 4.75 2.6E-04
19 MME 4.72 7.1E-04
20 FOSL1 4.69 6.5E-06
21 MMP3 4.68 1.9E-04
22 RND1 4.62 3.4E-05
23 NPTX1 4.60 1.8E-03
24 DKFZp451A211 4.53 3.5E-05
25 CALCA 4.48 6.4E-04
26 IL22 4.47 1.4E-05
27 PALM2 4.40 5.3E-05
28 MEDAG 4.39 2.2E-05
29 PALM2 4.39 2.2E-05
30 DPYSL4 4.38 2.1E-04
31 CSF3 4.28 5.0E-04
32 IL22 4.27 1.7E-05
33 C12orf50 4.24 3.6E-05
34 GEM 4.20 2.9E-04
35 SERPINB2 4.20 2.1E-03
Continued...
Gene logFC adj.P.Val
36 MAFF 4.18 2.2E-05
37 BDKRB1 4.18 2.2E-04
38 CRYM 4.17 1.5E-05
39 IL1RN 4.17 2.5E-03
40 INHBA 4.14 1.7E-05
41 SPHK1 4.13 5.1E-04
42 SERPINE1 4.12 1.1E-05
43 P2RX2 4.11 6.7E-05
44 THBS2 4.06 2.0E-04
45 PRRX1 4.06 2.5E-04
46 MAFF 4.06 8.9E-04
47 MME 4.05 1.8E-04
48 ABL2 4.05 3.1E-04
49 C2CD4B 4.03 2.3E-05
50 AKAP2 4.03 1.8E-04
51 ANO3 4.01 4.8E-03
52 IL1RL1 3.98 5.1E-05
53 DYRK3 3.96 1.9E-04
54 SPHK1 3.94 1.3E-03
55 CSF2 3.93 3.4E-05
56 PRRX1 3.90 2.8E-05
57 CXCL5 3.88 3.6E-03
58 EGR3 3.87 2.7E-05
59 SLC2A14 3.87 6.7E-05
60 CRLF2 3.86 1.6E-04
61 G0S2 3.86 3.1E-04
62 HAS1 3.85 2.1E-03
63 KRT17 3.84 1.6E-03
64 UCN2 3.83 8.0E-05
65 ARC 3.82 2.6E-05
66 MIR210 3.82 9.3E-03
67 PTGIS 3.81 7.1E-05
68 CA9 3.81 2.7E-04
69 ATF3 3.79 2.2E-03
70 SPP1 3.77 5.3E-05
71 LRFN5 3.77 2.7E-04
72 SGIP1 3.77 4.7E-04
73 FGF5 3.71 4.0E-05
74 STC2 3.71 2.6E-04
75 NR4A2 3.69 1.0E-03
76 SOCS3 3.68 2.2E-05
Continued...
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Table A.3.: WG-DASL Assay: Top 200
significantly upregulated genes
for observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
77 PTGS2 3.67 4.5E-05
78 PDLIM4 3.67 4.0E-04
79 CCL21 3.67 2.6E-03
80 DYRK3 3.65 5.1E-05
81 NFKB2 3.64 1.7E-03
82 RGS16 3.62 1.3E-04
83 TNFRSF11B 3.61 1.1E-03
84 UPP1 3.61 1.5E-03
85 FAM180A 3.58 1.2E-04
86 SLCO4A1 3.57 6.7E-05
87 IL13RA2 3.55 1.2E-03
88 GREM1 3.53 2.1E-04
89 MAFA 3.52 1.4E-02
90 TMEFF1 3.50 2.6E-04
91 IL1RL1 3.49 1.7E-04
92 TRIML2 3.49 6.8E-03
93 IL1A 3.48 3.6E-04
94 ICAM4 3.47 3.2E-04
95 GDF15 3.46 2.6E-04
96 GREM1 3.46 3.4E-04
97 PMAIP1 3.46 4.9E-04
98 IL8 3.45 7.1E-05
99 MT1A 3.45 2.4E-03
100 ATF3 3.45 2.6E-03
101 UBD 3.44 5.7E-04
102 MAFF 3.43 4.3E-05
103 NOG 3.42 9.5E-04
104 ANGPT2 3.41 3.0E-03
105 LOC440570 3.40 4.4E-04
106 PDPN 3.37 2.2E-04
107 C1orf100 3.36 3.7E-04
108 TNFRSF12A 3.35 1.1E-03
109 SERPINB2 3.35 2.2E-02
110 EFCAB3 3.34 1.3E-03
Continued...
Gene logFC adj.P.Val
111 CBLN2 3.33 1.6E-03
112 MYC 3.33 2.3E-03
113 CHRDL1 3.33 4.3E-03
114 MURC 3.31 6.4E-05
115 RRAD 3.30 1.7E-04
116 ZBTB1 3.30 2.3E-02
117 RPL23AP82 3.29 6.8E-04
118 TNFRSF9 3.28 2.0E-04
119 GFPT2 3.26 1.1E-04
120 GEM 3.25 3.7E-05
121 ICAM4 3.23 7.1E-04
122 MIR212 3.20 1.8E-03
123 VEGFA 3.20 1.9E-03
124 NEURL3 3.19 1.7E-02
125 FDCSP 3.15 9.2E-04
126 LIF 3.15 1.0E-03
127 FGF2 3.14 3.4E-04
128 EGR3 3.14 2.0E-03
129 FAM71A 3.14 2.3E-03
130 PRG2 3.13 2.5E-04
131 BAALC 3.13 3.0E-04
132 RRAD 3.11 7.7E-05
133 MME 3.11 1.8E-03
134 MIR199A1 3.08 7.9E-05
135 SELE 3.08 2.2E-03
136 STC1 3.05 2.3E-04
137 APCDD1L 3.04 6.4E-05
138 ARG2 3.03 9.3E-05
139 PTGES 3.03 3.2E-04
140 AK4 3.03 4.4E-03
141 PCOLCE2 3.03 1.8E-02
142 SLC7A11 3.02 8.6E-04
143 KCNN2 3.02 1.5E-02
144 SLC11A1 3.02 3.9E-02
145 TNFSF9 3.00 5.8E-04
146 TNFSF15 2.99 2.7E-05
147 ZNF385D 2.99 7.9E-05
148 ESM1 2.99 1.3E-02
149 TNFAIP6 2.98 7.2E-05
150 TAC1 2.98 3.0E-03
151 GAP43 2.96 1.8E-02
Continued...
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Table A.3.: WG-DASL Assay: Top 200
significantly upregulated genes
for observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
152 FJX1 2.94 4.0E-03
153 CHRDL2 2.93 1.5E-03
154 NR1D1 2.90 1.3E-04
155 PFKFB4 2.90 1.9E-04
156 NCS1 2.90 1.4E-03
157 POU5F1 2.90 4.8E-03
158 IRX3 2.88 1.4E-03
159 P2RX2 2.87 8.9E-03
160 DES 2.87 1.3E-02
161 DDIT3 2.86 5.7E-04
162 DHDH 2.86 1.9E-03
163 KDM6B 2.86 7.9E-03
164 ULBP2 2.84 5.9E-04
165 HGF 2.84 1.3E-03
166 SLC41A1 2.83 4.2E-03
167 LYPD5 2.82 2.8E-04
168 PRDM16 2.82 2.8E-03
169 NR4A1 2.82 3.9E-02
170 CCRN4L 2.81 6.4E-05
171 ARL13B 2.81 7.1E-05
172 LYPD5 2.81 7.3E-05
173 TRPC4 2.81 9.6E-05
174 TCEAL7 2.81 6.4E-04
175 TAC1 2.81 2.5E-03
176 SPP1 2.80 2.6E-04
177 IGFN1 2.80 3.4E-02
178 TMEM132A 2.79 8.2E-05
179 NR4A1 2.79 1.4E-03
180 MAFF 2.77 1.1E-02
181 TGIF1 2.76 2.0E-03
182 DOK5 2.75 6.7E-05
183 OSMR 2.75 1.5E-04
184 NRIP3 2.75 3.4E-04
185 NEK10 2.75 6.4E-04
186 MYCN 2.75 9.3E-04
Continued...
Gene logFC adj.P.Val
187 TGIF1 2.75 1.6E-02
188 NAV2 2.74 3.9E-04
189 BNIP3 2.74 4.0E-04
190 PI16 2.74 1.9E-03
191 IL33 2.74 3.1E-03
192 KCNF1 2.74 4.3E-03
193 PPP2R4 2.74 2.2E-02
194 IL24 2.73 2.3E-04
195 ULBP1 2.73 3.7E-04
196 UBC 2.73 1.7E-03
197 MIR645 2.73 8.7E-03
198 HAPLN3 2.73 1.1E-02
199 MMP19 2.72 1.3E-03
200 MMP19 2.72 1.4E-03
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Table A.4.: WG-DASL Assay: Top 200 sig-
nificantly downregulated genes
for observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 TMIGD1 -7.15 7.1E-06
2 MS4A12 -7.08 3.0E-06
3 SLC17A4 -6.75 3.1E-06
4 GUCA2B -6.56 5.9E-05
5 PLA2G4F -6.45 9.7E-05
6 MARVELD3 -6.44 2.2E-05
7 CEACAM7 -6.42 1.4E-05
8 ZG16 -6.40 1.4E-05
9 PIGR -6.39 7.4E-05
10 C10orf99 -6.38 6.7E-05
11 CDHR5 -6.33 3.0E-06
12 CLCA4 -6.15 2.3E-05
13 AQP8 -6.08 2.1E-05
14 GGT6 -6.06 3.1E-06
15 HMGCS2 -6.06 1.7E-05
16 BTNL3 -6.02 6.7E-06
17 B3GALT5 -5.93 4.4E-06
18 PLA2G10 -5.93 3.3E-06
19 CDHR5 -5.91 2.2E-05
20 CDH17 -5.86 1.0E-04
21 KRT20 -5.83 2.8E-05
22 CKMT1B -5.82 5.1E-05
23 SULT1B1 -5.80 2.2E-05
24 EDN3 -5.76 2.2E-05
25 GBA3 -5.75 3.1E-05
26 GCNT3 -5.72 9.8E-05
27 CAPN13 -5.69 1.3E-05
28 TFF1 -5.68 8.5E-03
29 HEPACAM2 -5.66 1.0E-05
30 FXYD3 -5.65 2.0E-04
31 HSD11B2 -5.62 2.6E-05
32 CLRN3 -5.58 3.1E-06
33 NXPE4 -5.57 1.2E-05
34 SLC51B -5.56 1.1E-05
35 TM4SF5 -5.51 2.0E-04
Continued...
Gene logFC adj.P.Val
36 EFNA2 -5.50 1.3E-05
37 B3GALT5 -5.50 1.2E-05
38 TRIM15 -5.49 9.1E-04
39 FXYD3 -5.46 3.6E-05
40 NXPE1 -5.44 1.3E-05
41 ITLN1 -5.44 9.7E-05
42 CDX2 -5.43 1.1E-05
43 ADH1C -5.42 1.6E-04
44 C12orf36 -5.39 2.3E-05
45 PPP1R14D -5.36 5.9E-05
46 MYO1A -5.35 1.5E-05
47 NOX1 -5.34 1.1E-04
48 PDZD3 -5.32 1.2E-05
49 TBX10 -5.32 3.5E-05
50 ERN2 -5.31 9.1E-05
51 CAPN9 -5.31 1.1E-05
52 CLDN8 -5.27 1.3E-04
53 FABP1 -5.26 6.4E-05
54 UGT2A3 -5.25 9.3E-06
55 MEP1A -5.24 3.8E-05
56 FAM83E -5.23 2.9E-04
57 ANKS4B -5.23 1.4E-05
58 MUC4 -5.21 2.4E-04
59 TUBAL3 -5.18 6.7E-05
60 METTL7B -5.16 1.4E-05
61 SRI -5.11 2.1E-04
62 NR1I2 -5.11 1.7E-04
63 NOX1 -5.10 5.1E-05
64 GBA3 -5.09 5.1E-05
65 BEST2 -5.09 9.7E-05
66 TSPAN8 -5.08 6.4E-05
67 LRRC26 -5.08 1.4E-05
68 LGALS4 -5.06 2.3E-04
69 CDHR2 -5.04 4.4E-06
70 EPS8L3 -5.03 4.3E-05
71 TMPRSS2 -5.03 1.7E-04
72 GUCA2A -5.02 1.1E-05
73 ITGB6 -5.01 8.1E-05
74 MUC2 -5.01 3.6E-04
75 BCAS1 -5.01 1.5E-05
76 SLC26A3 -5.01 2.1E-04
Continued...
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Table A.4.: WG-DASL Assay: Top 200 sig-
nificantly downregulated genes
for observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
77 CLDN8 -5.00 2.1E-04
78 CD207 -4.99 3.5E-05
79 LRRC19 -4.98 1.8E-04
80 A1CF -4.97 1.1E-03
81 YBX2 -4.97 9.7E-05
82 CLCA1 -4.94 7.1E-06
83 USH1C -4.94 2.2E-05
84 GUCY2C -4.91 8.0E-05
85 GPA33 -4.91 9.9E-06
86 LRRC26 -4.88 2.3E-05
87 C1orf210 -4.88 2.3E-05
88 EPS8L3 -4.87 1.3E-04
89 AGR3 -4.86 4.4E-06
90 SLC13A2 -4.86 2.9E-04
91 TMEM45B -4.86 7.8E-05
92 AOC1 -4.85 2.2E-05
93 SCGB2A1 -4.84 8.1E-06
94 MYH14 -4.84 2.2E-05
95 RPL10L -4.81 3.0E-05
96 DHRS9 -4.80 1.4E-05
97 STX19 -4.78 2.3E-05
98 ISX -4.75 4.4E-06
99 DHRS9 -4.74 4.8E-05
100 NXPE4 -4.74 4.3E-05
101 BCL2L15 -4.73 4.1E-04
102 BCAS1 -4.71 4.3E-05
103 CA7 -4.70 1.6E-04
104 HRCT1 -4.69 5.6E-04
105 MARVELD3 -4.68 1.4E-05
106 FUT3 -4.66 1.6E-04
107 CA1 -4.66 1.7E-04
108 ARL14 -4.65 3.6E-03
109 VIL1 -4.64 6.3E-05
110 MT1H -4.62 7.5E-05
Continued...
Gene logFC adj.P.Val
111 RAB25 -4.61 2.0E-05
112 TRPM6 -4.61 9.4E-06
113 OVOL2 -4.60 4.4E-04
114 CEACAM5 -4.59 3.4E-03
115 PTK6 -4.58 1.1E-05
116 HNF4A -4.57 8.0E-05
117 EPB41L4B -4.56 2.2E-04
118 TTLL6 -4.55 1.7E-05
119 MUC13 -4.55 1.8E-03
120 COL17A1 -4.55 8.2E-04
121 DDC -4.54 2.0E-05
122 SLC44A4 -4.54 3.8E-05
123 NXPE4 -4.53 1.4E-05
124 WNK4 -4.52 5.6E-04
125 FAM3D -4.52 1.1E-05
126 ATP2C2 -4.51 3.2E-04
127 BCMO1 -4.50 2.5E-04
128 LRRC31 -4.50 7.5E-04
129 UGT1A8 -4.47 1.6E-03
130 SLC5A1 -4.45 2.1E-04
131 MUC17 -4.45 3.8E-04
132 CLEC10A -4.44 8.2E-04
133 PTPRR -4.44 1.6E-04
134 FOXA1 -4.43 6.7E-05
135 SCNN1A -4.43 9.8E-05
136 CAPN9 -4.41 7.2E-05
137 ESRP1 -4.40 9.7E-05
138 PPP1R14C -4.38 1.5E-04
139 NAT8B -4.37 2.6E-05
140 GDA -4.37 7.5E-05
141 CDX1 -4.37 1.1E-04
142 CYP2J2 -4.37 5.2E-05
143 SHROOM3 -4.35 2.3E-04
144 SHD -4.35 9.7E-05
145 CD177 -4.34 2.6E-04
146 EDN3 -4.32 2.0E-05
147 C1orf106 -4.31 4.3E-04
148 ATOH1 -4.31 1.8E-04
149 SLC39A5 -4.31 1.6E-05
150 PDE6A -4.31 1.6E-04
151 NAT2 -4.30 3.6E-05
Continued...
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Table A.4.: WG-DASL Assay: Top 200 sig-
nificantly downregulated genes
for observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
152 TFCP2L1 -4.29 5.3E-05
153 DNAJC22 -4.29 1.0E-03
154 FCGBP -4.29 5.2E-05
155 TMEM171 -4.28 1.1E-03
156 ACSL5 -4.27 1.4E-05
157 TMEM139 -4.26 7.1E-05
158 CEACAM6 -4.26 5.4E-03
159 EPCAM -4.24 3.4E-04
160 CBLC -4.23 8.1E-05
161 ESPN -4.23 1.1E-05
162 CHP2 -4.23 2.3E-05
163 PTK6 -4.22 2.3E-04
164 AXDND1 -4.22 2.5E-03
165 TJP3 -4.21 2.1E-03
166 GPX2 -4.20 5.6E-04
167 C1orf116 -4.20 7.2E-03
168 LOC389332 -4.19 2.1E-05
169 ELF3 -4.18 2.9E-03
170 TRIM31 -4.18 2.8E-05
171 AGR2 -4.17 1.4E-02
172 BEST4 -4.16 1.1E-02
173 FOXA2 -4.16 2.0E-04
174 LOC100124692 -4.15 2.3E-05
175 MB -4.15 3.1E-05
176 CLDN7 -4.15 1.1E-03
177 PLS1 -4.15 1.2E-04
178 PPP1R1B -4.15 1.1E-04
179 A1CF -4.14 2.2E-05
180 AP1M2 -4.14 3.0E-05
181 EPHA10 -4.13 5.4E-05
182 CD177 -4.13 2.6E-04
183 HHLA2 -4.12 1.1E-04
184 VAV3 -4.11 1.0E-03
185 TMEM37 -4.11 1.5E-05
186 LGALS9B -4.10 1.1E-04
Continued...
Gene logFC adj.P.Val
187 OTOP2 -4.10 1.7E-03
188 PLEKHH1 -4.08 6.7E-05
189 RNF43 -4.08 1.6E-03
190 C1orf210 -4.07 3.4E-04
191 LIPH -4.06 7.3E-05
192 TST -4.05 3.4E-04
193 CTSE -4.03 2.7E-04
194 EPCAM -4.02 7.3E-04
195 KRT20 -4.02 1.7E-04
196 CRB3 -4.01 1.5E-04
197 FMO5 -4.00 1.9E-04
198 KRT19 -4.00 9.8E-05
199 SLC4A4 -4.00 9.3E-05
200 DEFB1 -4.00 2.8E-04
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Table A.5.: WG-DASL Assay: Signifi-
cantly upregulated genes for
observation LEL-M 17 h vs.
LEL-M 5 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 KIAA1199 6.38 6.0E-03
2 MMP10 4.54 1.5E-02
3 MME 4.28 1.7E-02
4 IL11 4.25 6.0E-03
5 MMP1 4.21 2.0E-02
6 CDCP1 4.19 4.7E-03
7 CDCP1 4.11 1.5E-02
8 AGXT 3.88 4.8E-02
9 MME 3.77 1.8E-02
10 CXCL5 3.77 4.3E-02
11 MME 3.77 2.8E-02
12 TNFRSF11B 3.75 1.6E-02
13 CDCP1 3.47 1.5E-02
14 MIR126 3.32 2.0E-02
15 CDCP1 3.30 1.5E-02
16 CA9 3.29 1.5E-02
17 RPL23AP82 3.27 2.3E-02
18 C12orf50 3.27 1.2E-02
19 SGIP1 3.22 1.2E-02
20 IL13RA2 3.20 2.8E-02
21 TMEM132A 3.19 1.2E-02
22 EFCAB3 3.08 2.2E-02
23 PFKFB4 3.04 2.7E-02
24 VLDLR 3.02 1.2E-02
25 FGF11 3.01 1.5E-02
26 CBLN2 3.00 1.5E-02
27 C12orf50 3.00 4.0E-02
28 IL24 2.98 1.8E-02
29 IL22 2.94 1.5E-02
30 HK2 2.84 1.2E-02
31 C1orf100 2.83 1.8E-02
32 MMP12 2.77 4.6E-02
33 IL22 2.74 2.0E-02
34 TMEFF1 2.73 2.7E-02
35 HMGN2P46 2.71 3.0E-02
Continued...
Gene logFC adj.P.Val
36 NPTX1 2.66 1.6E-02
37 AK4 2.63 1.8E-02
38 MYCN 2.59 2.7E-02
39 PPIAL4G 2.56 4.0E-02
40 C4orf3 2.55 1.8E-02
41 ADCY8 2.50 1.2E-02
42 AKAP2 2.49 1.8E-02
43 KCNE2 2.44 1.6E-02
44 ITGA2 2.43 1.2E-02
45 PDLIM4 2.41 1.8E-02
46 RAB33A 2.41 3.7E-02
47 PANX2 2.41 4.3E-02
48 NAV2 2.39 3.4E-02
49 B3GNT4 2.38 2.0E-02
50 TFR2 2.38 2.7E-02
51 CLMP 2.36 2.5E-02
52 MURC 2.35 1.2E-02
53 INSIG2 2.30 1.8E-02
54 FOXD1 2.29 1.6E-02
55 TNFSF15 2.24 4.0E-02
56 NEK10 2.24 1.9E-02
57 HS3ST3A1 2.23 2.7E-02
58 VEGFA 2.23 1.5E-02
59 SLC8A3 2.20 3.7E-02
60 SLC41A3 2.20 4.3E-02
61 HMGA2 2.18 2.7E-02
62 ZNF160 2.18 1.5E-02
63 FAM162A 2.18 2.7E-02
64 IKBIP 2.17 1.5E-02
65 ZNF470 2.17 4.6E-02
66 TBX3 2.15 3.6E-02
67 PGK1 2.14 4.0E-02
68 BNIP3 2.13 2.7E-02
69 C4orf47 2.07 1.8E-02
70 PALM2 2.06 4.1E-02
71 PPFIA4 2.04 1.5E-02
72 KCNK1 2.04 1.5E-02
73 NEURL3 2.01 2.8E-02
74 EFCAB13 2.01 2.3E-02
75 WISP1 2.01 1.9E-02
76 EML5 1.98 4.6E-02
Continued...
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Table A.5.: WG-DASL Assay: Signifi-
cantly upregulated genes for
observation LEL-M 17 h vs.
LEL-M 5 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|. Contin-
ued from previous page.
Gene logFC adj.P.Val
77 GPR174 1.98 2.3E-02
78 SNX33 1.98 2.3E-02
79 RUNDC1 1.93 1.5E-02
80 MIR30D 1.92 4.2E-02
81 EFTUD1 1.90 2.8E-02
82 FUT11 1.86 2.7E-02
83 TBX3 1.84 4.2E-02
84 PRG2 1.83 4.3E-02
85 N4BP3 1.81 1.8E-02
86 HERC4 1.80 5.0E-02
87 OXTR 1.80 4.0E-02
88 SIGLEC15 1.80 3.3E-02
89 ZSWIM4 1.79 2.0E-02
90 FAM117B 1.79 4.2E-02
91 EFTUD1 1.74 3.7E-02
92 ZNF654 1.73 2.7E-02
93 CLDN14 1.73 4.8E-02
94 RSPH10B 1.70 4.2E-02
95 MXI1 1.70 2.8E-02
96 UPF3B 1.68 2.7E-02
97 IZUMO4 1.68 5.0E-02
98 TMEM194A 1.66 1.6E-02
99 AGPAT5 1.65 4.7E-02
100 MTFP1 1.63 2.7E-02
101 PGAM1 1.62 3.3E-02
102 KIAA0930 1.59 3.8E-02
103 EFTUD1 1.56 4.2E-02
104 THAP2 1.55 4.8E-02
105 DNHD1 1.53 2.7E-02
106 CLEC2D 1.50 2.7E-02
107 ZNF84 1.49 4.6E-02
108 JAK3 1.48 4.8E-02
109 GAD1 1.45 5.0E-02
110 AK2 1.44 4.2E-02
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Table A.6.: WG-DASL Assay: Signifi-
cantly downregulated genes for
observation LEL-M 17 h vs.
LEL-M 5 h. Adj.P.Val <
0.05 (Benjamini-Hochberg cor-
rected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 IGSF21 -3.23 2.7E-02
2 SIGLEC1 -3.09 2.7E-02
3 PRND -2.98 1.8E-02
4 CD163 -2.96 1.5E-02
5 CLEC10A -2.92 3.4E-02
6 RAB7B -2.75 4.8E-02
7 FMO2 -2.69 4.9E-02
8 CLEC10A -2.57 2.7E-02
9 WNT11 -2.56 1.2E-02
10 ENHO -2.43 1.8E-02
11 FOLR2 -2.40 1.5E-02
12 GSTM5 -2.33 4.6E-02
13 SSPO -2.32 4.6E-02
14 MYO7A -2.31 1.5E-02
15 C2orf66 -2.30 3.6E-02
16 PADI4 -2.24 4.0E-02
17 CDH23 -2.23 1.5E-02
18 SRPK3 -2.23 2.7E-02
19 ISLR -2.23 1.5E-02
20 GALNT16 -2.22 1.5E-02
21 TMEM37 -2.21 1.8E-02
22 REM1 -2.20 2.7E-02
23 C20orf166-AS1 -2.19 2.8E-02
24 ANO1 -2.19 1.8E-02
25 OXER1 -2.19 4.8E-02
26 H1FX-AS1 -2.15 2.7E-02
27 CRISPLD1 -2.14 1.6E-02
28 OBSCN -2.12 1.5E-02
29 ACCS -2.12 3.7E-02
30 REEP2 -2.05 4.0E-02
31 FGFR4 -2.04 2.8E-02
32 CC2D2A -2.03 4.3E-02
33 ANO1 -2.02 1.8E-02
34 COL4A5 -2.02 3.7E-02
35 EGFLAM -1.98 1.6E-02
36 CYP11A1 -1.92 4.3E-02
Continued...
Gene logFC adj.P.Val
37 VIPR1 -1.92 2.7E-02
38 MEI1 -1.90 2.7E-02
39 RTN1 -1.90 4.9E-02
40 NOSTRIN -1.89 3.7E-02
41 CAND2 -1.88 2.7E-02
42 C17orf82 -1.87 2.0E-02
43 PDLIM7 -1.87 3.8E-02
44 IL11RA -1.85 4.9E-02
45 MROH7 -1.85 1.8E-02
46 LTC4S -1.84 4.6E-02
47 MS4A6A -1.84 2.7E-02
48 CD1C -1.78 4.2E-02
49 FCER1A -1.78 4.2E-02
50 FBLN1 -1.73 2.7E-02
51 LILRB5 -1.69 2.7E-02
52 CD34 -1.69 4.8E-02
53 FGGY -1.68 4.8E-02
54 TENC1 -1.67 3.4E-02
55 FAM181B -1.67 2.7E-02
56 MAPK10 -1.66 4.2E-02
57 EXOC3L1 -1.64 4.9E-02
58 ZBTB16 -1.62 3.7E-02
59 STAP1 -1.61 4.0E-02
60 ZNF488 -1.59 2.7E-02
61 MS4A6A -1.54 2.7E-02
62 C1QA -1.53 4.2E-02
63 THY1 -1.52 4.7E-02
64 ETV1 -1.49 4.3E-02
65 MAPK10 -1.48 4.0E-02
66 FRAT1 -1.38 4.8E-02
67 ULBP2 -1.33 4.0E-02
68 GRASP -1.31 4.2E-02
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Table A.7.: nCounter Assay: Significantly
upregulated genes for observa-
tion LEL-M 5 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|.
Gene logFC adj.P.Val
1 CXCL2 7.25 1.3E-05
2 IL6 6.54 5.1E-05
3 IL8 6.27 1.4E-04
4 SELE 6.06 8.9E-05
5 ICAM4 5.92 4.9E-07
6 SOCS3 5.27 5.6E-05
7 ICAM1 4.98 1.3E-05
8 IL1A 4.57 1.1E-03
9 IL1B 4.55 1.3E-04
10 CD83 4.37 1.3E-05
11 EGR1 4.08 4.0E-04
12 CCR7 4.00 6.9E-04
13 NFKBIZ 3.99 4.4E-05
14 IRF1 3.83 1.3E-05
15 PTGS2 3.76 1.3E-04
16 IL23A 3.65 2.3E-05
17 ICAM5 3.57 6.2E-05
18 TNFAIP3 3.26 4.7E-05
19 CXCL1 3.19 1.6E-03
20 RELB 3.17 6.2E-05
21 TRAF1 3.14 9.6E-04
22 CCL4 3.13 2.3E-05
23 TNFRSF9 3.08 3.4E-04
24 CCL20 2.91 1.6E-03
25 DUSP4 2.89 1.4E-03
26 NFATC1 2.72 3.1E-04
27 CCL3 2.69 2.9E-03
28 IRAK2 2.65 7.3E-05
29 TNFRSF4 2.62 2.8E-04
30 CSF2 2.57 1.6E-03
31 C7 2.51 1.3E-03
32 STAT4 2.48 3.1E-04
33 IL1RN 2.31 1.8E-02
34 TNFAIP6 2.29 1.3E-04
35 NFATC2 2.28 3.0E-04
Continued...
Gene logFC adj.P.Val
36 CD274 2.27 1.2E-03
37 C3 2.22 3.7E-02
38 BATF 2.20 1.6E-03
39 POLR2A 2.16 5.3E-05
40 IRF7 2.16 2.1E-04
41 BCL3 2.09 2.0E-03
42 NFKB1 2.09 1.7E-04
43 CCL2 2.08 1.8E-02
44 TNF 2.06 2.9E-03
45 CD40 2.03 7.1E-04
46 NFIL3 1.99 3.4E-04
47 BCL6 1.97 1.6E-04
48 ICOSLG 1.96 2.6E-04
49 CCRL2 1.92 1.6E-03
50 CDKN1A 1.90 1.4E-03
51 IL22 1.84 2.7E-02
52 C9 1.84 3.8E-02
53 LIF 1.78 1.6E-02
54 PLAUR 1.76 4.0E-03
55 CD70 1.74 9.0E-03
56 CD44 1.69 6.0E-04
57 C8A 1.58 2.2E-02
58 IFIH1 1.57 1.6E-03
59 FYN 1.57 2.0E-03
60 MARCO 1.57 3.6E-02
61 TGFB1 1.55 3.0E-04
62 ITLN2 1.49 2.4E-02
63 ITGA5 1.49 2.0E-03
64 IFI16 1.47 6.0E-04
65 EGR2 1.45 1.2E-02
66 SMAD3 1.45 1.9E-03
67 PLAU 1.42 2.5E-03
68 NOTCH1 1.40 2.6E-03
69 CEBPB 1.40 8.0E-04
70 TRAF3 1.37 1.6E-03
71 CCL26 1.37 1.1E-02
72 ARG2 1.36 1.7E-02
73 IL13 1.33 1.8E-02
74 MX1 1.31 1.4E-02
75 STAT5A 1.30 1.2E-03
76 IFNB1 1.29 1.1E-02
Continued...
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Table A.7.: nCounter Assay: Significantly
upregulated genes for observa-
tion LEL-M 5 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|. Continued from previous
page.
Gene logFC adj.P.Val
77 ICOS 1.29 2.4E-02
78 SKI 1.29 1.3E-03
79 TBK1 1.28 3.4E-03
80 MAP4K4 1.27 1.5E-03
81 CX3CL1 1.23 1.8E-02
82 TNFSF15 1.19 1.3E-02
83 GBP1 1.19 2.0E-02
84 TNFRSF10C 1.13 2.7E-02
85 JAK1 1.09 4.8E-03
86 CDH5 1.06 5.9E-03
87 CXCR4 1.05 2.0E-02
88 CD7 1.04 2.8E-02
89 CD80 1.04 4.1E-02
90 VCAM1 1.03 4.6E-02
91 ADA 1.03 6.9E-03
92 MAPKAPK2 1.03 4.3E-03
93 CLU 1.02 4.2E-02
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Table A.8.: nCounter Assay: Significantly
downregulated genes for obser-
vation LEL-M 5 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|.
Gene logFC adj.P.Val
1 PIGR -8.27 8.9E-05
2 CEACAM6 -6.20 1.3E-05
3 ITLN1 -5.68 1.3E-05
4 CD24 -5.21 3.8E-06
5 CEACAM1 -4.91 1.3E-05
6 PLA2G2A -3.87 4.1E-03
7 MUC1 -3.69 4.8E-06
8 CCR2 -3.66 1.5E-04
9 GZMA -3.34 6.3E-04
10 CD164 -3.14 3.6E-04
11 CD3D -3.07 4.1E-04
12 CLEC7A -2.83 7.3E-05
13 HLA-DPA1 -2.82 1.5E-03
14 C1QB -2.80 2.9E-04
15 CD40LG -2.74 6.8E-04
16 MRC1 -2.61 7.1E-04
17 TNFRSF17 -2.60 1.2E-04
18 FCGR3A/B -2.58 2.1E-03
19 TNFRSF11A -2.54 1.5E-04
20 HLA-DMB -2.51 3.4E-04
21 HAVCR2 -2.43 4.5E-03
22 MYD88 -2.41 4.1E-05
23 ITGAE -2.41 3.6E-04
24 C1QA -2.30 1.6E-03
25 TLR8 -2.30 7.3E-04
26 CCL24 -2.28 2.4E-04
27 MSR1 -2.28 1.1E-04
28 FCGR2B -2.28 8.9E-04
29 CCL15 -2.27 1.6E-04
30 IL18 -2.26 6.6E-05
31 SLAMF6 -2.26 8.7E-04
32 CD27 -2.24 6.6E-04
33 BTLA -2.19 1.2E-02
34 HLA-DRB1 -2.13 2.8E-02
35 CD9 -2.11 1.2E-03
Continued...
Gene logFC adj.P.Val
36 CCL8 -2.11 8.9E-04
37 KLRC3 -2.08 1.0E-03
38 FCER1G -2.08 1.9E-03
39 XCR1 -2.08 9.4E-03
40 KLRC1 -2.05 2.1E-02
41 ITGA6 -2.02 3.1E-04
42 CD3E -2.01 1.0E-03
43 CD163 -2.00 1.2E-03
44 CD209 -1.99 4.0E-03
45 CCR1 -1.99 2.9E-03
46 KLRC4 -1.98 5.8E-03
47 PSMB5 -1.96 1.8E-03
48 CD1D -1.94 1.2E-03
49 KLRD1 -1.93 5.7E-03
50 LEF1 -1.93 5.7E-03
51 PPARG -1.90 4.2E-04
52 CD1A -1.90 2.2E-03
53 SYK -1.89 5.0E-04
54 CTSS -1.84 1.8E-03
55 MR1 -1.83 9.9E-03
56 SIGIRR -1.82 3.5E-03
57 PRF1 -1.80 2.0E-04
58 FCER1A -1.79 5.9E-03
59 CASP1 -1.78 2.8E-04
60 HLA-DPB1 -1.78 2.9E-03
61 TLR7 -1.76 1.6E-03
62 LCK -1.76 4.3E-03
63 PTPN6 -1.76 2.5E-04
64 TNFSF13B -1.75 9.6E-03
65 LY96 -1.74 2.9E-03
66 CMKLR1 -1.72 3.0E-04
67 CD4 -1.72 1.3E-03
68 C1QBP -1.71 1.2E-03
69 RORC -1.71 3.2E-03
70 FCGRT -1.69 1.8E-04
71 LAIR1 -1.69 1.6E-03
72 CSF1R -1.67 2.1E-02
73 CXCR6 -1.66 2.4E-03
74 HFE -1.66 6.4E-04
75 GZMB -1.65 5.7E-03
76 IL23R -1.65 1.8E-03
Continued...
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Table A.8.: nCounter Assay: Significantly
downregulated genes for obser-
vation LEL-M 5 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|. Continued from previous
page.
Gene logFC adj.P.Val
77 ARHGDIB -1.64 4.7E-03
78 IL16 -1.63 6.1E-04
79 CD53 -1.63 1.4E-03
80 EDNRB -1.62 4.1E-03
81 LILRA6 -1.60 5.9E-03
82 CTSC -1.59 2.9E-03
83 ITGAL -1.58 4.1E-03
84 ITGA4 -1.57 4.9E-04
85 IFITM1 -1.57 2.1E-02
86 CD74 -1.57 2.4E-03
87 KLRC2 -1.57 2.3E-02
88 GZMK -1.56 1.1E-02
89 MIF -1.54 2.4E-03
90 B2M -1.54 7.6E-03
91 HLA-DRA -1.54 1.1E-02
92 CD2 -1.54 5.6E-03
93 UBE2L3 -1.52 2.4E-03
94 PYCARD -1.52 1.6E-03
95 CCR5 -1.50 1.4E-03
96 PSMB10 -1.50 6.6E-04
97 FCGR2A/C -1.49 1.9E-02
98 CD86 -1.49 3.8E-02
99 CD160 -1.48 5.0E-02
100 CD14 -1.46 3.2E-02
101 TLR5 -1.43 4.7E-03
102 FCGR2A -1.42 2.2E-03
103 OAZ1 -1.41 6.9E-03
104 ITGB2 -1.40 2.0E-03
105 GAPDH -1.39 4.0E-03
106 KIR2DL1 -1.39 5.2E-03
107 CIITA -1.39 1.3E-02
108 TLR3 -1.38 1.5E-02
109 LILRA4 -1.38 5.7E-03
110 TIRAP -1.37 5.2E-03
Continued...
Gene logFC adj.P.Val
111 BTK -1.35 8.8E-04
112 HLA-DOB -1.35 3.7E-03
113 KLRF1 -1.34 2.5E-02
114 TUBB -1.33 1.6E-02
115 TNFSF8 -1.33 9.3E-03
116 KLRB1 -1.32 3.7E-02
117 PSMB8 -1.32 3.1E-03
118 BAX -1.31 8.8E-04
119 CASP10 -1.27 9.9E-03
120 PTPN22 -1.26 5.4E-03
121 IKBKE -1.24 3.4E-03
122 LTB4R2 -1.23 9.0E-03
123 ITGA2B -1.22 4.5E-02
124 LILRB4 -1.22 3.8E-02
125 KLRAP1 -1.22 6.2E-03
126 CX3CR1 -1.22 2.4E-02
127 HLA-DMA -1.21 2.9E-03
128 PPIA -1.20 6.3E-03
129 PSMB9 -1.19 3.5E-03
130 DPP4 -1.19 2.0E-02
131 CUL9 -1.18 9.5E-03
132 GFI1 -1.17 7.9E-03
133 IL7 -1.17 4.8E-03
134 IL1R2 -1.16 4.5E-03
135 CCL5 -1.16 4.0E-02
136 GPI -1.16 1.5E-03
137 ATG16L1 -1.16 2.0E-03
138 CYBB -1.14 1.1E-02
139 FADD -1.12 9.4E-03
140 CLEC4A -1.12 2.4E-02
141 SH2D1A -1.10 2.2E-02
142 BCL10 -1.10 6.9E-03
143 PSMB7 -1.09 8.7E-03
144 BCAP31 -1.08 2.7E-03
145 CD45R0 -1.08 2.7E-02
146 TAL1 -1.08 5.7E-03
147 CR1 -1.06 4.0E-02
148 MAP4K1 -1.05 2.1E-02
149 PSMC2 -1.05 4.0E-03
150 ITGAM -1.03 3.7E-03
151 DEFB1 -1.03 3.2E-02
Continued...
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Table A.8.: nCounter Assay: Significantly
downregulated genes for obser-
vation LEL-M 5 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|. Continued from previous
page.
Gene logFC adj.P.Val
152 SMAD5 -1.02 8.0E-03
153 CARD9 -1.02 1.8E-02
154 NFATC3 -1.02 1.3E-02
155 LILRB5 -1.02 3.7E-02
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Table A.9.: nCounter Assay: Significantly
upregulated genes for observa-
tion LEL-M 17 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|.
Gene logFC adj.P.Val
1 IL8 8.55 1.4E-05
2 CXCL2 7.48 1.4E-05
3 IL6 6.42 4.2E-04
4 LIF 5.84 1.7E-05
5 SOCS3 5.37 2.6E-04
6 CXCL1 4.89 1.4E-05
7 IL1A 4.85 6.5E-04
8 PTGS2 4.82 3.1E-05
9 ICAM4 4.66 5.4E-05
10 PLAU 4.62 3.4E-05
11 TNFSF15 4.44 5.9E-05
12 SELE 4.32 1.3E-03
13 ICAM1 4.24 5.9E-05
14 TNFRSF9 3.92 5.9E-05
15 IL1RL1 3.80 1.5E-04
16 IRF1 3.70 1.6E-04
17 IL22 3.65 8.3E-03
18 IL1RN 3.35 6.6E-04
19 IRAK2 3.33 1.4E-05
20 CD274 3.21 6.6E-04
21 IL1B 3.20 8.1E-05
22 TRAF1 3.20 1.3E-03
23 EGR1 3.19 4.0E-03
24 CCR7 3.09 1.8E-03
25 MME 3.03 4.6E-02
26 BCL6 2.98 1.0E-04
27 TNFAIP3 2.95 1.6E-04
28 SPP1 2.94 6.4E-04
29 CSF2 2.94 1.8E-03
30 NFKBIZ 2.89 4.2E-04
31 C9 2.78 1.2E-02
32 CD83 2.72 4.2E-04
33 ICAM5 2.41 5.7E-04
34 CD70 2.41 3.0E-03
35 CCL20 2.32 9.9E-03
Continued...
Gene logFC adj.P.Val
36 CCL2 2.29 1.2E-02
37 TNFAIP6 2.23 7.7E-04
38 ITGA5 2.23 1.8E-04
39 GBP1 2.21 2.4E-02
40 IL23A 2.21 1.3E-03
41 NFIL3 2.20 4.8E-04
42 RELB 2.19 4.4E-04
43 TNFRSF4 2.15 1.6E-03
44 CEBPB 2.15 9.1E-05
45 IDO1 2.09 1.1E-02
46 BCL3 2.08 3.4E-03
47 C3 2.02 4.7E-02
48 SLC2A1 1.97 7.1E-04
49 IFI16 1.96 2.2E-03
50 SMAD3 1.95 4.0E-04
51 DEFB103B 1.86 9.5E-03
52 MAPKAPK2 1.85 1.4E-03
53 STAT5A 1.83 1.7E-03
54 CCL22 1.80 1.2E-02
55 ARG2 1.78 1.1E-02
56 MAP4K4 1.70 4.0E-04
57 ETS1 1.69 1.1E-03
58 RUNX1 1.67 4.4E-03
59 ZEB1 1.67 5.0E-04
60 PLAUR 1.66 6.3E-03
61 TAP1 1.65 2.2E-02
62 NFKB1 1.65 1.6E-03
63 NFATC1 1.64 1.0E-03
64 CD59 1.64 1.3E-03
65 IL1RL2 1.59 8.3E-03
66 CDKN1A 1.57 3.4E-03
67 IL1R1 1.55 1.3E-03
68 IRF7 1.51 4.9E-03
69 CD44 1.49 2.7E-03
70 CCL19 1.45 4.3E-02
71 CD40 1.37 1.6E-03
72 DUSP4 1.35 4.7E-02
73 CD80 1.32 4.1E-02
74 IL2RA 1.32 3.8E-03
75 TBX21 1.32 7.3E-03
76 BATF3 1.30 4.2E-02
Continued...
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Table A.9.: nCounter Assay: Significantly
upregulated genes for observa-
tion LEL-M 17 h vs. TM 0 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|. Continued from previous
page.
Gene logFC adj.P.Val
77 STAT3 1.28 4.4E-03
78 NOD2 1.27 7.5E-03
79 RELA 1.26 5.7E-03
80 IL18R1 1.25 8.3E-03
81 IFIH1 1.21 3.5E-02
82 FYN 1.20 7.9E-03
83 GNLY 1.20 1.5E-02
84 EGR2 1.19 2.0E-02
85 SKI 1.19 6.7E-03
86 CD22 1.18 9.4E-03
87 JAK1 1.17 2.2E-03
88 BATF 1.14 4.9E-02
89 POLR2A 1.14 4.4E-03
90 ICOSLG 1.13 6.3E-03
91 TNFRSF13B 1.12 1.3E-02
92 MCL1 1.11 2.2E-02
93 FOXP3 1.10 2.0E-02
94 TBK1 1.03 6.6E-03
95 ICOS 1.03 3.8E-02
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Table A.10.: nCounter Assay: Significantly
downregulated genes for
observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg
corrected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 PIGR -8.57 4.2E-04
2 CEACAM6 -6.32 1.5E-05
3 ITLN1 -6.25 2.3E-05
4 CD24 -5.83 1.5E-05
5 CEACAM1 -4.82 2.3E-05
6 PLA2G2A -4.59 4.2E-04
7 CD163 -4.42 7.2E-04
8 C1QB -4.33 6.4E-04
9 CCL24 -4.09 4.2E-04
10 MRC1 -3.99 1.8E-04
11 C1QA -3.88 8.6E-04
12 MUC1 -3.82 1.7E-05
13 IL18 -3.55 1.8E-05
14 MSR1 -3.38 4.4E-04
15 HLA-DPA1 -3.36 6.6E-04
16 CMKLR1 -3.28 4.2E-04
17 FCER1A -3.17 6.6E-04
18 HLA-DMB -3.16 4.8E-04
19 CCR2 -3.07 6.6E-04
20 HLA-DRB1 -3.02 2.1E-02
21 GZMA -2.93 4.2E-04
22 CYBB -2.89 2.2E-03
23 FCGR3A/B -2.84 2.2E-03
24 CLEC7A -2.83 2.7E-03
25 CD209 -2.80 9.1E-03
26 LILRB5 -2.73 7.1E-04
27 CD74 -2.72 7.7E-04
28 CSF1R -2.71 7.0E-03
29 TLR8 -2.68 4.2E-04
30 HLA-DPB1 -2.60 6.4E-04
31 HLA-DRB3 -2.59 6.6E-04
32 PYCARD -2.55 1.9E-03
33 CCL18 -2.54 4.4E-03
34 FCGRT -2.47 1.2E-04
35 PPARG -2.47 4.2E-04
Continued...
Gene logFC adj.P.Val
36 CTSG -2.45 3.1E-03
37 HLA-DRA -2.40 2.3E-03
38 CCL8 -2.35 6.6E-04
39 CSF3R -2.34 1.8E-03
40 TLR5 -2.34 1.1E-04
41 FKBP5 -2.30 6.6E-03
42 CD4 -2.29 1.2E-03
43 LAIR1 -2.28 6.5E-04
44 CCL13 -2.25 4.4E-03
45 CD36 -2.25 8.0E-04
46 IL1R2 -2.24 4.4E-04
47 CD40LG -2.24 1.7E-03
48 LILRA4 -2.23 1.3E-03
49 HLA-DMA -2.21 1.2E-04
50 FCER1G -2.18 7.9E-03
51 CXCR2 -2.18 8.7E-03
52 CCL15 -2.14 4.2E-04
53 CD9 -2.09 7.1E-04
54 ITGA6 -2.07 4.2E-04
55 CCR1 -2.05 4.8E-03
56 HAVCR2 -2.04 1.1E-02
57 ITGB2 -2.02 7.2E-04
58 GZMK -2.02 1.8E-03
59 CD14 -2.00 3.1E-02
60 TNFRSF17 -1.98 4.4E-03
61 ITGAM -1.90 7.4E-04
62 SIGIRR -1.89 5.3E-03
63 TNFRSF11A -1.89 4.2E-04
64 GUSB -1.88 4.9E-04
65 ARHGDIB -1.87 5.6E-03
66 RORC -1.87 1.2E-03
67 DEFB1 -1.84 1.7E-03
68 CLEC6A -1.84 2.3E-03
69 CARD9 -1.82 1.7E-03
70 TLR7 -1.82 2.3E-03
71 XCR1 -1.81 4.6E-03
72 CD164 -1.81 6.4E-04
73 MYD88 -1.78 2.6E-04
74 TLR4 -1.78 9.0E-03
75 C5 -1.77 3.6E-03
76 CTSC -1.75 1.4E-03
Continued...
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Table A.10.: nCounter Assay: Significantly
downregulated genes for
observation LEL-M 17 h
vs. TM 0 h. Adj.P.Val <
0.05 (Benjamini-Hochberg
corrected); logFC ≥ |1|.
Continued from previous
page.
Gene logFC adj.P.Val
77 CXCR3 -1.66 3.9E-03
78 ITGAE -1.66 2.2E-03
79 HFE -1.66 5.5E-03
80 KLRF1 -1.63 8.0E-04
81 TLR3 -1.61 2.3E-03
82 NCF4 -1.58 7.0E-03
83 ABCB1 -1.57 1.6E-02
84 IL7 -1.56 2.4E-02
85 CX3CR1 -1.52 3.2E-02
86 PTPN6 -1.51 2.5E-03
87 SYK -1.50 1.6E-02
88 LILRA6 -1.48 1.5E-02
89 TNFSF8 -1.46 1.6E-02
90 CD34 -1.44 2.0E-02
91 PLA2G2E -1.43 3.3E-02
92 CD1D -1.41 4.6E-02
93 LILRA2 -1.40 7.5E-03
94 SELL -1.39 1.7E-03
95 CCBP2 -1.39 2.4E-02
96 NLRP3 -1.38 7.3E-03
97 BST1 -1.37 5.5E-03
98 CCND3 -1.37 6.6E-03
99 CD160 -1.32 2.1E-02
100 CASP10 -1.31 2.0E-03
101 PTGER4 -1.30 3.7E-03
102 CD1A -1.29 1.1E-02
103 TLR2 -1.27 4.9E-02
104 CD27 -1.27 2.1E-02
105 KLRF2 -1.27 2.7E-02
106 LEF1 -1.23 1.1E-02
107 IL11RA -1.23 4.4E-02
108 ENTPD1 -1.23 3.0E-02
109 CLEC4E -1.21 2.5E-02
Continued...
Gene logFC adj.P.Val
110 CTSS -1.19 4.5E-02
111 IL12RB1 -1.18 3.2E-02
112 KLRC1 -1.16 2.9E-02
113 IFNGR1 -1.15 7.2E-03
114 CCR6 -1.14 3.2E-02
115 IL10 -1.13 1.1E-02
116 CD55 -1.13 1.1E-02
117 ATG16L1 -1.13 5.2E-03
118 PTAFR -1.12 1.4E-02
119 LILRA1 -1.11 7.5E-03
120 LILRB3 -1.07 4.8E-02
121 TLR1 -1.07 3.7E-02
122 TNFSF12 -1.05 1.3E-02
123 MR1 -1.05 4.6E-02
124 KIR2DS1 -1.04 4.9E-02
125 C1QBP -1.04 7.2E-03
126 BCAP31 -1.04 7.4E-03
127 CR2 -1.03 2.0E-02
128 PSMB5 -1.02 3.8E-02
129 SLAMF6 -1.02 3.4E-02
130 PRF1 -1.00 4.7E-03
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Table A.11.: nCounter Assay: Significantly
upregulated genes for ob-
servation LEL-M 17 h vs.
LEL-M 5 h. Adj.P.Val
< 0.05 (Benjamini-Hochberg
corrected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 LIF 4.07 1.1E-03
2 TNFSF15 3.25 3.0E-03
3 PLAU 3.19 1.6E-03
4 IL1RL1 3.06 2.1E-03
5 GZMB 2.69 2.8E-02
6 SLC2A1 2.46 1.1E-03
7 MIF 2.32 1.6E-03
8 IL8 2.29 2.3E-02
9 IDO1 2.20 2.4E-02
10 SPP1 2.16 1.3E-02
11 CD3D 2.11 2.4E-02
12 GPI 2.01 1.1E-03
13 CCL22 1.87 3.7E-02
14 GAPDH 1.87 3.0E-03
15 LCK 1.84 1.6E-02
16 TNFRSF13B 1.84 1.1E-03
17 ETS1 1.82 3.6E-03
18 CXCL1 1.70 4.8E-02
19 CASP1 1.67 1.2E-02
20 PSMB9 1.64 1.3E-02
21 EDNRB 1.63 2.8E-02
22 CXCR6 1.59 1.7E-02
23 PSMB8 1.48 2.8E-02
24 GFI1 1.47 7.6E-03
25 TIGIT 1.44 2.7E-02
26 GNLY 1.38 2.4E-02
27 CLEC4A 1.34 3.5E-02
28 ITGAL 1.33 2.0E-02
29 IKZF3 1.30 1.6E-02
30 SLAMF6 1.24 2.4E-02
31 PDCD1LG2 1.20 4.9E-02
32 TAL1 1.19 2.4E-02
33 ZEB1 1.18 1.6E-02
34 IL1R1 1.16 2.9E-02
35 CD59 1.12 3.6E-02
36 RELA 1.11 2.4E-02
Continued...
Gene logFC adj.P.Val
37 RUNX1 1.10 4.8E-02
38 TBX21 1.08 4.6E-02
39 LTA 1.08 2.8E-02
40 SMAD5 1.07 2.6E-02
41 PAX5 1.06 4.1E-02
42 CD53 1.06 3.8E-02
43 BAX 1.06 2.0E-02
44 IL23R 1.04 4.8E-02
45 CASP8 1.03 2.8E-02
46 JAK3 1.02 3.6E-02
47 BCL6 1.01 5.0E-02
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Table A.12.: nCounter Assay: Significantly
downregulated genes for ob-
servation LEL-M 17 h vs.
LEL-M 5 h. Adj.P.Val
< 0.05 (Benjamini-Hochberg
corrected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 CCL4 -2.99 1.2E-02
2 CXCR2 -2.43 3.7E-02
3 CCL3 -2.42 3.5E-02
4 CD163 -2.42 3.4E-02
5 HLA-DRB3 -2.26 5.3E-03
6 CCRL2 -2.14 1.0E-02
7 CTSG -2.03 2.8E-02
8 CSF3R -1.95 2.8E-02
9 CLEC4E -1.94 1.0E-02
10 NFATC2 -1.84 2.0E-02
11 NLRP3 -1.81 6.6E-03
12 CCL24 -1.81 4.8E-02
13 CD34 -1.76 2.5E-02
14 CYBB -1.76 5.0E-02
15 CLEC6A -1.72 2.8E-02
16 LILRB5 -1.72 2.9E-02
17 STAT4 -1.68 6.3E-03
18 CD83 -1.65 6.3E-03
19 PLA2G2E -1.58 3.0E-02
20 CMKLR1 -1.55 3.9E-02
21 DUSP4 -1.53 1.7E-02
22 GP1BB -1.46 2.0E-02
23 IL23A -1.45 3.7E-02
24 KIR2DS1 -1.42 3.4E-02
25 TNF -1.40 4.7E-02
26 IRAK3 -1.39 3.6E-02
27 FCER1A -1.39 3.4E-02
28 CCL13 -1.31 3.3E-02
29 IL18 -1.29 1.7E-02
30 CD36 -1.27 3.6E-02
31 SELL -1.23 2.7E-02
32 ICAM5 -1.16 3.3E-02
33 NFKBIZ -1.10 2.8E-02
34 IL10RA -1.09 3.6E-02
35 CCR10 -1.08 4.2E-02
36 IL1R2 -1.07 3.6E-02
Continued...
Gene logFC adj.P.Val
37 TGFB1 -1.03 2.8E-02
38 CD55 -1.02 4.5E-02
39 POLR2A -1.02 2.8E-02
40 HLA-DMA -1.00 3.3E-02
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Table A.13.: nCounter Assay: Significantly
upregulated genes for observa-
tion LEL-M 5 h vs. TM 5 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|.
Gene logFC adj.P.Val
1 ICAM4 5.88 3.2E-07
2 CXCL2 4.62 1.1E-03
3 ICAM5 4.41 1.1E-03
4 IL6 4.11 1.6E-03
5 SELE 3.87 2.0E-03
6 IL1A 3.76 8.6E-03
7 IL1B 3.62 6.2E-03
8 CCR7 3.47 4.3E-03
9 ICAM1 3.47 8.0E-05
10 IRF1 3.23 1.2E-04
11 IL8 3.07 1.3E-02
12 SOCS3 2.80 1.0E-03
13 IL23A 2.74 1.7E-03
14 TRAF1 2.70 2.9E-03
15 NFATC1 2.63 9.8E-04
16 RELB 2.58 2.7E-04
17 EGR1 2.51 2.1E-03
18 NFKBIZ 2.46 7.3E-04
19 CD83 2.45 1.7E-03
20 C7 2.39 1.7E-03
21 CXCL1 2.32 3.6E-02
22 IFNB1 2.28 1.8E-03
23 NFATC2 2.25 1.2E-03
24 IRAK2 2.24 1.1E-03
25 STAT4 2.18 1.1E-03
26 DUSP4 2.12 7.9E-03
27 TNF 2.10 3.2E-02
28 TNFAIP6 2.09 7.3E-04
29 POLR2A 2.05 2.6E-04
30 CCRL2 2.04 1.7E-03
31 CD40 1.94 1.7E-03
32 ICOSLG 1.92 3.2E-04
33 IRF7 1.91 1.1E-03
34 CXCR2 1.88 4.0E-02
35 BATF 1.80 2.8E-02
Continued...
Gene logFC adj.P.Val
36 TNFSF15 1.79 5.3E-03
37 CD274 1.75 7.1E-03
38 TNFRSF4 1.73 5.6E-03
39 PTGS2 1.63 1.8E-02
40 CDKN1A 1.60 4.1E-03
41 BCL6 1.59 1.4E-03
42 NFKB1 1.58 1.4E-03
43 CCL4 1.55 3.7E-02
44 TGFB1 1.54 9.5E-04
45 ITLN2 1.51 2.9E-02
46 NOTCH1 1.51 1.6E-03
47 C8A 1.48 3.7E-03
48 STAT5A 1.48 1.9E-03
49 TRAF3 1.47 1.9E-03
50 CD80 1.41 8.0E-03
51 MX1 1.41 1.3E-02
52 SKI 1.41 1.4E-03
53 MARCO 1.39 4.9E-02
54 IRAK3 1.37 2.5E-02
55 BCL3 1.36 1.7E-03
56 CD44 1.35 3.5E-03
57 ITGA5 1.34 4.8E-03
58 TBK1 1.33 3.7E-03
59 BCL2 1.32 1.8E-02
60 GP1BB 1.32 4.6E-03
61 CSF2 1.32 2.2E-02
62 MBL2 1.30 1.2E-02
63 IFI16 1.29 1.9E-03
64 NFIL3 1.29 6.2E-03
65 PLA2G2E 1.25 1.1E-02
66 MAP4K4 1.23 3.3E-03
67 CLEC4E 1.20 2.8E-02
68 FYN 1.18 9.6E-03
69 TNFAIP3 1.18 2.8E-02
70 TNFRSF10C 1.15 4.2E-02
71 EBI3 1.14 8.7E-03
72 ARG2 1.13 5.0E-03
73 SMAD3 1.12 7.9E-03
74 IFIH1 1.11 2.1E-02
75 CDH5 1.05 8.7E-03
76 IL18R1 1.04 8.6E-03
Continued...
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Table A.13.: nCounter Assay: Significantly
upregulated genes for observa-
tion LEL-M 5 h vs. TM 5 h.
Adj.P.Val < 0.05 (Benjamini-
Hochberg corrected); logFC ≥
|1|. Continued from previous
page.
Gene logFC adj.P.Val
77 PLAUR 1.02 1.5E-02
78 IL4R 1.02 1.3E-02
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Table A.14.: nCounter Assay: Signifi-
cantly downregulated genes
for observation LEL-M 5 h
vs. TM 5 h. Adj.P.Val <
0.05 (Benjamini-Hochberg
corrected); logFC ≥ |1|.
Gene logFC adj.P.Val
1 PIGR -8.17 4.6E-04
2 ITLN1 -5.46 9.2E-04
3 CEACAM6 -5.41 2.1E-04
4 PLA2G2A -4.86 1.7E-03
5 CD24 -4.60 4.6E-05
6 CEACAM1 -3.68 6.1E-04
7 MUC1 -3.63 2.6E-04
8 GZMA -3.57 2.7E-03
9 CD3D -3.39 1.1E-03
10 CCR2 -3.19 5.2E-04
11 CD40LG -2.95 1.9E-03
12 CD164 -2.77 1.9E-03
13 CD3E -2.72 1.2E-03
14 IFNG -2.68 1.2E-02
15 TNFRSF17 -2.67 1.2E-04
16 CCL8 -2.62 1.1E-03
17 GZMB -2.62 3.6E-03
18 KLRC3 -2.55 4.3E-03
19 HLA-DPA1 -2.51 3.7E-03
20 ITGAE -2.49 4.6E-04
21 KLRD1 -2.44 4.6E-03
22 KLRB1 -2.39 5.5E-03
23 CCL5 -2.39 8.6E-03
24 KLRC1 -2.36 1.4E-02
25 CCL15 -2.31 4.2E-03
26 HLA-DMB -2.30 2.4E-03
27 MRC1 -2.30 1.7E-03
28 TNFRSF11A -2.29 4.3E-03
29 SH2D1A -2.29 2.2E-03
30 BTLA -2.28 1.8E-02
31 CD27 -2.26 1.1E-03
32 CD160 -2.26 1.3E-02
33 KLRC4 -2.24 1.2E-02
34 CLEC7A -2.23 4.0E-03
35 LCK -2.22 8.5E-03
Continued...
Gene logFC adj.P.Val
36 GZMK -2.19 2.2E-02
37 SLAMF6 -2.16 2.7E-03
38 C1QBP -2.16 1.4E-03
39 XCR1 -2.14 1.8E-02
40 C1QB -2.13 9.1E-03
41 MIF -2.04 9.5E-04
42 SIGIRR -2.02 2.2E-03
43 FCGR2B -2.00 1.7E-03
44 PRF1 -1.98 4.8E-03
45 KLRC2 -1.97 1.1E-02
46 PSMB5 -1.93 1.9E-03
47 FCER1A -1.92 2.8E-03
48 ARHGDIB -1.91 1.9E-03
49 GAPDH -1.86 1.2E-03
50 CD9 -1.86 1.1E-02
51 B2M -1.84 1.9E-03
52 KLRK1 -1.83 2.9E-02
53 MYD88 -1.82 9.5E-04
54 ITGA6 -1.82 1.4E-03
55 LEF1 -1.82 9.7E-03
56 CD53 -1.80 1.2E-03
57 FCGR3A/B -1.79 3.6E-02
58 PTPN6 -1.78 9.5E-04
59 IFITM1 -1.78 9.1E-03
60 CXCR6 -1.78 9.8E-03
61 TNFSF13B -1.77 1.2E-02
62 CTSS -1.75 1.4E-03
63 HAVCR2 -1.74 4.9E-02
64 IL16 -1.74 3.5E-03
65 CASP1 -1.74 1.5E-03
66 SYK -1.74 1.6E-03
67 C1QA -1.72 1.3E-02
68 KIR2DL3 -1.71 1.2E-02
69 CD1A -1.71 7.9E-03
70 GPR183 -1.70 9.1E-03
71 ITGAL -1.70 1.5E-02
72 CTSC -1.70 1.8E-03
73 EEF1G -1.66 3.3E-03
74 IL23R -1.65 3.8E-03
75 CD79A -1.63 3.0E-03
76 LY96 -1.61 7.8E-03
Continued...
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Table A.14.: nCounter Assay: Signifi-
cantly downregulated genes
for observation LEL-M 5 h
vs. TM 5 h. Adj.P.Val <
0.05 (Benjamini-Hochberg
corrected); logFC ≥ |1|.
Continued from previous
page.
Gene logFC adj.P.Val
77 PSMB10 -1.60 1.3E-03
78 IL18 -1.59 1.7E-03
79 TUBB -1.59 6.2E-03
80 ITGA4 -1.58 1.7E-03
81 PPARG -1.58 1.7E-03
82 FCER1G -1.57 1.7E-02
83 RORC -1.57 7.0E-03
84 KLRF1 -1.55 2.0E-02
85 CD2 -1.51 3.7E-02
86 TIGIT -1.51 1.1E-02
87 UBE2L3 -1.49 5.0E-03
88 RARRES3 -1.47 2.5E-02
89 PSMB9 -1.45 5.6E-03
90 OAZ1 -1.44 4.4E-03
91 PYCARD -1.43 3.6E-03
92 CD45R0 -1.43 1.4E-02
93 PSMB8 -1.42 4.5E-03
94 TLR7 -1.41 4.4E-03
95 PTPN22 -1.41 1.8E-02
96 DPP4 -1.39 7.1E-03
97 GPI -1.38 1.8E-03
98 CCR5 -1.38 4.8E-02
99 IL1R2 -1.37 7.0E-03
100 CD4 -1.37 1.2E-02
101 HLA-DRA -1.37 2.2E-02
102 HLA-DPB1 -1.36 2.8E-02
103 KIT -1.35 9.0E-03
104 IL2RG -1.35 5.0E-03
105 CD1D -1.35 1.5E-02
106 MSR1 -1.33 1.6E-02
107 FCGR2A/C -1.31 3.8E-02
108 HLA-DOB -1.31 5.7E-03
109 BTK -1.26 2.5E-03
Continued...
Gene logFC adj.P.Val
110 EDNRB -1.26 2.8E-02
111 KIR2DS1 -1.21 3.6E-02
112 KLRG1 -1.20 2.2E-02
113 GFI1 -1.20 1.1E-02
114 ICAM3 -1.19 6.2E-03
115 CD163 -1.19 1.7E-02
116 PSMB7 -1.18 7.8E-03
117 ATG10 -1.18 7.9E-03
118 BAX -1.17 3.4E-03
119 PDCD1LG2 -1.16 1.7E-02
120 LILRA6 -1.15 8.5E-03
121 MAP4K1 -1.13 2.9E-02
122 PSMC2 -1.12 4.4E-03
123 PTPRCall -1.11 1.7E-02
124 PPIA -1.11 1.4E-02
125 CD74 -1.11 1.5E-02
126 LAIR1 -1.10 2.8E-02
127 FCGRT -1.09 7.1E-03
128 TNFSF10 -1.09 1.3E-02
129 CIITA -1.08 2.6E-02
130 IL7 -1.08 1.3E-02
131 CXCR4 -1.07 2.2E-02
132 CD19 -1.07 2.8E-02
133 TNFSF8 -1.07 1.2E-02
134 SMAD5 -1.06 8.0E-03
135 CCL13 -1.06 4.4E-02
136 ITGB2 -1.03 4.1E-02
137 TLR5 -1.03 2.8E-02
138 HFE -1.02 8.6E-03
139 CD45RB -1.02 4.8E-02
140 NFATC3 -1.01 1.6E-02
141 LTB4R2 -1.01 1.9E-02
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Obs.1: LEL-M 5 h vs. TM 0 h (↑) Obs.2: LEL-M 17 h vs. TM 0 h(↑)
ARG2 IL23A TNFRSF9 ARG2 ICAM5 NFIL3
BCL6 IL6 TRAF1 BCL6 IDO1 NFKB1
C3 IL8 C3 IFI16 NFKBIZ
C7 IRAK2 CCL19 IL1A PLAU
CCL2 IRF1 CCL2 IL1B PLAUR
CCL3 IRF7 CCL20 IL1R1 PTGS2
CD274 NFATC1 CD274 IL1RL1 RELA
CD40 NFATC2 CD40 IL1RL2 RELB
CD83 NFIL3 CD59 IL1RN RUNX1
CDKN1A NFKB1 CD70 IL22 SELE
CSF2 NFKBIZ CD80 IL23A SKI
CXCL1 PLAUR CD83 IL2RA SLC2A1
CXCL2 PTGS2 CDKN1A IL6 SOCS3
DUSP4 RELB CSF2 IL8 SPP1
EGR1 SELE CXCL1 IRAK2 STAT3
FYN SOCS3 CXCL2 IRF1 TNFAIP3
GBP1 STAT4 DUSP4 IRF7 TNFAIP6
ICAM1 TGFB1 EGR1 LIF TNFRSF9
ICAM4 TNFAIP3 EGR2 MAP4K4 TNFSF15
ICAM5 TNFAIP6 GBP1 MCL1 TRAF1
IL1A TNFRSF10C ICAM1 MME ZEB1
IL1B TNFRSF4 ICAM4 NFATC1
Table A.15.: List of common upregulated genes in WG-DASL and nCounter Assay.
Genes shown in red were unique for the specified observation. Genes were
defined as upregulated for specified time point vs. TM = 0 h by showing a
logFC ≥ 1 and an adj.P.Val < 0.05. ↑: upregulated
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Obs.1: LEL-M 5 h vs. TM 0 h (↓) Obs.2: LEL-M 17 h vs. TM 0 h(↓)
ARG2 EGR1 PTGS2 ABCB1 CEACAM6
C7 FYN PYCARD C1QA CLEC7A LILRA6
CCL24 GBP1 RELB C1QB CMKLR1 LILRB5
CCR2 GZMA SELE C5 CSF1R MRC1
CD1D HLA-DPB1 SLAMF6 CARD9 CSF3R MSR1
CD24 IL18 STAT4 CCL13 CTSG MUC1
CD40 IL23R TLR7 CCL24 CX3CR1 NCF4
CDKN1A IRF1 TLR8 CCL8 DEFB1 PIGR
CEACAM1 ITLN1 TNFRSF10C CCR2 FCER1A PLA2G2A
CEACAM6 KLRC4 TNFRSF4 CD160 GZMA PPARG
CIITA KLRD1 TNFRSF9 CD163 HLA-DMB PYCARD
CLEC7A MUC1 TRAF1 CD209 HLA-DPB1 RORC
CSF2 NFATC2 CD24 IL11RA TLR3
CX3CR1 NFIL3 CD36 IL18 TLR4
CXCR6 NFKB1 CD4 ITGAM TLR5
DEFB1 PIGR CD74 ITLN1 TLR8
DUSP4 PPARG CEACAM1 KLRF1 XCR1
Table A.16.: List of common downregulated genes in WG-DASL and nCounter Assay.
Genes shown in red were unique for the specified observation. Genes were
defined as downregulated for specified time point vs. TM = 0 h by showing
a logFC ≤ -1 and an adj.P.Val < 0.05. ↓: downregulated
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Obs. 1 & 2 (Overlap) Obs. 1 Obs. 2
ATF3 IL6 BHLHE22 ACSL4 IRF1 PITPNC1
BCL6 LYPD5 C3 ADM KRT17 PLAU
C2CD4B MMP9 CCL3 ALDH1A2 KYNU PRRX1
CCL2 NAMPT NFKBIZ BHLHE40 MME PTGS2
CD83 NR4A2 PCDH17 CEMIP MMP1 SERPINB8
CXCL1 PFKFB3 PDLIM7 CXCL5 MMP10 SGIP1
CXCL2 PLAUR TAGLN FLNC MMP3 SLC11A1
CXCL8 SERPINA3 HIF1A MTHFD2 SLC2A3
EGR1 SERPINE1 IDO1 NCOA7 TMEM158
FDCSP SIK1 IER3 OSM TNFRSF12A
GEM SOD2 IFI16 PDE4B TNFRSF6B
GREM1 TGM2 IL13RA2 PDPN UBD
IL1A TNFAIP6 IL1RN PHLDA1
IL1B ZC3H12A IL33 PIM3
Table A.17.: Gene expression overlap between upregulated genes in the LEL-M model
(WG-DASL Assay) and the UC vs. NC dataset [Granlund et al., 2013].
Obs. 1: LEL-M 5 h vs. TM 0 h, Obs. 2: LEL-M 17 h vs. TM 0 h.
Columns 2 and 3 show overlap of genes detected uniquely for Obs.1 or
Obs.2, respectively. Significant differential expression was defined by a
logFC ≥ 1 and an adj.P.Val < 0.01. UC: ulcerative colitis, NC: normal
colon
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Obs. 1 & 2 (Overlap) Obs. 1 Obs. 2
A1CF ITPKA SLC30A10 EXPH5 ABCG2 SLC4A4
ACADS KRT12 SLC35G1 GPR160 ACAA2 SPIRE2
ACOX1 LDHD SLC39A5 MEP1B ACSF2 SUGCT
ACSL5 LRRC19 SLC3A1 MIER3 ADH1C WDR78
AHCYL2 LRRC31 SLC51A PHLPP2 ASAP3 YBX2
AKR1B10 MARVELD3 SLC51B CHP2
AMACR MB SLC9A2 CHST13
AQP8 MEP1A SOWAHA CKB
BEST2 METTL7B SRI CLYBL
BRINP3 MPST STAP2 CNTFR
C1orf115 MS4A10 TEX11 CNTNAP2
CA1 MS4A12 TINAG CYP4F12
CA12 MS4A8 TM4SF5 DDC
CA2 MT1F TMEM171 EPHX2
CDHR5 MT1G TMEM236 ERBB2
CDKN2B MT1H TMEM37 GCNT2
CEACAM7 MYO1A TMEM56 GOLT1A
CES2 MYO1D TMIGD1 GSTA1
CGN NAT8B TRPM6 HPGD
CHAD NXPE4 TUBAL3 HSD17B11
CLDN8 OTOP2 UGT1A10 LINC01559
CMBL PDE6A UGT1A7 MAOA
CYP2C18 PDZD3 UGT1A8 MROH7
CYP4F2 PLA2G12B UGT2A3 MTMR11
DEFB1 PLEKHG6 VIPR1 NPY
DHRS11 PP7080 XK OTC
EDN3 PPARG ZG16 PBLD
ENTPD5 PPP1R14C PCK1
EPB41L4B PROM2 PIGZ
FMO5 PTGDR PKDCC
FRMD1 PTPRR PKIB
GBA3 RAPGEFL1 PRAP1
GUCA2A SATB2 PRKG2
GUCA2B SCIN PXMP2
HMGCS2 SGK2 RAVER2
HSD11B2 SHD SELENBP1
IGSF9 SLC16A9 SEMA6A
IMPA2 SLC17A4 SLC19A3
INPP5J SLC22A5 SLC22A18AS
ISX SLC26A2 SLC22A23
Table A.18.: Gene expression overlap of downregulated genes in the LEL-M model (WG-
DASL Assay) and the UC vs. NC dataset [Granlund et al., 2013]. Obs. 1:
LEL-M 5 h vs. TM 0 h, Obs. 2: LEL-M 17 h vs. TM 0 h. Columns 2
and 3 show overlap of genes detected uniquely for Obs.1 or Obs.2, respec-
tively. Significant differential expression was defined by a logFC ≤ -1 and
an adj.P.Val < 0.01. UC: ulcerative colitis, NC: normal colon
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↓ ↑
Obs.1 & 2 (Overlap) Obs.1 Obs.2 Obs.2
CTSE S100P PI3 AIF1 MNDA ABCG1
CASP5 SLC5A1 SLAMF6 ASS1 OLFM4 HES5
CEACAM6 TFF1 CCL24 P2RY13 LAMA1
LCN2 TFF2 CD74 SERPINA1 VLDLR
DMBT1 XDH CSF3R SIGLEC10
MUC1 GPX2 SPINK5
FFAR4 HLA-DMB TMEM200A
PDZK1IP1 LST1 ZG16B
PLEKHS1 MDK
Table A.19.: Anticorrelation of differentially regulated genes between LEL-M model
(WG-DASL Assay) and the UC vs. NC dataset [Granlund et al., 2013].
Obs. 1: LEL-M 5 h vs. TM 0 h, Obs. 2: LEL-M 17 h vs. TM 0 h.
Shown are genes that were downregulated ↓or upregulated ↑in the WG-
DASL Assay but regulated the opposite direction in the UC vs. NC data
set. Significant differential expression was defined by a logFC ≥ |1| and an
adj.P.Val < 0.01. UC: ulcerative colitis; NC: normal colon; ↑: upregulated;
↓: downregulated
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Obs.1 & 2 (Overlap) Obs.1 Obs.2
Gene SNP Gene SNP Gene SNP
ATF4 rs2413583 FLRT1 rs559928 CXCR5 rs630923
CD40 rs1569723 FYN rs3851228 FOSL2 rs925255
CSF2 rs2188962 STAT4 rs1517352 IL1R1 rs917997
FOSL1 rs2231884 IL22 rs7134599
ICAM1 rs11879191 IL24 rs3024505
IL1RL1 rs917997 LIF rs2412970
IL1RL2 rs917997 PDLIM4 rs2188962
NFIL3 rs4743820 PFKFB4 rs3197999
REL rs7608910 RELA rs2231884
TNFAIP3 rs6920220 SMAD7 rs7240004
TNFRSF9 rs35675666 SPRY4 rs6863411
UCN2 rs3197999 STAT3 rs12942547
TNFSF15 rs4246905
TRAF3IP2 rs3851228
Table A.20.: WG-DASL upregulated genes linked to single nucleotid polymorphisms
(SNP) loci [Jostins et al., 2012], which are upregulated in the LEL model
but not present in the UC vs. NC dataset [Granlund et al., 2013]. Obs.
1: LEL-M 5 h vs. TM 0 h, Obs. 2: LEL-M 17 h vs. TM 0 h. Column
1 contains genes that were present for both observations. Significant dif-
ferential expression was defined by a logFC ≥ |1| and an adj.P.Val < 0.01.
UC: ulcerative colitis; NC: normal colon
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